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Protein secretion is an essential process in cell biology. The conventional secretion pathway is well 
known, and involves proteins with a signal sequence being directed into the endoplasmic reticulum 
(ER). Once in the lumen of the ER, proteins are trafficked through the Golgi and remain separate from 
the cytosol throughout their journey to the outside of the cell. More recently, proteins without a signal 
sequence have been found outside the cell. These proteins are secreted unconventionally, and avoid 
the ER-Golgi route. For both pathways, some aspects remain unclear, particularly surrounding the 
regulation of protein secretion.  
Galectin-3, an unconventionally secreted protein, was used here to investigate both conventional and 
unconventional protein secretion. The unconventional protein secretion of galectin-3 is poorly 
understood. To address this, genetic manipulation of galectin-3 was used to gain insights into the 
mechanism of galectin-3 secretion. It was found that galectin-3 does not require unfolding or binding 
to cell surface glycoproteins to be secreted. 
Galectin-3 was also used to assess protein secretion using a genome-wide CRISPR screen. As galectin-3 
binds to cell surface glycoproteins, galectin-3 on the cell surface was used to assess secretion of these 
glycoproteins. Hits were validated by a glycoprotein secretion assay. Using this pipeline, 93 hits were 
identified as involved in protein secretion, of which 51 were novel hits not previously associated with 
protein secretion. Many of the hits identified also resulted in a phenotype of altered Golgi morphology, 
and five of these were investigated further. Two novel hits that localised to the Golgi were identified, 
TMEM220 and GPR161. GPR161 likely mediates its effect on Golgi morphology by its interaction with 
golgin A5.  
This thesis presents new insights into both conventional and unconventional protein secretion. Insights 
into the mechanism for galectin-3 secretion were revealed. A novel Golgi-localised regulator of 
secretion, GRP161, was identified, with a mechanism for action suggested. Importantly, the list of 51 
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Protein secretion is essential for cells to function correctly. There are two main pathways for protein 
secretion: conventional and unconventional secretion. In conventional secretion, proteins are directed 
into the endoplasmic reticulum by a signal sequence. They are then trafficked through the Golgi, where 
they may be glycosylated, to reach the plasma membrane. Unconventionally secreted proteins do not 
enter the Golgi. A subset of these unconventionally secreted proteins, known as leaderless proteins, 
do not have a signal sequence for secretion and completely avoid the ER-Golgi route to the plasma 
membrane. How leaderless proteins are secreted is generally unknown, although there are several 
proposed pathways for secretion. While conventional secretion is well-described, there are still 
unknown aspects, especially surrounding regulation of secretion. To identify novel regulators of either 
conventional or unconventional protein secretion, unbiased methods such as genome-wide screening 
need to be employed. These methods involve the use of a selection pressure to generate a treated 
population; comparison of the treated population to the untreated library allows important genes to 
be identified. As yet, these methods have only been used to investigate conventional protein secretion.  
The overarching aim of this thesis was to investigate both conventional and unconventional protein 
secretion, using galectin-3. Galectin-3 is an unconventionally secreted protein that binds to 
conventionally secreted glycoproteins on the cell surface. As such, it can be used as a model protein 





1.1 Protein secretion 
In eukaryotes, key biological processes and physiological functions are mediated by secreted proteins, 
located either at the cell surface or in the extracellular space. Broadly, secreted proteins allow cells to 
communicate and respond to their external environment. Key examples of cellular communication 
mediated by secreted proteins include hormone signalling in the endocrine system, in which proteins 
typically travel long distances in the blood stream; paracrine functions during neurotransmission, and 
autocrine signalling used by the immune cells. Secreted proteins act both as the ligands and receptors 
required to mediate these types of cell signalling. Transmembrane proteins at the cell surface act to 
transmit signals from the outside of the cell to the inside; for example, G-protein coupled receptors 
(GPCRs), the largest family of cell membrane proteins, which transmit signals by the activation of 
G-proteins (Sutkeviciute and Vilardaga, 2020). Additionally, soluble secreted proteins often act as the 
signal sent by one cell that other cells need to respond to, such as cytokines, hormones and growth 
factors. Other roles for secreted proteins include in the extracellular matrix, where they provide 
structural scaffolds and have regulatory roles for cell signalling (Theocharis et al., 2016). A recent study 
found that approximately 35 % of proteins are secreted (Chen et al., 2019), but defined the secretome 
as proteins released from the cell, not counting the membrane-spanning proteins that remain at the 
cell surface. Therefore, the number of secreted proteins is likely to be higher than this.  
1.2 Conventional protein secretion 
In the 1950s, George Palade first established that secreted proteins can be trafficked along the 
endoplasmic reticulum (ER)-Golgi secretory pathway by vesicle-mediated transport in eukaryotic cells 
(Palade, 1975). This pathway is known as conventional protein secretion and since its initial discovery, 
more precise details of the complex molecular machinery of conventional protein secretion have been 
described. An overview of this process is shown in Figure 1.1. 
Proteins that are secreted by the conventional pathway are translated from mRNA on ER ribosomes 
and co-translationally inserted into the ER, directed by a signal sequence (Benham, 2012). This initial 
step of co-translational insertion into the ER ensures that proteins remain separate from the cytosol 
throughout secretion, as they are then trafficked through membrane-bound compartments. Proteins 
are exported from the ER via ER exit sites (ERES), which form coat protein complex II (COPII) coated 
vesicles that are delivered to the Golgi. In higher eukaryotes this occurs via the ER-Golgi intermediate 
compartment (ERGIC), the first post-ER sorting site (Appenzeller-Herzog and Hauri, 2006). In the Golgi, 
proteins and sorted, then are trafficked to the cell surface via membrane-bound vesicles. The 
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localisation and activity of proteins involved in this secretory pathway must be tightly regulated to 
ensure correct spatio-temporal distribution of membranes and cargo proteins along the pathway.  
 
Figure 1.1: Organelles involved in the conventional protein secretion pathway. Once proteins enter 
the lumen of the ER, they remain separate from the cytoplasm throughout their journey to the cell 
surface. Proteins leave the ER in COPII coated vesicles, are sorted in the ERGIC and the Golgi, and are 
trafficked to the cell surface in vesicles. COPI coated vesicles are involved in retrograde traffic from the 
Golgi back to the ER. 
1.2.1 ER targeting 
To synthesise proteins, mRNA is translated on ribosomes to polypeptides, which need to fold correctly 
to form their protein structure. All translation begins on ribosomes in the cytoplasm, and for proteins 
without a signal sequence, translation is completed in the cytosol. In the conventional secretory 
pathway, an N-terminal signal sequence or hydrophobic segment emerges from the ribosome and is 
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recognised by signal recognition particle (SRP) (Wild et al., 2004). This recognition slows translation, 
and the entire complex is targeted to the ER by the SRP receptor (Wild et al., 2004). Although there is 
no consensus sequence of amino acids, the signal sequence is typically 20-30 residues and has three 
domains – a basic N domain, a hydrophobic H domain and a polar C domain (Izard and Kendall, 1994). 
Binding to SRP is enhanced when a REST sequence, an mRNA sequence which slows translation, is 
downstream of the signal sequence or transmembrane domain; this REST sequence acts as an initial 
regulatory step in the conventional protein secretory pathway (Pechmann et al., 2014). The SRP-
ribosome-nascent chain complex binds to a protein pore, the translocon, in the membrane of the ER, 
which enables the nascent polypeptide to be cotranslationally directed into the lumen of the ER or 
anchored in its membrane (Aviram and Schuldiner, 2017; Wild et al., 2004). Variations in the signal 
sequence can lead to differences in protein targeting to different organelles, and timing of cleavage of 
the signal sequence can affect downstream events such as glycosylation (Hegde and Bernstein, 2006). 
Proteins that will be secreted into the extracellular space have their signal sequence cleaved off to be 
released from the ER membrane, but the signal sequence remains intact for proteins anchored in the 
membrane (Hegde and Bernstein, 2006).  
During translation and translocation into the ER, proteins are folded with the help of chaperones, 
which act to prevent aggregation and promote correct folding of proteins (Dobson, 2003; Guerriero 
and Brodsky, 2012). The ER environment itself also helps protein folding, as the oxidising environment 
is needed for enzymes which catalyse the formation of disulfide bonds to function (Oka and Bulleid, 
2013). It is also possible for proteins which are translated and folded in the cytoplasm to be post-
translationally directed into the ER membrane; these are often tail-anchored membrane proteins 
which do not have a hydrophobic N-terminal transmembrane domain (Ast et al., 2013; Hegde and 
Keenan, 2011). These proteins then follow the conventional secretory pathway.  
1.2.2 ER-Golgi traffic 
The ER is the first organelle in which post-translational modification can take place. Inside the ER, the 
process of N-linked glycosylation begins, where a branch of glycans is added to a protein. Interestingly, 
the assembly of the branch begins on the cytosolic side of the ER membrane, then is translocated into 
the ER lumen where it can be transferred to a protein, although it is unclear which proteins facilitate 
this process (Rush, 2015). This initiation of N-linked glycosylation is important for protein folding and 
quality control in the ER (Cherepanova et al., 2016). For further modification, proteins must be 
trafficked to the Golgi. 
ER-to-Golgi traffic is regulated in order to allow only correctly folded proteins to proceed through the 
secretory pathway. Proteins leave the ER at ERES and may be transported by bulk flow, in which 
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proteins progress through the secretory pathway non-specifically, or by selective packaging into 
vesicles (Barlowe and Helenius, 2016; Dancourt and Barlowe, 2010). In both cases, vesicles are COPII-
coated. Sar1, Sec23, Sec24, Sec13 and Sec31 form the minimal machinery required to form COPII 
vesicles from membranes in vitro (Matsuoka et al., 1998), shown in Figure 1.2, adapted from review 
(Peotter et al., 2019). COPII-coated vesicle formation is regulated by many different factors, with 
multiple levels of regulation (D’Arcangelo et al., 2013). For example, Sec16 is known to maintain ERES, 
and is thought to form a scaffold for COPII coat assembly (Hughes et al., 2009; Watson et al., 2006). 
The kinase ERK2, part of the MAPK signalling pathway, phosphorylates Sec16, and phosphorylation of 
Sec16 is correlated with an increase in the number of ERES (Farhan et al., 2010). Interestingly, the COPII 
coat itself has been shown to have a role in sorting and in excluding ER-resident proteins and misfolded 
proteins from COPII-coated vesicles (Ma et al., 2017). COPII vesicles travel from the ER to the ERGIC, a 
distinct compartment located a short distance away from the ER and marked by ERGIC53 (Hauri et al., 
2000; Peotter et al., 2019). The ERGIC is widely accepted to be a sorting site, and may also have roles 
in protein quality control and protein folding (Appenzeller-Herzog and Hauri, 2006; Saraste and Marie, 
2018). For secretion, proteins progress from the ERGIC to the Golgi. Different models have been 
proposed for ERGIC to Golgi trafficking; either the ERGIC moves along microtubules towards the Golgi, 
or ERGIC to Golgi traffic is long range and microtubule dependent (Brandizzi and Barlowe, 2013; 
Saraste and Marie, 2018). It is also possible that both models may be used in different circumstances.  
It is important that ER-resident proteins remain in the ER, so when resident proteins do leave the ER 
by bulk flow, they must be transported back into the ER. COPI-coated vesicles are used for this 
retrograde traffic. One mechanism to retrieve soluble proteins back to the ER is by the C-terminal KDEL 
sequence and its variants, which are recognised in the ERGIC or cis-Golgi by three different KDEL 
receptors with varying specificities and efficiencies (Raykhel et al., 2007). While this mechanism is well 
known, there are also proteins which lack a KDEL sequence but can still be retrieved. Some of these 
may interact with KDEL-containing cargo (Raykhel et al., 2007), while others utilise different 
mechanisms. For example, the Erv41–Erv46 complex in yeast returns proteins such as glucosidase I to 
the ER (Shibuya et al., 2015); later work showed that Erv46 alone is sufficient to bind cargo while Erv41 
has a regulatory role (Keiser and Barlowe, 2019). The human orthologues of Erv41 and Erv46, ERGIC2 
and ERGIC3, have also been shown to form a complex (Yoo et al., 2019). ERGIC3 was previously 
identified as ERp43 and found to have a role in resisting ER stress (Nishikawa et al., 2007). The 
Erv41-Erv46 complex also functions in anterograde trafficking, although to date only one substrate has 




Figure 1.2: Model for COPII-mediated transport at the ER/ERGIC interface. Figure proposed by 
Peotter et al., adapted from review (Peotter et al., 2019). Proteins forming the minimal machinery 
involved in sequential steps in the ER to ERGIC transport process are shown.  
1.2.3 Intra-Golgi traffic 
The Golgi itself is another site for post-translational modification. For example, the short glycan branch 
formed by N-linked glycosylation in the ER is further modified in the Golgi, and the Golgi is the site for 
the whole process of O-linked glycosylation (Stanley, 2011). The Golgi is also a major site for sorting 
proteins to be trafficked to their destinations, which may be the plasma membrane, endosome, 
secretory granules, and specialised compartments in specific cell types (De Matteis and Luini, 2008). 
The organisation of the Golgi itself is poorly understood, and many explanations for transport within 
the Golgi exist (Glick and Luini, 2011; Mironov and Beznoussenko, 2019). There are two main transport 
models: the vesicle based model, in which proteins travel through Golgi stacks via vesicles; and the 
cisternal maturation model, in which the Golgi changes and cis-Golgi matures through the stack to 
become trans-Golgi (Glick and Luini, 2011). Other models have also been proposed which are generally 
variations of these models, such as a variation of cisternal maturation in which cargo can also be 
transported in tubules which connect the cisternae. 
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Although historically, vesicle based transport within the Golgi was the preferred model for intra-Golgi 
traffic, it is now less well accepted. COPI-coated vesicles are known to be involved in retrograde traffic, 
and they may also participate in anterograde traffic, evidenced by the presence of anterograde cargo, 
including VSVG, and lack of KDEL receptors in subpopulations of COPI vesicles (Orci et al., 2000, 1997). 
However, more recent work has suggested that COPI functions in an anterograde direction through 
tubules and not vesicles (Park et al., 2015). This may help to reconcile a key limitation of the vesicle 
based model, which is that it does not explain transport of large proteins such as pro-collagen which 
are too big to fit into COPI-coated vesicles. There is evidence for cisternal maturation in yeast, as it has 
been shown both that cisternae change over time (Losev et al., 2006; Matsuura-Tokita et al., 2006) 
and that cargo remain in cisternae (Kurokawa et al., 2019). This process was found to be dependent 
on COPI function, and it was proposed that retrograde traffic in COPI vesicles may act as a quality 
control mechanism (Kurokawa et al., 2019).  
Overall, there is not a clear consensus on intra-Golgi traffic, but the conflicting routes can be reconciled 
by the idea that multiple trafficking routes for transport coexist within the Golgi complex; small soluble 
proteins can diffuse through the Golgi, most likely through tubules, whereas large, non-diffusible cargo 
move through the Golgi complex by progression-maturation (Beznoussenko et al., 2014; Lavieu et al., 
2013). The regulation of these different routes remains poorly understood. 
1.2.4 Glycosylation 
Glycoproteins are formed when proteins are glycosylated as they travel through the conventional 
secretory machinery described above. Approximately half of all proteins are glycosylated, making 
glycosylation the most common post-translational modification of proteins (Stanley, 2011). 
Glycoproteins are formed by two main mechanisms: N-linked glycosylation in the ER and O-linked 
glycosylation in the Golgi. N-linked glycosylation takes place on the nitrogen atom of asparagine (N) 
and O-linked glycosylation occurs on the side chain oxygen atom of serine (S) or threonine (T). Other 
routes for glycosylation also exist, such as the production of hyaluronic acid-based glycosaminoglycans, 
which takes place in the cytoplasm (Casale and Crane, 2019). On the cell surface, glycoproteins have 
essential roles in cell signalling and immunity.  
Since glycosylation occurs in every cell and has many functions for the correct functioning of cells, 
disruption of glycosylation can lead to disease, known as congenital disorder of glycosylation (CDG). 
These are rare and have diverse clinical presentations, which have been difficult to identify in the past 
(Gilfix, 2019). In more recent years, many CDGs have been identified by next generation sequencing 
(Gilfix, 2019; Ng and Freeze, 2018). Cell surface glycoproteins also have key roles in host-pathogen 
interactions. Recently, genome-wide screens have been employed to investigate genes required for 
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these interactions. These have revealed key genes involved in glycosylation, summarised in a review 
by Ng and Freeze (Ng and Freeze, 2018). These screens identified both genes established to be involved 
in CDG and novel genes.  
1.2.4.1 Glycosylation to regulate protein folding 
N-linked glycosylation occurs on the side chain nitrogen of asparagine residues in an N-X-S/T sequence, 
where X is any amino acid except proline. This process is important for protein folding, as glycan 
processing allows lectin chaperones to ensure proteins are correctly folded (Tannous et al., 2015). The 
initial addition of the hydrophilic glycan Glc3Man9GlcNAc2 (G3M9) is followed by a process of glycan 
trimming and modification, which acts to regulate protein folding in the ER, as shown in Figure 1.3. 
G3M9 is trimmed to Glc2Man9GlcNAc2 (G2M9) by α-glucosidase I. G2M9 on terminally misfolded 
glycoproteins can be recognised by malectin (Schallus et al., 2010), a lectin whose expression is induced 
by ER stress and is thought to prevent export of misfolded proteins, and so acts as an additional quality 
control mechanism in stress conditions (Galli et al., 2011). The mechanism for how this happens is 
unclear, and requires further investigation. If the protein has more than one glycan, G2M9 is then 
trimmed by α-glucosidase II to Glc1Man9GlcNAc2 (G1M9) (Deprez et al., 2005). G1M9 is recognised and 
retained in the ER by the lectin chaperones calnexin (CNX) or calreticulin (CRT). These lectins have the 
same binding profile, but bind different glycoproteins due to their different locations: CNX is 
membrane-bound at ER exit sites whereas CRT is in the lumen of the ER. CNX and CRT also bind either 
ERp57, a thiol oxidoreductase which catalyses breakage and formation of disulfide bonds to facilitate 
correct protein folding. The last glucose is cleaved off by α-glucosidase II and the glycoprotein is 
released from CNX or CRT. If the protein is correctly folded, the protein leaves the ER. If not correctly 
folded, UDP-glucose:glycoprotein glucosyltransferase (UGT1) recognises exposed hydrophobic regions 
and glucose is added again by UGT1 to recreate G1M9 (Kiuchi et al., 2018). This CNX/CRT cycle 
continues until either they are correctly folded, and they are exported from the ER via the ERGIC, or 
they are directed to the ER associated degradation (ERAD) pathway. Details surrounding how proteins 
exit the CNX/CRT cycle are unclear. It is not fully understood how proteins exit the CNX/CRT cycle 
(Tannous et al., 2015), but the slow-acting ER mannosidase I is thought to allow time for proteins to 




Figure 1.3: Processing of N-linked glycosylation in the ER. Figure adapted from Tannous et al. 
(Tannous et al., 2015). After G3M9 is added to the N-X-S/T sequence, it is sequentially trimmed by 
glucosidase I then glucosidase II. G1M9 enters the CNX/CRT cycle, where glucose is trimmed and re-
added until correctly folded. If it cannot be correctly folded, it is degraded, signalled by removal of 
multiple mannose residues. Although here one glycan chain is shown for simplicity, proteins are not 
trimmed by glucosidase II unless they have more than one site for N-linked glycosylation (Deprez et 
al., 2005).  
1.2.4.2 Glycosylation in the Golgi 
N-linked glycosylation continues in the Golgi, where mannose is trimmed and other monosaccharides 
are added to form the mature glycoprotein. There are many possible modifications to the core glycan 
structure to create different glycan profiles. A computational model has recently shown that a cell’s 
glycan profile is dependent on both Golgi architecture and time taken to travel through the Golgi 
(Fisher et al., 2019). Several genes are important for glycoprotein maturation, including transferases 
such as MGAT1, which add GlcNac subunits to build the glycan chain (Kumar et al., 1990); solute 
transporters which transport subunits required to build complex glycans into the Golgi, such as 
SLC35A2 (Hadley et al., 2019), and ion transporters such as SLC39A9 which can act to regulate 
glycosylation (Yamaji et al., 2019).  
Unlike N-linked glycosylation, there is no consensus sequence for O-linked glycosylation, and 
glycosylation takes place entirely in the Golgi. Although there is no consensus sequence, a neural 
network approach has recently been developed which is able to predict glycosylated serine sites with 
over 96 % accuracy (Akmal et al., 2020). As O-linked glycosylation fully takes place in the Golgi, proteins 
are already fully folded by the time they are glycosylated. Initially, N-acetylgalactosamine (GalNAc) is 
10 
 
transferred to an S or T residue by GalNAc transferase. Glycan chains are built up by addition of 
monosaccharides by glycosyltransferases (Akmal et al., 2020).  
1.2.5 Trafficking to the cell surface and extracellular space  
In the trans-Golgi network, proteins are sorted to be trafficked to their various different locations. This 
traffic is via vesicles, which may originate from vesicle budding or derive from longer tubules which 
elongate from the trans-Golgi network (De Matteis and Luini, 2008). Proteins contain sorting signals 
which are recognised in the trans-Golgi. These include sorting motifs within the protein sequence, 
protein affinity for membrane domains, the formation of protein complexes or post-translational 
modification of proteins (De Matteis and Luini, 2008; Rodriguez-Boulan and Müsch, 2005). For 
example, glycosylation can act as a sorting signal to direct proteins to the apical membrane of polarised 
Madin-Darby canine kidney (MDCK) epithelial cells (Schelffele et al., 1995; Yeaman et al., 1997). A well-
described pathway from the Golgi is via clathrin-coated vesicles, which traffic proteins from the trans-
Golgi network to the endosomal pathway (Traub, 2005). Clathrin itself is involved in sorting (Traub, 
2005). While clathrin has not been found to be required for constitutive secretion (Robinson, 2015), 
proteins sorted into endosomes can still be secreted. Other, non-clathrin coated vesicles can traffic 
cargo to the plasma membrane. It is thought that a different type of coat protein might be involved in 
the direct transport from the Golgi to the plasma membrane, but this remains unclear (Bard and 
Malhotra, 2006; Spang, 2015). 
Once vesicles reach the cell surface, or indeed another destination where vesicle fusion is required, 
soluble N-ethylmaleimide-sensitive factor (NSF) activating protein receptor (SNARE) proteins allow 
secretory vesicles to fuse with the plasma membrane (Bonifacino and Glick, 2004; Han et al., 2017). 
SNARE proteins are essential for membrane fusion, and different types of SNARE proteins ensure the 
specificity of membrane fusion (Bonifacino and Glick, 2004; Han et al., 2017). After fusion, proteins 
inside secretory vesicles are released into the cytoplasm, and proteins embedded in the membrane of 
vesicles stay in the membrane, but this membrane is now part of the plasma membrane.  
1.2.6 Unknown aspects of conventional protein secretion 
While the molecular machinery of secretion is relatively well understood, knowledge of protein 
secretion remains incomplete, and new details of the pathway continue to be uncovered. For example, 
it has more recently been established that COPII-coated vesicles are captured directly by regions of the 
cis-Golgi in yeast, and not released into the cytosol, to ensure efficient transport from ERES to the Golgi 
(Kurokawa et al., 2014). As the ERGIC does not exist in yeast, it may be that these regions of cis-Golgi 
represent something similar to ERGIC, but to date there is no evidence that ERGIC directly captures 
COPII-coated vesicles in this way in higher eukaryotes. The question of whether specific proteins are 
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packaged into COPII-coated vesicles, or whether packaging is random, also remains to be fully 
answered (Kurokawa and Nakano, 2019). While it appears that both non-specific bulk transport and 
specific packaging takes place, the mechanisms regulating specific packaging require more 
investigation. There is also the question of how large proteins such as procollagen are transported 
through the cell: although COPII vesicles are usually considered to be smaller than procollagen, the 
transport of procollagen has been found to be dependent on COPII vesicles (Stephens and Pepperkok, 
2002). It is thought that large COPII-dependent carriers are used in the transport of procollagen from 
the ER to the Golgi, which may be dependent on ERGIC, as reviewed (McCaughey and Stephens, 2019). 
Other models suggest that tunnels transport collagen from the ER to the ERGIC, and this tunnel could 
extend to the Golgi (Raote and Malhotra, 2019). A number of questions remain, particularly about the 
role of ERGIC and the regulation of transport of large proteins (McCaughey and Stephens, 2019).  
The mechanism of transport through the Golgi is not completely understood, as discussed above. The 
complex process of sorting proteins at the Golgi into vesicles for their correct destinations requires 
further investigation for a full understanding of protein secretion (De Matteis and Luini, 2008; Guo et 
al., 2014; Kienzle and von Blume, 2014; Pakdel and von Blume, 2018; Spang, 2015). Some aspects of 
protein release in vesicles at the trans-Golgi network have been at least partly characterised, including 
release in clathrin-coated vesicles (Daboussi et al., 2012; Traub, 2005) and secretory storage granules 
(Borgonovo et al., 2006). Mechanisms of sorting continue to be uncovered; for example, the role of 
clathrin adaptor proteins to sort specific membrane signalling proteins into different types of coated 
vesicles (Ma et al., 2018). Recently, carriers of the trans-Golgi network (TGN) to the cell surface (CARTS) 
have been discovered as a new vesicle class, which are thought to transport small secretory proteins 
(Wakana et al., 2013, 2012). CARTS require PKD for biogenesis and exclude certain proteins (Wakana 
et al., 2012), but again, how this process is regulated is unknown. A Ca2+-dependent sorting mechanism 
has recently been described for sorting soluble secretory cargo, but questions remain about the 
regulation of the process, recognition of cargo and packaging into vesicles after sorting (Pakdel and 
von Blume, 2018). There are likely to be other vesicle types involved in exiting the trans-Golgi network, 
but these are poorly characterised. 
At first glance, protein secretion may appear to be a well-defined pathway, but in reality, it has complex 
aspects and a number of questions still to be answered. As at least one third of human proteins are 
secreted, a complete understanding of the regulation of their transport is essential in order to target 
specific proteins important in health and disease.  
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1.3 Unconventional protein secretion 
In the last thirty years, a growing number of proteins with extracellular functions, yet without a signal 
sequence to enter the lumen of the ER to follow the conventional secretory pathway, have been 
described (Nickel and Rabouille, 2018; Prudovsky et al., 2008). These leaderless proteins are typically 
investigated using drugs such as brefeldin A, which collapses the Golgi and causes protein 
accumulation in the ER, therefore inhibiting conventional secretion (Fujiwara et al., 1988). Treatment 
with drugs like brefeldin A do not inhibit their secretion (Nickel, 2003), showing that they do not use 
the classical ER-Golgi-plasma membrane pathway for secretion. Leaderless proteins have no conserved 
structural features which might suggest a common pathway for secretion, although many of them bind 
phospholipids (Prudovsky et al., 2003). They not only have roles in the healthy function of cells, but 
are often associated with disease (Daniels and Brough, 2017). Unconventional secretion has been 
reported in eukaryotic cells, including mammalian cells, yeast, and plants (Rabouille et al., 2012). In 
plants, it has been reported that 50 % of secreted proteins lack a signal sequence for secretion 
(Agrawal et al., 2010). Unconventional secretion in plants is particularly controversial as the pathways 
these proteins would take is less clear than for mammalian cells, although there is more evidence for 
plant unconventional secretion in response to pathogens (Robinson et al., 2016).  
Since these leaderless proteins do not have a signal sequence that identifies them, unconventionally 
secreted proteins are discovered by observations of both their extracellular localisation and their lack 
of a signal sequence. As early as 1985, it was hypothesised that proteins such as interleukin-1β (IL-1β) 
(March et al., 1985) and fibroblast growth factors (FGFs) (Abraham et al., 1986) may not follow the 
conventional secretory pathway. One of the first mechanisms proposed for unconventional secretion 
was for galectin-1, then known as L-14 (Cooper and Barondes, 1990). Its location within and outside 
cells had been documented prior to 1990, but the idea of its secretion was controversial. In 1989, it 
was found that galectin-1 was synthesised on free ribosomes in the cytosol, not at the ER (Wilson et 
al., 1989), which was surprising at the time given previous reports of its extracellular function 
(Barondes, 1984). As Wilson et al. remarked, “if indeed these lectins function extracellularly, their 
secretion must involve either post-translational translocation into the ER or an entirely novel 
mechanism” (Wilson et al., 1989). One such novel mechanism was proposed in 1990: galectin-1 was 
proposed to be released in microvesicles after accumulation at the plasma membrane (Cooper and 
Barondes, 1990). Since then, many other galectins which also lack a signal sequence have been shown 
to be located outside of the cell, with galectins 1 and 3 being well-documented due to their well-
established functions and their interactions with other extracellular proteins (Wang et al., 2004; Yang 
et al., 2008).  
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1.3.1 The requirement for unconventional protein secretion 
The existence of this unconventional route for secretion has been controversial at times. However, 
considering that it is now thought that the conventional secretion pathway also comprises of multiple 
pathways, such as the Golgi using both cisternal maturation and vesicles for intra-Golgi transport, it 
should not be particularly surprising that cells have more than the conventional protein secretion 
pathway to export proteins. One key function of this alternative route may be to help in preventing 
inappropriate interactions, for example between a receptor and its ligand (Nickel and Rabouille, 2009). 
It is likely that unconventionally secreted proteins bypass the classical protein secretion pathway either 
to avoid misfolding, premature interaction with their receptors or inappropriate post-translational 
modification (Nickel, 2010). For example, when an N-terminal signal sequence is added to the 
unconventionally secreted protein FGF-2, it is efficiently secreted but is O-glycosylated, which 
abolishes its function (Wegehingel et al., 2008). In the case of unconventionally secreted lectins such 
as the galectins, it makes sense that glycoproteins and their ligands should be kept apart at some stages 
of trafficking to stop them interacting at the wrong time or place. Exactly how these proteins are 
secreted is a fundamental question in cell biology. Beyond the desire to understand this at a basic 
science level, an understanding of this process could reveal interesting insights into disease, as the 
levels of many unconventionally secreted proteins are perturbed in disease. 
1.3.2 Pathways for unconventional protein secretion 
Multiple pathways have been proposed to explain the mechanisms by which these unconventionally 
secreted proteins leave the cell, which have been categorised by Rabouille et al. (Rabouille et al., 
2012), shown in Figure 1.4. All types involve crossing a membrane. Until each unconventionally 
secreted protein is studied individually, it is not possible to predict which of these pathways is used, 
so this must be experimentally determined. For types I and II, proteins are directly translocated across 
the plasma membrane. Type I refers to translocation across the plasma membrane; either aided by 
other protein complexes, transported through pores, or unfacilitated. In type II secretion, translocation 
is via ATP-binding-cassette (ABC)-transporter proteins. Type III describes the secretion of cytoplasmic 
proteins that first enter the lumen of an organelle, which then fuses with the plasma membrane. In 
contrast to the first three types, type IV secretion describes transmembrane proteins which are 
inserted into the ER membrane, but reach the plasma membrane without passing through the Golgi. 
Type IV secreted proteins are therefore similar to conventionally secreted proteins, in that they have 
a signal sequence and cross the ER membrane; their defining feature is that they bypass the Golgi. 





Figure 1.4: Pathways of unconventional protein secretion for leaderless proteins. Type I, direct 
translocation across the plasma membrane, may be unfacilitated or facilitated by a protein 
transporter. Type II involves transport facilitated by ABC transporter proteins. Type III 
unconventionally secreted proteins do not cross the plasma membrane directly but are transported 
into membrane-bound compartments inside the cell, which then fuse with the plasma membrane to 
release their contents. Other pathways proposed for secretion involve the use of EVs, either via 
microvesicles or exosomes, but these pathways do not fully explain secretion as the proteins remain 
inside EVs and are not free in the extracellular space.  
In addition, cytoplasmic proteins can be released in extracellular vesicles (EVs), which are categorised 
as exosomes or microvesicles according to their origins (Raposo and Stoorvogel, 2013). Exosomes are 
formed from multivesicular bodies (MVBs) via invagination of the MVB membrane which creates 
internal vesicles – exosomes – that are loaded with cytoplasmic proteins. Upon fusion of MVBs with 
the plasma membrane, exosomes are released. This may be another example of type III secretion, 
although it is unclear if proteins are able to reach the lumen of MVBs, in which case they may be 
secreted by fusion with the plasma membrane, or whether they are strictly confined inside exosomes. 
The second type of EVs are microvesicles, which derive from direct budding from the plasma 
membrane. Pathways involving EVs do not fully explain how an unconventional protein might be 
secreted; although proteins are outside the cell, they should remain encapsulated inside vesicles, as 
shown in Figure 1.4. As all routes of unconventional secretion must involve crossing a membrane, it is 
possible that the EVs could lyse to release their contents.  
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1.3.2.1 Type I: direct translocation across the plasma membrane 
Type I unconventional secretion may be further divided into two categories: facilitated and 
unfacilitated (Figure 1.4). It is unlikely that a protein may be secreted directly across a membrane 
without the help of any other regulator of secretion, but the distinction here is whether the 
unconventionally secreted protein traverses the membrane through a protein transporter or without 
using a protein transporter.  
FGF-2 is one of the most well-studied examples of a protein secreted by direct translocation. FGF-2 is 
initially recruited to the inner leaflet of the plasma membrane by binding to ATPA1, a subunit of the 
Na+/K+-ATPase (Legrand et al., 2020; Zacherl et al., 2015). It then binds to phosphatidylinositol 
4,5-bisphosphate (PI(4,5)P2) in order to anchor FGF-2 to the inner plasma membrane for its 
translocation across the membrane (Temmerman et al., 2008). Binding to PI(4,5)P2 leads to 
oligomerisation of FGF-2, facilitated by phosphorylation by the non-receptor tyrosine kinase Tec, to 
form a short-lived pore able to transport lipids across the membrane (Müller et al., 2015; Steringer et 
al., 2017, 2012). FGF-2 also requires heparan sulfate proteoglycans on the cell surface to disassemble 
the oligomer and drive export from the cell (Zehe et al., 2006). FGF-2 is an example of unfacilitated 
transport as only PI(4,5)P2 and heparan sulfate are absolutely required for membrane translocation 
(Steringer et al., 2017).  
The three key aspects of the direct translocation pathway for FGF-2 secretion are recruitment to the 
plasma membrane, insertion into the membrane, and the use of cell surface anchors to ensure one-
directional transport. These features may represent a more general mechanism for unconventional 
secretion than specifically for FGF-2. Two other proteins secreted by type I direct translocation, IL-1β 
and the viral protein HIV-Tat (Rayne et al., 2010a), also share some of these features. Upon monocyte 
stimulation, IL-1β is also secreted by formation of a PI(4,5)P2-dependent pore (Brough et al., 2017; Sitia 
and Rubartelli, 2018; Steringer et al., 2017). Additionally, HIV-Tat binding to PI(4,5)P2 is a requirement 
for its localisation to the plasma membrane and its secretion (Rayne et al., 2010b), and binds to 
heparan sulfate on the cell surface (Chang et al., 1997). The common use of PI(4,5)P2, and the fact that 
both FGF-2 and HIV-Tat bind heparan sulfate initially suggests a common mechanism for direct 
translocation. However, there are several differences in the secretion of IL-1β and HIV-Tat compared 
to FGF-2. IL-1β does not directly bind to PI(4,5)P2, unlike FGF-2 (Martin-Sanchez et al., 2016). IL-1β is 
secreted through a gasdermin-D pore formed by GSDMD-N, a product of caspase cleavage (Evavold et 
al., 2018; Heilig et al., 2018). As such, this route would be an example of facilitated type I secretion. 
Another difference is that IL-1β requires conformational flexibility to cross the membrane (Zhang et 
al., 2015), whereas FGF-2 crosses the membrane when tightly folded (Backhaus et al., 2004). It is 
possible that this difference may be explained by the fact that IL-1β passes through a pore, whereas 
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FGF-2 itself forms the pore, which is a transient structure in the secretion of FGF-2. Although FGF-2 
and HIV-Tat are more similar in their secretion, there are also differences here. In vitro experiments 
have shown that unlike FGF-2, HIV-Tat requires a lipid membrane to bind PI(4,5)P2, indicating that the 
mechanisms of PI(4,5)P2 binding are likely different for these two proteins (Rayne et al., 2010b). It is 
also unclear whether HIV-Tat secretion requires the Na+/K+-ATPase, whether HIV-Tat forms a pore, or 
whether cytosolic chaperones are required for its secretion (Schatz et al., 2018).  
Annexin A2 is another protein that likely uses type I direct translocation as a mechanism for secretion, 
although details of the full mechanism are not well known. Annexin A2 translocates across the 
membrane by binding phospholipids in a Ca2+-dependant manner, and translocation is facilitated by 
phospholipid flipping by TMEM16F (Stewart et al., 2018). Annexins are known to insert into 
membranes (Lizarbe et al., 2013) and it has been proposed that they function as calcium channels 
(Gerke and Moss, 2002), which would require them to span membranes. If annexin oligomers do span 
the membrane, the secretion of annexin A2 shares the feature of oligomerisation for membrane 
insertion with the well-described FGF-2 secretion pathway. 
Even though these proteins can be grouped together into the direct translocation type I secretion 
pathway, it is not clear that these proteins follow the same specific route. However, common themes 
in direct translocation do emerge. Many unconventionally secreted proteins bind phospholipids, some 
specifically PI(4,5)P2, and in the context of type I direct translocation this lipid binding can be utilised 
to anchor them to the plasma membrane as an initial step for translocation. For unfacilitated transport, 
insertion of the protein into the membrane must be required. There is direct evidence that FGF-2 forms 
a pore in order to cross the membrane (Müller et al., 2015; Steringer et al., 2017, 2012), but the picture 
is less clear for other proteins. Other unconventionally secreted proteins that may use direct 
translocation are known to insert into membranes, such as the annexins (Lizarbe et al., 2013), and 
externalisation of annexin A2 and annexin A5 is dependent on phospholipid remodelling at the plasma 
membrane (Stewart et al., 2018). Although there are common themes in type I unconventional 
secretion, there is diversity in the mechanism for membrane translocation.  
1.3.2.2 Type II: direct translocation facilitated by ATP-binding cassette proteins 
Similarly to type I secretion, type II secretion involves translocation at the plasma membrane, but here 
transport is directly facilitated by ATP-binding cassette (ABC) transporters, a family of proteins found 
in prokaryotes and eukaryotes which hydrolyse ATP to transport substrates including peptides, lipids, 
oligonucleotides and polysaccharides, as well as small molecules, across the plasma membrane 
(Wilkens, 2015). This is a rare type of unconventional protein secretion. To date, only lipidated proteins 
and yeast mating peptides are known to be secreted by this pathway (Rabouille, 2016; Rabouille et al., 
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2012). Annexin A1 has been proposed to use type II secretion as a mechanism, but there is only indirect 
evidence for this and results are sometimes conflicting, as reviewed (Popa et al., 2018). Overall, it is 
unclear whether this pathway is a widely used pathway for secretion by mammalian cells. 
1.3.2.3 Type III: export from cells using intracellular compartments as vesicular intermediates  
Type III secretion covers a range of secretion using intracellular compartments. This includes secretory 
lysosomes and autophagosomes, intracellular vesicles and a specific compartment for secretion called 
compartment for unconventional protein secretion (CUPS), as identified in yeast. CUPS is distinct from 
the Golgi and ER membranes, and forms close to ER exit sites under starvation conditions (Bruns et al., 
2011). CUPS have similar features to omegasomes, compartments in mammalian cells which are 
involved in autophagosome formation (Roberts and Ktistakis, 2013). However, CUPS are not involved 
in formation of autophagosomes and an alternative mechanism for secretion from CUPS has been 
proposed via fusion with endosomes to form multivesicular bodies, which release exosomes 
(Malhotra, 2013). Another example of a pathway for type III secretion is via secretory lysosomes, which 
fuse directly with the plasma membrane to release their contents. This is a process carried out by all 
cell types in response to different stimuli, regulated by Ca2+ and involved in many physiological 
processes, including cell signalling (Andrews, 2000; Buratta et al., 2020).  
A well-studied example of a protein that uses type III secretion is acyl-CoA binding protein (Acb1), a 
yeast protein with a mammalian orthologue, diazepam binding inhibitor (DBI). Acb1 is secreted via 
CUPS in a process triggered by nutrient starvation leading to the production of reactive oxygen species 
(Cruz-Garcia et al., 2020). Other proteins are also required for secretion of Acb1, including ESCRTs and 
Grh1, the yeast orthologue of GRASP55 and GRASP65, and are present in CUPS (Bruns et al., 2011). 
Similarly, IL-1β has been shown to be secreted via vesicles that become autophagosomes when 
autophagy is triggered by nutrient starvation (Zhang et al., 2015), although some reports are 
contradictory, and it is not clear which intracellular compartment is used for secretion. As mentioned 
above, IL-1β is also exported from the cell by type I secretion in other situations. Interestingly, GRASP55 
is required for IL-1β secretion in macrophages, and knockdown of GRASP65 also reduced secretion of 
IL-1β (Chiritoiu et al., 2019). This suggests there may be a conserved, GRASP-dependent mechanism 
for this specific type III secretion.  
1.3.2.4 Secretion in EVs 
Unconventional secretion in EVs comprises of release in microvesicles, which originate from plasma 
membrane blebbing, or in exosomes from MVBs (Raposo and Stoorvogel, 2013). According to the 
current nomenclature, secretion in EVs does not fall within any of the three types of unconventional 
secretion (Nickel and Rabouille, 2018; Rabouille et al., 2012). However, there is some overlap with type 
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III secretion, as exosomes originate from multivesicular bodies (Raposo and Stoorvogel, 2013). This 
additional pathway is not well understood, and does not fully explain unconventional secretion on its 
own, as proteins are sequestered inside EVs once outside the cell without access to the cell surface or 
extracellular space where they function (Figure 1.4). One way to explain this is vesicle lysis, but it has 
not been demonstrated that EVs release their contents outside of the cell, and this is unlikely to 
represent a basal mechanism for secretion as it would lead to inflammation. Furthermore, some 
proteins on the surface of EVs have been found to have “inside-out” topology (Cvjetkovic et al., 2016), 
suggesting that there may be a specific mechanism for transporting proteins to the EV surface. EVs do 
not necessarily match the composition of the plasma membrane; for example, it is reported that FGF-2 
and galectin-1 are detected on the surface of CHO cells, but are not associated with EVs from the same 
cells (Seelenmeyer et al., 2008). However, it could be that the assay used was not sensitive to detect 
proteins on the surface of, rather than packaged into, EVs. 
Annexin A2 is one example of a protein that has been detected on the surface of EVs (Stewart et al., 
2016). While it is possible that annexin A2 on the surface of EVs could be transferred from the cell 
surface, there is evidence that exosomes are involved in annexin A2 secretion. The interferon-γ-
stimulated increase in annexin A2 translocation is blocked by reagents that are thought to block 
exosome biogenesis (Fang et al., 2012). One proposed pathway, called exophagy, is that annexin A2 is 
trafficked into autophagosomes which then fuse with multivesicular bodies (Chen et al., 2017).  
1.3.2.5 Use of multiple routes in unconventional secretion 
Although these separate pathways exist, unconventionally secreted proteins have rarely been shown 
to only use one of these pathways for secretion. Evidence often points to multiple different pathways 
for secretion, and one way of reconciling this is that proteins may use different pathways in different 
cell types or conditions. For example, evidence shows that annexin A2 is secreted both directly across 
the plasma membrane and via EVs (Mayran et al., 2003; Stewart et al., 2018). It is possible that 
annexin A2 is secreted at a basal level by type I direct translocation and by EVs in stress conditions, as 
previously suggested (Popa et al., 2018). Further support for this suggestion comes from the fact that 
under normal conditions, annexin A2 export is facilitated by phospholipid flipping by TMEM16F 
(Stewart et al., 2018). In the case of IL-1β, at least two routes for secretion exist in response to different 
intensity pro-inflammatory signals (Sitia and Rubartelli, 2018). IL-1β has been shown to be directly 
secreted across the plasma membrane via a gasdermin D pore under strong pro-inflammatory 
pressure, in an example of type I secretion; under less strong stimuli, IL-1β has been reported to use 
an intermediate membrane compartment, in an example of type III secretion (Evavold et al., 2018; 
Heilig et al., 2018; Zhang et al., 2015). The use of multiple routes has also been suggested for galectin-3 
(Barondes et al., 1994b; Hönig et al., 2015; Popa et al., 2018) and will be further discussed in Chapter 3. 
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1.4 Galectins  
Galectins are galactose-specific lectins: proteins with conserved carbohydrate recognition domains 
(CRDs) which bind β-galactosides via this domain (Barondes et al., 1994a). As the galectins lack a signal 
sequence for secretion, any that are secreted must be secreted unconventionally. Galectins can be 
categorised into three groups, shown in Figure 1.5: prototypical galectins, which have one CRD; 
tandem repeat galectins, with two CRDs with different specificities to each other; and the chimeric 
group consisting only of galectin-3, which has one CRD and a large, flexible N-terminal domain (NTD) 
(Yang et al., 2008). Most of the prototypical galectins have been shown to exist as homodimers 
(Rabinovich and Toscano, 2009). Tandem repeat galectins are bivalent by definition, with each galectin 
in this group having two CRDs with different specificities to each other (Leffler et al., 2002; Rabinovich 
et al., 2002). Galectin-3’s NTD confers multivalent properties via self-association (Hsu et al., 1992), 
both via NTD-NTD interactions and NTD-CRD interactions (Lin et al., 2017). This multivalent property 
of galectins allows the formation of galectin-glycan lattices (Rabinovich and Toscano, 2009), which 
regulate T cells and cell signalling pathways (Nabi et al., 2015).  
1.4.1 Functions of galectin-3 
Many galectins have been shown to be located outside of the cell, with galectins 1 and 3 perhaps being 
the best documented due to their well-established functions and their interactions with other 
extracellular proteins (Wang et al., 2004; Yang et al., 2008). The galectins are known to be 
unconventionally secreted, and it is well established that galectin-3 in particular is an unconventionally 
secreted protein (Hughes, 1999; Linstedt et al., 1993; Popa et al., 2018). Outside the cell, galectins are 
involved in cell-cell and cell-matrix interactions via interactions with proteins including laminin and 
fibronectin (Kuwabara et al., 2003). They have highly diverse functions, including in cell adhesion, 
epithelial homeostasis and as chemoattractants in the immune system (Barondes et al., 1994b; 
Henderson and Sethi, 2009; Vasta, 2012, 2009; Viguier et al., 2014). As the specific functions of 
galectins are dependent on both the cell type they are expressed in and on their cellular or extracellular 
localisation, their secretion must by tightly regulated in order for them to function correctly. 
Galectin-3 has a range of functions at a cellular level, especially in inflammation and immunity 
(Henderson and Sethi, 2009), including recognition of host glycans on damaged vesicles to promote 
bacterial autophagy in response to infection (Weng et al., 2018) and regulation of mast cell signalling 
(Bambouskova et al., 2016). Intracellular galectin-3 is able to regulate mast cell signalling both 
positively and negatively (Bambouskova et al., 2016). Recently, the interaction between TRIM16 and 
galectin-3 has been shown to organise autophagy factors in response to lysosomal damage (Chauhan 
et al., 2016; Jia et al., 2020). Outside the cell, galectin-3 binds to β-galactosides in the extracellular 
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matrix, on the cell surface or on the surface of EVs (Nabi et al., 2015; Yang et al., 2008). Here it has 
important roles in cell signalling and cell adhesion (Ochieng et al., 2004). Interestingly, many studies 
have found that galectins have different and sometimes opposing functions inside and outside of the 
cell, particularly for galectin-3 (Kuwabara et al., 2003; Liu et al., 2002; Ochieng et al., 2004; Viguier et 
al., 2014; Yang et al., 2008). For example, galectin-3 is able to induce apoptosis outside the cell, thought 
to be mediated by its interactions with glycans (Fukumori et al., 2003; Rabinovich et al., 2000; Stillman 
et al., 2006). In contrast, galectin-3 inhibits apoptosis inside the cell, likely via protein-protein 
interactions (Kuwabara et al., 2003; Liu et al., 2002; Yang et al., 1996). This highlights the complexity 
of galectin-3’s functions, and the need to understand its secretion to fully understand its role.  
 
Figure 1.5: Types of galectins, and known galectins which are in these categories. Prototypical 
galectins have one CRD and tandem repeat galectins have two. Chimeric galectins have an N-terminal 
domain as well as a CRD; only galectin-3 falls into this category. 
Galectin-3 is a particularly interesting protein as it is implicated as a biomarker for cardiovascular 
disease, kidney disease, cancer and metabolic disease, for both diagnostic and prognostic use. Plasma 
galectin-3 is used as a biomarker for cardiovascular disease, and positively correlates with risk factors 
for cardiovascular disease such as smoking, body mass index (BMI) and age (de Boer et al., 2012). 
Serum levels of galectin-3 are used to predict outcomes in heart failure (Amin et al., 2017; Chen et al., 
2015), and low serum levels of galectin-3 are associated with insulin resistance in type-2 diabetic 
patients (Ohkura et al., 2014). There are many studies on the use of galectin-3 as a biomarker in specific 
situations or patient groups, with some studies demonstrating that galectin-3 has diagnostic or 
predictive value and others finding no difference in galectin-3 levels between test and control groups, 
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but the general consensus appears to be that it is best used in combination with other biomarkers 
(Amin et al., 2017; Dong et al., 2017). Although the correlation between secreted galectin-3 levels and 
disease is clear, it remains unclear whether galectin-3 protects against or promotes disease. 
Additionally, higher levels of galectin-3 have been implicated in asthma, but again it is unclear whether 
galectin-3 protects against or promotes asthma. Extracellular galectin-3 increases the ability of 
macrophages to ingest apoptotic cells, reversing some of the effects of asthma (Erriah et al., 2019), 
whereas cell-associated galectin-3 activates basophils, which may contribute to pathogenesis of 
asthma (Schroeder et al., 2019). A better understanding of the mechanism by which galectin-3 is 
secreted will allow specific targeting of the pathway and therefore a better understanding of these 
diseases. 
1.4.2 Unconventional secretion of galectin-3  
Galectin-3 was first known to be unconventionally secreted in 1993, when its secretion was observed 
from cells treated with brefeldin A (Linstedt et al., 1993; Sato et al., 1993). Secretion takes places from 
cells at a basal level, with different cell types secreting up to 45 % of their total galectin-3 (Hughes, 
1999). It is not clear which pathway galectin-3 uses for secretion, and like other unconventionally 
secreted proteins, it is possible that galectin-3 makes use of more than one pathway for secretion.  
Work to date has suggested that both type I direct translocation and release in extracellular vesicles 
are potential pathways for secretion. It is thought that galectin-3 accumulates on the cytoplasmic side 
of the plasma membrane before being secreted. This has only been clearly demonstrated for another 
member of the galectin family, galectin-1, and has been assumed for galectin-3 (Cooper and Barondes, 
1990; Mehul and Hughes, 1997). This accumulation would be required for either direct translocation 
or release in microvesicles. Evidence for direct translocation is limited. Two studies have found that 
galectin-3 interacts with lipids found in the plasma membrane, using liposomes as a membrane model 
(Lukyanov et al., 2005; Stewart et al., 2018), but these studies differ in their findings as to whether 
galectin-3 can cross liposome membranes.  
The evidence for secretion of galectin-3 in EVs implicates both exosomes and microvesicles, with more 
direct evidence for release in exosomes (Bänfer et al., 2018). Evidence for release in exosomes comes 
from imaging studies with MDCK cells, which showed that galectin-3 is sorted into MVBs, and is 
detected in the lumen of exosomes derived from these cells (Bänfer et al., 2018). Additionally, a 
galectin-3 fusion protein targeted to accumulate at the cytoplasmic side of the plasma membrane was 
shown to be secreted in microvesicles (Mehul and Hughes, 1997). As with other unconventionally 
secreted proteins, stress can increase the secretion of galectin-3. Induction of autophagy has been 
shown to direct galectin-3 to the late endosome and/or lysosomes (Chen et al., 2014). Other work has 
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shown accumulation of galectin-3 in endosomes (Delacour et al., 2005; Schneider et al., 2010). As 
MVBs are a type of late endosome, this may also implicate the exosomal pathway. It is important to 
note that if galectin-3 is released in either microsomes or exosomes, the question of how galectin-3 is 
released into the extracellular space from these vesicles remains unanswered. 
1.4.2.1 Regulation of galectin secretion 
Little is known about the regulation of galectin secretion, and it is unclear whether regulation is 
universal to all galectins as only galectin-3 and galectin-9 have been well-studied in this context. Two 
key regulators of galectin-3 secretion identified are calcium and serum. The calcium ionophore 
A23187, which induces a Ca2+ influx to the cytosol, increases transport of galectin-3 into the 
extracellular space from MDCK cells and from Baby Hamster Kidney (BHK) cells (Linstedt et al., 1993; 
Sato et al., 1993). Serum free media decreases galectin-3 secretion in BHK cells (Sato et al., 1993), while 
the serum protein fetuin can stimulate rapid export of galectin-3 from breast cancer cells (Zhu and 
Ochieng, 2001). Work in the Jurkat T cell line has shown that phorbol 12-myristate 13-acetate (PMA), 
an activator of protein kinase C (PKC), induces both an overall upregulation of galectin-9 mRNA and an 
increase in galectin-9 on the cell surface (Chabot et al., 2002). However, further work is needed to 
clarify the role of PKC here, as a PKC inhibitor appeared to have no effect on galectin-9 secretion into 
the media (Chabot et al., 2002). Additionally, PKC is involved in many signalling pathways in the cell 
and it is unknown which of these pathways would be involved in galectin-9 secretion. Furthermore, 
another study found that PMA treatment of human THP-1 cells induces an increase in galectin-3 mRNA 
and protein levels of galectin-3 both in the medium and in exosomes, but this study attributes the 
change to the role of PMA as an inducer of NADPH activity (Madrigal-Matute et al., 2014). The evidence 
for NADPH as a mediator of galectin release is stronger than for PKC, since apocynin, an inhibitor of 
NADPH, reverses the increase in extracellular levels of galectin-3 (Madrigal-Matute et al., 2014). While 
these studies are in accordance with each other in that they show PMA upregulates galectin release, 
they both lack direct evidence for the underlying mechanism by which this drug mediates this change. 
Another potential regulator of galectin secretion is caspase-1. Both galectin-3 and galectin-1 were 
identified as possibly being regulated by stress-activated caspase-1, alongside annexin A2 and other 
unconventionally secreted proteins. However, regulation of galectin secretion by caspase-1 has not 
been specifically verified (Keller et al., 2008). Stress in general, particularly as a result of infection, is 
implicated in the secretion of other galectins. A number of viral infections are associated with an 
increase in galectin-9 levels in serum and plasma, reviewed by Merani et al (Merani et al., 2015). A 
recent study showed that secretion of galectin-9 increases upon dengue viral infection in human THP-1 
cells, suggested to function as a protective mechanism for cells by limiting viral attachment to surface 
glycans (Dapat et al., 2017). 
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Other regulators of extracellular galectin levels have been identified, but these do not directly affect 
galectin secretion. For example, galectin-3 expression can be modulated by the hormones 
17β-oestradiol, progesterone and human chorionic gonadotropin, which all stimulate translation of 
galectin-3 and lead to increased secretion of galectin-3 from the embryonic cell line BeWo (Yang et al., 
2011). Outside the cell, matrix metalloproteinases (MMPs) cleave galectins, so extracellular levels of 
galectin-3 decrease when MMP2 and MMP9 increase (Ochieng et al., 1994; Yu et al., 2016). Conversely, 
broad-range MMP inhibitors suppress the release of galectin-9 from Jurkat cells, possibly suggesting 
MMPs are needed to release galectin-9 from the cell surface (Chabot et al., 2002). 
Overall, although the extracellular localisation of galectin-3 has been well-established, many questions 
surrounding its unconventional secretion still need to be resolved. There is evidence for secretion via 
direct translocation and using a vesicle-based pathway, but it is unclear how these separate pathways 
relate to each other. Studies into the regulation of secretion often rely on drugs which may have 
multiple effects, so few conclusions on the mechanism for regulation can be confidently drawn. There 
is a clear need for more work to investigate the mechanism and regulation of galectin secretion.  
1.5 Genome-wide screening to identify novel regulators of protein secretion   
There is more to discover about the regulation of both conventional and unconventional secretion. To 
uncover novel factors in protein secretion, unbiased methods must be employed. The most effective 
way to remain unbiased in the search for novel factors involved in protein secretion is to perform a 
genome-wide screen. In particular, silencing or knocking out every gene individually allows the effect 
of each gene to be studied. Genome-wide siRNA screening and CRISPR screening have both been used 
to investigate protein secretion.  
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1.5.1 Pooled screening compared to arrayed screening 
Screening may be performed in a pooled format, in which all genes in the library are studied in the 
same plate, or an arrayed format, in which each gene function is studied in its own well (Figure 1.6). A 
pooled screen can be carried out at a lower cost than an arrayed screen, and without the requirement  
 
Figure 1.6: Pooled screens compared to arrayed screens. In both cases, a selection pressure is applied 
to an unbiased library of cells each with one gene silenced. In a pooled screen, cells with different 
genes silenced are maintained in the same plate or tube. In an arrayed screen, cells with different 
genotypes are separated from each other. 
for automation. Therefore, pooled screens can more easily be performed as genome-wide screens 
than arrayed screens. One commonly employed strategy to retain some of the advantages of both 
screen types is a targeted arrayed screen, in which a subset of genes is studied in an arrayed format. 
While this strategy mitigates some cost, a bias is then introduced, and many potential regulators may 
be missed. Another key advantage to pooled screens is that technical variability is reduced because 
cells are simultaneously infected and analysed in the same plate or tube. Additionally, in a pooled 
format, large complex libraries can more easily be used, in which each gene is targeted with multiple 
sgRNAs, increasing the likelihood that each gene is targeted effectively. However, in pooled screening, 
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cells with different gene knockouts can interact with each other, which cannot happen in arrayed 
screening; as such, arrayed screening has higher sensitivity than pooled screening.  
1.5.2 CRISPR screening compared to siRNA screening  
CRISPR technology has developed as an efficient gene editing method to generate gene knockouts in 
mammalian cells, reliant on two components: Cas9, which acts as molecular scissors to introduce a 
double stranded break in the DNA, and the single guide RNA (sgRNA), which directs Cas9 to the DNA 
sequence to be cut (Cong et al., 2013; Mali et al., 2013). The repair of these double stranded breaks by 
non-homologous end joining results in either an insertion or deletion of DNA, which leads to a 
knockout of gene function if an appropriate region of DNA within a gene is targeted (Komor et al., 
2017). CRISPR-Cas9 efficiencies vary by cell type, but it is able to introduce mutations with rates greater 
than 1 in 2, compared to previously used methods which had efficiencies varying from 1 in 103 to 
1 in 109, as reviewed (Komor et al., 2017). This, combined with the relative ease of designing sgRNA, 
has resulted in its now common use in generating knockout cells. Further developments of CRISPR 
technology by the modification of Cas9 has allowed for other modification to gene function, including 
the introduction of specific mutations, gene activation (CRISPRa) and gene knockdown (CRISPRi) 
(Komor et al., 2017).  
After its initial discovery for editing mammalian cells, CRISPR technology was quickly applied to 
genome-wide screening, and has emerged as a powerful strategy to identify novel gene functions 
(Sanjana, 2017). An overview of the CRISPR screening process is shown in Figure 1.7. RNA interference 
(RNAi) genome wide screening was previously considered the gold-standard method for identification 
of novel gene functions. As both RNAi and CRISPR can be used in genome-wide screening, both are 
unbiased, but CRISPR has the additional advantage of having greater sensitivity compared to RNAi 
screening. A comparison of gene expression changes after shRNA or CRISPR perturbation across 
multiple cell lines found that although on-target effects were comparable, CRISPR introduced 
significantly fewer off-target effects (Smith et al., 2017). Another difference is that CRISPR results in a 
complete gene knockout, while RNAi only causes knockdown of gene expression. This difference can 
be an advantage, and has resulted in the identification of essential genes that were not identified by 
RNAi screening (Sanjana, 2017). Conversely, generation of a knockout can result in lethality; where this 
is an issue, the use of CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) screens would be 
more suitable. Compared to RNAi, CRISPRi produces a more robust knockdown (Boettcher and 




Figure 1.7: Overview of CRISPR screening process. Cells expressing Cas9 are first transduced with a 
library of sgRNAs, resulting in an unbiased library of knockout cells. A phenotype can be selected for 
using a selection pressure, for example by drug treatment or cell sorting. Analysis of the sgRNAs in the 
treated population compared to the unselected library allows for the identification of genes important 
for the phenotype selected for. 
1.5.3 Application of pooled CRISPR screening 
Pooled CRISPR screening is becoming frequently used as an initial screening method for a wide range 
of applications. Examples include the investigation of drug-resistance mechanisms in cancer cells (Le 
Sage et al., 2017), the genetics of pluripotency (Li et al., 2018), autophagy regulators (Moretti et al., 
2018; Morita et al., 2018) and host factors required for viral infection (Zhang et al., 2018). To utilise 
the power of pooled CRISPR screening, there must be a robust method to select the population of 
interest, based on either cell viability or the expression or localisation of a protein that can be 
measured by fluorescence-assisted cell sorting (FACS). Using FACS, the development of pooled CRISPR 
screening provides an opportunity to uncover new information about the regulation of protein 
secretion.  
A problem with pooled CRISPR screens is that it is not clear from the initial output whether few or 
many genes have been identified as hits, and the most significant hits do not necessarily have the 
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strongest phenotype as additional factors may affect the representation of hits in the selected pool, 
such as cell survival and proliferation rates. Therefore, the whole population must be sequenced in 
order to identify hits. However, this downside is mitigated by the fact that pooled CRISPR screens are 
much less expensive than an arrayed CRISPR screen, and can quickly reduce the list of genes of interest 
from genome-wide to a number that can realistically be screened in an arrayed format. To compensate 
for the lack of a direct link between genotype and phenotype, a lenient false discovery rate (FDR) 
should be used in initial analysis and a pipeline of secondary screening can then be used to assess the 
hits with strongest phenotype in the primary screen.  
1.5.4 Application of screening to investigate conventional protein secretion 
In the 1970s and 80s, many components of the conventional secretory pathway were discovered by 
genetic screens in yeast. The Schekman lab identified 23 genes required for secretion in yeast, named 
Sec1-Sec23 (Novick et al., 1981, 1980; Novick and Schekman, 1979). The conventional yeast secretory 
pathway is now well understood, and since the basic secretory machinery is conserved from yeast to 
humans, yeast continues to be used as a model organism; for example, to study human diseases 
related to protein secretion (Delic et al., 2013; Feyder et al., 2015). However, there are several 
differences between yeast and mammalian secretion; for example, the Golgi apparatus in some yeast 
is less organised and yeast do not have the ERGIC (Kurokawa et al., 2014), and there are differences in 
the structure of glycoproteins (Stanley, 2011). As such, recent genetic screens investigating 
conventional protein secretion have been performed in more complex eukaryotes. 
The first siRNA genome-wide screen to investigate protein secretion in metazoan cells was performed 
by Bard et al (Bard et al., 2006). Cells secreting ss-HRP were used to measure conventional protein 
secretion in an arrayed format, and several regulators of secretion were identified, including TANGO1, 
a protein later shown to organise membranes at ERES (Bard et al., 2006; Raote et al., 2018). Simpson 
et al. performed the first genome-wide siRNA screen to investigate secretion in mammalian cells using 
secretion of a transmembrane model protein, tsO45G, in human cells as a phenotypic readout 
(Simpson et al., 2012). Over 500 genes in the secretory pathway were identified; while many of these 
genes were known to be involved in secretion, further analysis of the screen revealed links between 
the early secretory pathway and other cellular processes such as small GTP-binding protein regulation, 
actin cytoskeleton organisation and EGF-mediated signalling (Simpson et al., 2012). Other siRNA 
screens investigating protein secretion have aimed to answer more specific questions and generally 
are not genome-wide, relying instead on a targeted approach. For example, two studies have 
investigated the role of cell signalling pathways in protein secretion in mammalian cells by screening a 
library of kinases and phosphatases. One of these investigated changes in localisation of ERGIC-53, a 
marker for changes in trafficking and morphology of the early secretory pathway, and identified 122 
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factors important for protein secretion (Farhan et al., 2010). The other assessed Golgi organisation, 
using markers of the cis, medial, and trans-Golgi, and found 159 of the 948 cell signalling genes 
screened had an effect on Golgi organisation; 110 of these also affected general secretion (Chia et al., 
2012). Both of these screens identified the mitogen activated protein kinase (MAPK) family as 
regulators of the secretory pathway (Chia et al., 2012; Farhan et al., 2010). These siRNA screens 
investigating protein secretion have both been performed in an arrayed format, but focus on a subset 
of targets, so many potential regulators of secretion may be missed. Recently, genome-wide CRISPR 
screening has been used to investigate protein secretion, and the novel factors TTC17 and CCDC157 
were discovered to be important for protein transport (Bassaganyas et al., 2019). 
1.6 Galectin-3 as a model protein 
Galectin-3 is a convenient protein to study as a model for the unconventional secretion of galectins, 
and possibly of unconventionally secreted proteins more generally. Most importantly, it is already well-
established that galectin-3 is unconventionally secreted (Hughes, 1999; Linstedt et al., 1993; Popa et 
al., 2018). Galectin-3 is expressed in most cells and tissues (Uhlén et al., 2015), and when secreted, it 
is retained at the cell surface, making its secretion easier to study than proteins which are only released 
into the extracellular space. Well-characterised antibodies exist that enable the study of galectin-3 by 
methods such as Western blot and flow cytometry. Additionally, it has been demonstrated that 
galectin-3 fused to GFP still behaves as wild type galectin-3; it is still able to oligomerise (Bänfer et al., 
2018), is recruited to damaged lysosomes (Stewart et al., 2017) and is still secreted (Bänfer et al., 2018; 
Stewart et al., 2017). Many unknown aspects of its secretion remain, so its study will be important in 
determining whether there are shared features of unconventional protein secretion.  
Once outside the cell, galectin-3 binds to β-galactosides resident on the cell surface (Nabi et al., 2015) 
and can therefore be used as an indirect measure of glycoprotein transport to the cell surface via the 
conventional ER-Golgi secretory pathway. Using a binding partner of glycans as a measure of 
glycoprotein secretion rather than one specific glycoprotein allows regulators of general glycoprotein 
secretion to be discovered. It has already been demonstrated that galectin-3 can be used to study cell 
surface glycoproteins in the context of a genome-wide CRISPR screen which showed that regulators of 
glycosylation such as MGAT1 and SLC35A2 are required for cell surface localisation, but not secretion, 
of galectin-3 (Stewart et al., 2017). As galectin-3 is unconventionally secreted but binds to 
conventionally secreted glycoproteins, galectin-3 is a good model protein to investigate both 





The overarching aim of this thesis was to investigate both conventional and unconventional protein 
secretion, using galectin-3 as a model protein. This can be divided into three key objectives, which each 
have their own chapter: 
- To investigate the mechanism of galectin-3 secretion, using hypothesis-driven 
experiments 
- To identify regulators of both conventional and unconventional secretion by monitoring 
galectin-3 on the cell surface in pooled genome-wide CRISPR screens 
- To validate any regulators identified 
Experiments to directly investigate the secretion of galectin-3 were intended to reveal further insights 
into the unconventional mechanism for galectin-3 secretion, detailed in Chapter 3. As an example of 
an unconventionally secreted protein, it is possible that mechanism for galectin-3 secretion could be 
more widely applied to unconventionally secreted proteins.  
Additionally, galectin-3 binds glycoproteins on the cell surface, so studies of its cell surface location 
may reveal novel players in glycoprotein secretion, which represents approximately half of all protein 
secretion. A full understanding of both conventional and unconventional protein secretion is important 
not only on a basic biology level, but also in the context of understanding disease. To investigate both 
unconventional and conventional secretion, the aim was to use a genome-wide CRISPR screen to 
identify novel factors in secretion, described in Chapter 4. The Moreau lab previously demonstrated 
that pooled genome-wide CRISPR screening could effectively reveal key players required for 
glycoprotein secretion, using galectin-3 retention at the cell surface to assess glycoprotein secretion 
(Stewart et al., 2017).  
After this initial screen, secondary screening and further experiments to investigate specific genes 
were then employed to validate genes involved in glycoprotein secretion, detailed in Chapter 5. This 
work successfully validated 51 novel genes involved in glycoprotein secretion; this list of novel genes 
identified will serve as useful resource for other researchers investigating protein secretion. Two hits 
were further investigated: GPR161 and TMEM220, and some additional insights into the mechanism 










This chapter describes the general experimental and statistical methods used throughout this thesis. 
Any methods specific to one of the following chapters (3-5) are described within that chapter. Reagents 




2.1.1 Cell culture 
The human epithelial cervical carcinoma cell line HeLa was used for cell work. HeLa cells, suspension 
HeLa cells (sHeLa), suspension HeLa cells expressing Cas9 (sHeLa-Cas9) and HeLa cells expressing 
horseradish peroxidase fused to a signal sequence (HeLa-ss-HRP) were cultured in complete medium, 
described below (2.1.1.3), in 5 % CO2 at 37 °C. All media was warmed to 37 °C before use and all cell 
work was performed in a microbiological safety cabinet. Cells were passaged at 1/10 to 1/15 three 
times a week, typically at 70-90 % confluency. Adherent cells were cultured in treated dishes and 
plates, while cells in suspension were cultured in non-treated dishes and plates. To passage adherent 
cells, cells were washed with serum free medium, treated with trypsin for 5 min at 37 °C then 
resuspended in complete medium in a new dish. To passage suspension cells, a cell lifter was used to 
detach cells from the surface of the dish. It was important to use sHeLa cells when looking at galectin-3 
on the cell surface of live cells, as adherent HeLa cells would require trypsin to detach from plates; this 
would cleave off glycoproteins, the binding partners of galectin-3 on the cell surface.  
2.1.1.1 Counting cells 
Cells were counted by detaching cells from the plate or dish surface as described above, resuspending 
in complete medium. A 10 µl sample was diluted in 10 µl 0.4 % (w/v) trypan blue, and live and dead 
cells were counted with a haemocytometer. 
2.1.1.2 Storing cells 
For long term storage, cells were stored in liquid nitrogen in CryoTube vials. For each vial, at least 
1 x 106 cells were collected and resuspended in 1 ml freezing medium. Vials were placed in a 
cryofreezer overnight at -80 °C, then transferred to liquid nitrogen. Cells were thawed by warming vials 
at 37 °C, resuspended by gentle pipetting then transferred to 60 mm diameter plate. Plates were kept 
in 5 % CO2 at 37 °C until they reached 80 % confluency (typically 2 days); from then on, cells were 
maintained as described above. 
2.1.1.3 Media recipes 
Complete medium 
High glucose DMEM with 10 % (v/v) FBS, 100 U Penicillin / 0.1 mg ml-1 streptomycin, 2 mM L-glutamine  
Serum free medium 




High glucose DMEM with 10 µg ml-1 blasticidin, 10 % (v/v) FBS, 100 U Penicillin / 0.1 mg ml-1 
streptomycin, 2 mM L-glutamine 
20 % serum-containing medium 
High glucose DMEM with 20 % (v/v) FBS, 100 U Penicillin / 0.1 mg ml-1 streptomycin, 2 mM L-glutamine 
Freezing medium 
High glucose DMEM with 10 % (v/v) FBS, 10 % (v/v) DMSO, 100 U Penicillin / 0.1 mg ml-1 streptomycin, 
2 mM L-glutamine  
2.1.2 Preparation of cDNA 
cDNA was prepared using miniprep and maxiprep kits. Firstly, 45 µl XL-Gold cells were transformed by 
incubation with 2 µl β-mercaptoethanol and 2 µl DNA on ice for 30 min followed by heat shock for 45 s 
at 42 °C and a further 2 min incubation on ice. Transformed cells were added to 500 µl super optimal 
broth with catabolite repression (SOC) media and incubated at 37 °C for 1 h, concentrated to 100 µl, 
plated onto an antibiotic-containing Luria-Bertani (LB) agar plate and grown overnight at 37 °C. One 
colony was picked from the transformation plate into antibiotic-containing LB medium and grown at 
37 °C, 200 rpm overnight. Depending on the amount of DNA required, miniprep or maxiprep kits were 
followed according to manufacturer’s instructions. 
2.1.3 Transient Transfection with cDNA 
HeLa or sHeLa cells at ~50 % confluency were transfected with a mix of complementary DNA (cDNA) 
at 1 µg µl-1 and 0.2 % (v/v) TransIT in OptiMEM. Cells were incubated at 37 °C, 5 % CO2 for 4 h, then 
washed and resuspended in either serum free medium, for Western blotting, or complete medium, for 
other applications, for 20 h. 
2.1.4 siRNA transfection  
HeLa cells at ~50 % confluency were transfected with an siRNA-lipofectamine 2000 mixture in wells of 
a 6 well treated plate. First, lipofectamine was diluted in OptiMEM in a 1:20 ratio. Next, 20 µM siRNA 
was diluted in OptiMEM in a 1:20 ratio. The two tubes were mixed in a 1:1 ratio and incubated for 
20 min at room temperature. Cell culture medium was replaced with OptiMEM, 210 µl siRNA-
lipofectamine 2000 mixture was added dropwise to each well, and cells were incubated at 37 °C, 5 % 
CO2 for 4 h. After incubation, medium was changed to fresh culture medium; cells were then incubated 
for a further 48 h, splitting cells during this time for different treatments if required. 
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2.1.5 Flow cytometry staining 
Approximately 1 x 106 cells were collected and washed with 1 ml DMEM (phenol red free). Each 
population was stained with primary antibody at 4 °C for 30 min. If the primary antibody was 
unconjugated, cells were washed again, then stained with secondary antibody at 4 °C for 1 h. Primary 
and secondary antibodies used, and the concentrations they were used. Primary and secondary 
antibodies, and the concentration they were used at for flow cytometry, are listed below in Table 2.1. 
Cells were washed, resuspended in 500 µl DMEM with one drop of propidium iodide (PI), and 
fluorescence was measured on a FACSCalibur, FACSAccuri C6 Plus or FACSAria. Compensation was 
calculated from singly stained samples using FlowJo. Cells were gated by size and shape (from FSC-A 
vs SSC-A plot) to exclude debris. If cells were sorted, additional gating to exclude doublets was 
performed, from the FCS-A vs FSC-H plot. If stained with PI, live cells (PI negative) were gated for. 
2.1.6 Western blot 
To prepare samples for Western blotting, cells were collected from each well of a 6 well plate and 
centrifuged at 300 xg at 4 °C for 5 min. Supernatant was removed and centrifuged at 10 000 xg at 4 °C 
for 10 min. Cells were lysed on ice in 100 µl 2x lysis buffer for 10 min. Next, all samples were diluted in 
4x sample buffer then boiled at 100 °C for 10 min.  
Each sample was run on 12 % SDS-PAGE in running buffer and transferred onto polyvinylidene fluoride 
(PVDF) membranes. The membranes were blocked with 5 % (w/v) Marvel / 1x PBS-0.1 % Tween 20 for 
30 min then washed with 1x PBS-0.1 % (v/v) Tween 20. Membranes were incubated with primary 
antibody at 4 °C overnight. The membranes were washed three times with 1x PBS-0.1 % Tween 20, 
incubated with secondary antibody for 1 h and again washed three times with 1x PBS-0.1 % Tween 20. 
Primary and secondary antibodies, and the concentration they were used at for Western blotting, are 
listed below in Table 2.1. Next, 1 ml ECL was added to the membrane to develop the reaction and 
images were taken with a Bio-Rad Chemidoc imager.  
2.1.6.1 Buffer recipes 
Running buffer 
1x Tris-glycine, 0.1 % (w/v) SDS 
Transfer buffer 
1x Tris-glycine 
4x sample buffer 
168 mM Tris-HCl, 400 mM DTT, 6.72 % (w/v) SDS, 0.34 % (w/v) bromophenol blue, 33.6 % (v/v) glycerol. 
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2x lysis buffer 
20 mM Tris-HCl, pH 6.8, 137 mM NaCl, 1 mM EDTA, 1 % (v/v) Triton X-100, 10 % (v/v) glycerol. 
2.1.6.2 Western blot analysis 
Where appropriate, bands were quantified using Fiji by defining each lane as a region of interest, 
plotting lanes as histograms, then measuring intensity of peaks using the wand tool. Relative intensity 
was calculated as the ratio of protein of interest to loading control. 
2.1.7 Agarose gel 
1-2 % agarose gels with 1/10000 SybrSafe were run at 80 V for 40 min. Images were taken with a Bio-
Rad Chemidoc. 
2.1.8 Immunofluorescence microscopy 
For immunofluorescence microscopy, cells were cultured on coverslips, fixed with either 4 % (w/v) 
paraformaldehyde in PBS for 5 min and permeabilised with 0.1 % Triton X-100 in PBS for 5 min, or fixed 
and permeabilised with ice cold methanol for 5 min. Cells were then blocked in 10 % (v/v) FBS / 1x PBS 
for 30 min, incubated with primary antibodies for 2 h, washed three times with PBS, and incubated 
with secondary antibodies for 30 min. Primary and secondary antibodies, and the concentration they 
were used at for immunofluorescence, are listed below in Table 2.1. Samples were mounted using 
ProLong Gold antifade reagent with DAPI and observed using a Leica SP8 laser confocal microscope, 
with a 20x objective unless stated otherwise. 
2.1.9 Data analysis 
2.1.9.1 Normalisation 
Equation 2.1 was used to normalise data as appropriate. Generally, it was appropriate to normalise 
data for comparison of data obtained in different conditions; for example, to compare results obtained 
using different plates. 
𝑥 − 𝑥𝑚𝑖𝑛
𝑥𝑚𝑎𝑥 − 𝑥 𝑚𝑖𝑛
 
Equation 2.1: Data normalisation. In most contexts, xmin is the mean background signal, and xmax is the 
mean signal from the positive control. If this is not the case, normalisation formula is specified in that 
chapter.  
2.1.9.2 Statistical tests 
In many circumstances, it was not appropriate to perform statistical tests since the assumption of 
normality could not be met. Many data have a binomial rather than a normal distribution, particularly 
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the data from lentiviral transduction, where cells may either be transduced or not transduced; or 
measurement of cell death, where cell may be alive or dead. As discussed by Greenland et al., statistical 
significance alone does not determine the practical significance of data; moreover, p values are only 
of use when all assumptions of the model are met (Greenland et al., 2016). Additionally, some 
optimisations only used n = 2, so statistical analysis would be inappropriate here. Instead, graphs 
shown indicate the standard error of the mean, a measure of the precision of the sample mean (Altman 
and Bland, 2005). These error bars are used to show an estimate of the true mean, and do not 
represent variability of the sample, which would be shown by standard deviation (Altman and Bland, 
2005; Barde and Barde, 2012). Where appropriate, ANOVA was performed for comparison of more 
than one sample, with a check that the data appeared normally distributed, followed by Tukey’s post-
hoc test in R using the code: 
# perform ANOVA 
anova <- aov(y~x, data = data) 
summary(anova) 
# If significant, check if ANOVA was a valid method. Look for 
normality by looking at graphs 
par(mfrow = c(2,2)) 
plot(anova) 
# If the above tests all look normal, move on to post-hoc testing. 
If they are not normal, do not perform posthoc testing and use 
Kruskal-Wallis instead of ANOVA 
TukeyHSD(anova) 
Where data is the data frame, y is the dependent variable and x is the independent variable. 
2.1.10 Annotation of genes 
The Gene Ontology (GO) Term Mapper was used to classify hits identified into broad categories, using 
the ontology aspect “process” or “component” and ontology category “Generic slim” (GO_Slim) for 
Homo sapiens (GOA @EBI + Ensembl) proteins (Boyle et al., 2004). A gene was defined as related to 
protein transport if it was annotated with any of the GO_Slim annotations: transport (GO:0006810), 
transmembrane transport (GO:0055085) or vesicle-mediated transport (GO:0016192). 
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2.2 Materials 
The source and identifiers of all antibodies, cell lines, lentivirus, plasmids, software, plates, primers, 
siRNA, and other reagents are listed in Table 2.1. Abbreviations used for experiments performed with 
antibodies in this table: FC, flow cytometry; IF, immunofluorescence; WB, western blot; mAb, 
monoclonal antibody; pAb, polyclonal antibody.
Table 2.1: List of reagents and resources 
Reagent or resource Source Identifier 
Antibodies 
Rabbit anti-actin pAb, WB concentration 
0.25 µg ml-1 
Sigma-Aldrich A2066, RRID: AB_476693 
Rabbit anti-calnexin pAb, IF concentration 
5 µg ml-1 
Abcam ab22595, RRID: 
AB_2069006 
Mouse anti-CCT2 mAb, WB concentration 
2 µg ml-1 
Sigma-Aldrich WH0010576M1, RRID: 
AB_1840501 
Rabbit anti-CCT4 pAb, WB concentration 
3.2 µg ml-1 
Merck ABS602, RRID: 
AB_2864324 
Mouse anti-CCT5 mAb, WB dilution 1/500 Sigma-Aldrich WH0022948M1, RRID: 
AB_1840502 
Rabbit anti-CCT7 pAb, WB dilution 1/500 Proteintech 15994-1-AP, RRID: 
AB_2073903 
Rabbit anti-DHFR mAb, WB dilution 
1/10000 
Abcam ab124814, RRID: 
AB_10975115 
Mouse anti-FLAG M2 mAb, IF 
concentration 0.5 µg ml-1 
Sigma-Aldrich F1804, RRID: AB_262044 
 
Table 2.1 – continued from previous page 
38 
 
Reagent or resource Source Identifier 
Mouse anti-FLAG M2-HRP mAb, WB 
concentration 0.25 µg ml-1 
Sigma-Aldrich A8592, RRID: AB_439702 
Rat anti-FLAG-PE mAb, FC concentration 
2 µg ml-1 
BioLegend 637309, RRID: 
AB_2563147 
Rat anti-galectin-3 mAb, WB concentration 
0.25 µg ml-1 
Biolegend 125401, RRID: 
AB_1134237 
Rat anti-galectin-3-647 mAb, FC 
concentration 50 µg ml-1  
BioLegend 125408, RRID: 
AB_1186110 
Mouse anti-GAPDH mAb, WB 
concentration 0.1 µg ml-1 
Santa Cruz sc-32233, RRID: 
AB_627679 
Rabbit anti-GFP pAb, FC dilution 1/100, WB 
dilution 1/1000 
Clontech 632592, RRID: 
AB_2336883 
Mouse anti-GM130 mAb, IF concentration 
25 µg ml-1 
BD Bioscienes 610822, RRID: 
AB_398141 
Rabbit anti-Golgin A5 pAb, IF concentration 
10 µg ml-1 
GeneTex GTX104255, RRID: 
AB_2037117 
Rabbit anti-GPR161 pAb, IF concentration 
10 µg ml-1 
MyBioSource MBS719938, RRID: 
AB_2801289 
Mouse anti-MHC (W6/32) mAb, IF 
concentration 20 µg ml-1, FC concentration 
10 µg ml-1 
ThermoFisher MA1-70111, RRID: 
AB_1076705 
Mouse anti-Sec31 mAb, IF concentration 
25 µg ml-1 
BD Bioscienes 612351, RRID: AB_39971 
Sheep anti-TGN46 pAb, IF concentration 
5 µg ml-1 
BioRad AHP500, RRID: 
AB_324049 
Rabbit anti-TMEM220 pAb, IF 
concentration 100 µg ml-1 
Aviva Systems Biology  ARP44467_ P050, RRID: 
AB_2801328 
 
Table 2.1 – continued from previous page 
39 
 
Reagent or resource Source Identifier 
Goat-anti-mouse-IgG HRP, WB 
concentration 0.2 µg ml-1 
Santa Cruz sc-2005, RRID: 
AB_631736 




7074, RRID: AB_2099233 
Rabbit-anti-rat IgG-HRP, WB concentration 
1 µg ml-1 
Abcam ab6734, RRID: 
AB_955450 
Goat anti-mouse IgG-488 pAb, IF 
concentration 4 µg ml-1 
Life Technologies A11001, RRID: 
AB_2534069 
Goat anti-rabbit IgG-488 pAb, IF 
concentration 4 µg ml-1 
Life Technologies A11008, RRID: 
AB_143165 
Goat anti-rabbit IgG-568 pAb, IF 
concentration 4 µg ml-1 
Life Technologies A11011, RRID: 
AB_143157 
Donkey anti-sheep IgG-568 pAb, IF 
concentration 4 µg ml-1 
Life Technologies A21099, RRID: 
AB_2535753 
Cell lines 
HeLa ATCC CCL-2 
HeLa-ss-HRP Gift from Vivek 
Malhotra 
As described (von Blume 
et al., 2011) 
sHeLa (HeLa S3) Gift from Paul Lehner Sigma-Aldrich, 87110901 
sHeLa-Cas9 In house production, 
Kevin Moreau 
As described (Sanjana et 
al., 2014) 
Lentivirus 
Clover Anna Albecka, 
University of Cambridge 
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Reagent or resource Source Identifier 
Plasmids 
Annexin A2-FLAG Lei Zheng, Johns 
Hopkins University 
School of Medicine 
As described (Zheng et 
al., 2011) 
Annexin A2-DHFR-3xFLAG pcDNA 3.1 (+) GeneArt, designed by 
Kevin Moreau 
Sequence of insert 
shown in Appendix Bi 
Galectin-3-DHFR-3xFLAG pcDNA3.1 (+) GeneArt, designed by 
Kevin Moreau 
Sequence of insert 
shown in Appendix Bii 
FLAG-BRS3 pcDNA plasmid Jacek Mokrosiński, 
University of Cambridge 
FLAG tag added to 
NP_001718 
FLAG-Gal-3-DHFR pcDNA3.1 (+) Constructed as 
described in chapter 3 
Sequence of insert 
shown in Appendix Biii 
FLAG-Gal3 pcDNA3.1 (+) Constructed as 
described in chapter 3 
Sequence of insert 
shown in Appendix Biv 
WT GFP-galectin-3 (pEGFP-hGal3) Tamotsu Yoshimori, 
Addgene 
Plasmid # 73080, 
RRID:Addgene_7308073
080 
R186S GFP-galectin-3 Constructed as 
described in chapter 3 
Sequence of insert 
shown in Appendix Bv 
GFP (pEGFP-C1) Clontech #6084-1, GenBank 
Accession: U55763 
Mouse-FAM98B-FLAG Insight Biotechnology 
LTD 
MR206836 
Mouse-FAM102B-FLAG Insight Biotechnology 
LTD 
MR212923 
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Reagent or resource Source Identifier 
Mouse-MXRA7-FLAG Insight Biotechnology 
LTD 
MR218215 








Drosophila RNAi Screening Centre 








downloaded 25th May 
2018 
FlowJo www.flowjo.com Version 10.6.1 
GO term mapper https://go.princeton.ed
u/cgi-
bin/GOTermMapper  
Accessed 7th Jan 2019 




Mol* https://molstar.org/ Accessed 8th July 2020 
MaGECK https://sourceforge.net






Table 2.1 – continued from previous page 
42 
 
Reagent or resource Source Identifier 
R https://www.r-
project.org/ 
Version 3.5.1  
Plates and cell culture resources 
96 well CulturPlate, black PerkinElmer 6005660 
96 well CulturPlate, white PerkinElmer 6005680 
96 well ViewPlate PerkinElmer  6005182 
Non-treated dish Corning CLS430167 
Non-treated plates Corning CLS3736 
Treated dish Corning CLS430166 
Treated plates Corning CLS3506 
C-Chip haemocytometer Labtech DHC-N01 
Nunc CryoTubes Merck V7884 
Cryofreezer, Mr Frosty Sigma Alrich C1562 
Primers and siRNA 








R186S F Sigma-Aldrich 5' TGGGGAAGGGAAG 
AAAGTCAGTCGGTTTTC 3' 
R186S R Sigma-Aldrich 5' GAAAACCGACTGAC 
TTTCTTCCCTTCCCCA 3' 
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Reagent or resource Source Identifier 
siGenome smart pool plate Dharmacon Identifiers deposited in 
Apollo repository, see 
Appendix Aii 
Reagents 
Agarose Invitrogen 16500-500 
Aminopterin Sigma-Aldrich A1784 
AMPure XP magnetic beads Beckman Coulter A63880 
100 bp ladder New England Biolabs N3231L 
β-mercaptoethanol Agilent 200315 
Ampicillin Merck A5354 
Blasticidin Invitrogen R210-01 
Bromophenol blue Sigma-Aldrich B0126 
Dithiothreitol (DTT) Sigma-Aldrich 10708984001 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 276855 
dNTP ThermoFisher R0191 
ECL Western Blotting Detection Reagent  Amersham RPN2106 
Elution buffer (EB, 10 mM Tris-Cl, pH 8.5) Qiagen 19086 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich E6758 
ExTaq polymerase and buffer Takara RR001B 
Fetal bovine serum (FBS) ThermoFisher 10270-106 
Gentra Puregene Cell kit Qiagen 158388 
Gibson assembly kit New England Biolabs E5510S 
Glycerol Sigma-Aldrich G5516 
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Reagent or resource Source Identifier 
High glucose Dulbecco’s Modified Eagle 
Medium (DMEM) 
Molecular Probes D6546 
Kanamycin Sigma-Aldrich K0254 
L-glutamine Sigma-Aldrich G7513 
LB agar plates with 1/1000 dilution of 
antibiotic 
Cambridge Institute of 
Medical Research 
In house production 
LB medium Cambridge Institute of 
Medical Research 
In house production 
Lipofectamine 2000 ThermoFisher 12566014 
Maxiprep kit ThermoFisher K210017 
Methanol Sigma-Aldrich MX0482 
Miniprep kit ThermoFisher K210002 
NaCl Sigma-Aldrich S7653 
OptiMEM Gibco 31985062 
Paraformaldehyde Sigma-Aldrich 158127 
Penicillin/streptomycin Sigma-Aldrich P0781 
Phenol red free Dulbecco’s Modified Eagle 
Medium (DMEM) 
ThermoFisher 21063-029 
Phosphate buffered saline (PBS) ThermoFisher D8537 
Polybrene Merck TR-1003-G 
Pre-stained protein ladder, 10-180 kDa Abcam ab116027 
ProLong Gold with DAPI ThermoFisher P36935 
Propidium iodide (PI) Biolegend 421301 
Puromycin Sigma-Aldrich  P8833 
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Reagent or resource 
Source Identifier 
PVDF membrane Merck Millipore IPVH00010 
QuikChange Lightning SDM kit Agilent 210518 
SOC medium New England Biolabs B9020S 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich L6026 
SybrSafe ThermoFisher S33102 
TransIT 2020 Mirus MIR 5405 
Tris-glycine National Diagnostics EC-870 
Tris-HCl Sigma-Aldrich T5941 
Triton X-100 Sigma-Aldrich 648463 
Trypsin Merck T3924 
Trypan blue Gibco 15250061 
Tween 20 Sigma-Aldrich P1379 
Westar XLS100 Cyanagen XLS100 








Chapter 3: Investigation into 




Although galectin-3 is known to be unconventionally secreted, the specific pathway by which 
galectin-3 is secreted is not understood. On a basic cell biology level, galectin-3 can act as a model 
protein for further understanding the underlying mechanisms of unconventional protein secretion. In 
this chapter, the requirements for galectin-3 secretion were investigated by modifying galectin-3 in 
two ways. Firstly, by mutation of the galectin-3 carbohydrate recognition domain (CRD) to investigate 
whether glycan binding is required for galectin-3 secretion. Secondly, by generation of a 
galectin-3-dihydrofolate reductase (DHFR) fusion protein, which can be used to assess whether 
galectin-3 needs to unfold in order to be secreted. Here, it was found that glycans are not required for 
galectin-3 secretion, and that galectin-3 does not need to unfold to be secreted. Putting this into the 
context of what is known about other unconventionally secreted proteins will help to build evidence 
as to whether there is a common pathway for unconventional secretion, or if different proteins use 






3.1.1 Mechanism of galectin-3 secretion 
Galectin-3 is well-known to be unconventionally secreted, but the mechanism for its export is not well 
understood (Popa et al., 2018). Once outside the cell, galectin-3 binds to β-galactosides resident on 
the cell surface (Nabi et al., 2015). Like other unconventionally secreted proteins, it is possible that 
galectins are able to make use of more than one pathway (Hönig et al., 2015). Work on the mechanism 
has pointed to different routes for secretion; specifically, type I direct translocation, and release in 
extracellular vesicles. It could also be that galectin-3 is secreted by different pathways in response to 
different signals, as suggested by Barondes et al. (Barondes et al., 1994b). Work with mutated forms 
of galectin-3 also suggests that oligomerisation may be required for galectin-3 secretion. 
3.1.1.1 Direct translocation 
Direct evidence for galectin-3 using type I direct translocation as a mechanism for secretion is limited. 
While it is assumed that galectin-3 accumulates at the plasma membrane, in itself this does not 
exclusively implicate direct translocation as a mechanism, as release in microvesicles budding from the 
plasma membrane would also involve this step. 
Galectin-3 has been shown to interact with lipids found in the plasma membrane and has been 
proposed to spontaneously move across the lipid bilayer, pointing to type I unfacilitated direct 
translocation as a pathway. The interaction between galectin-3 and phospholipids has been 
demonstrated in liposomes (Lukyanov et al., 2005; Stewart et al., 2018). Whether galectin-3 
spontaneously moves across the lipid bilayer is less clear. Lukyanov et al. used a fluorescence-based 
assay to measure galectin-3 in liposomes and found that fluorescence increased when asialofetuin, a 
glycoprotein binding partner of galectin-3, was inside liposomes, compared to no asialofetuin 
(Lukyanov et al., 2005). This study also looked at galectin-3 export from liposomes and live cells, but 
exogenous galectin-3 was used here and it was not conclusively demonstrated that galectin-3 had 
entered the cells or liposomes, rather than simply bound to their surface, before export was measured 
(Lukyanov et al., 2005). In contrast, Stewart et al. found that galectin-3 is able to bind to but not insert 
into the membrane of liposomes, assessed by a protease protection assay (Stewart et al., 2018). It 
would be surprising if galectin-3 is able to cross the membrane with no additional machinery, as other 
unconventionally secreted proteins require some minimal machinery for membrane translocation, as 
demonstrated in liposomes for FGF-2 (Steringer et al., 2017). 
It has previously been suggested that FGF-2, one of the most well-described unconventionally secreted 
proteins, may represent a more widely applicable route for secretion. One key aspect of FGF-2 




translocated in one direction, from inside to outside cells (Steringer et al., 2017; Zehe et al., 2006). If 
FGF-2 and galectins are exported from cells in the same way, it could be that glycans on the cell surface 
act in a similar way. However, the Moreau lab has shown that galectin-3 can be exported from cells 
when glycosylated proteins are not available; galectin-3 was detected only in the cell supernatant as it 
has no binding partners on the cell surface (Stewart et al., 2017). Additionally, FGF-2 is inserted into 
the membrane for secretion, but it has been demonstrated that galectin-3 is not inserted into the 
membrane of liposomes (Stewart et al., 2018). 
3.1.1.2 Release in extracellular vesicles 
There is evidence for the release of galectin-3 from cells in EVs, either being released in microvesicles 
formed from membrane blebbing, or from exosomes that originate from MVBs. Overall, these routes 
are not well defined, with the question of how galectins are released from these vesicles into the 
extracellular space remaining unanswered. Often, the picture is unclear as researchers studying EVs in 
the past have referred to galectin-3 “in” vesicles, but have not actually determined whether galectin-3 
is inside or on the surface of these vesicles (Thery et al., 2001). Additionally, it is not clear how 
galectin-3 would be released from EVs into the extracellular space in order to function there. 
Secretion in microvesicles has been demonstrated for a galectin-3 chimera protein: a fusion of 
galectin-3 and a lymphocyte-specific protein tyrosine kinase (Lck) segment, expressed in cos-7 cells 
(Mehul and Hughes, 1997). The Lck segment directs Lck, or in this case the chimera, to the cytoplasmic 
side of the plasma membrane. Alone, the Lck segment increases traffic to the membrane but does not 
affect secretion, demonstrated by the fact that the segment fused to the CRD of galectin-3 was not 
secreted (Mehul and Hughes, 1997). This is also in accordance with the finding that deletion of the first 
twelve residues of galectin-3’s NTD blocks galectin-3 export into the cell supernatant (Gong et al., 
1999); the galectin-3 chimera protein was also not secreted without galectin-3’s NTD (Mehul and 
Hughes, 1997). There is also evidence that galectin-1 is released in microvesicles from cultured mouse 
muscle cells (Cooper and Barondes, 1990); since it is likely that the galectins are secreted by a common 
pathway, this strengthens the evidence for galectin-3 release in microvesicles. Although together this 
is good evidence for release of galectin-3 in microvesicles, this model relies on the assumption that 
endogenous galectin-3 is able to accumulate under the plasma membrane. Again, it is not clear how 
galectin-3 would be transferred from inside microvesicles to the cell surface.  
On the cell surface, galectin-3 forms clusters with glycosphingolipids and glycosylated proteins, which 
causes mechanical strain that leads to formation of clathrin-independent carriers inside cells 
(Lakshminarayan et al., 2014). As these vesicles form in the opposite direction to microvesicles, this is 




able to induce membrane bending. Adding to this, other work has shown that a mechanical stimulus, 
of either scraping or trypsinisation to suspend cells, induces galectin-3 secretion; here it was suggested, 
although not demonstrated, that a mechanical stimulus might induce secretion in microvesicles 
(Baptiste et al., 2007). It is possible that this mechanism invoked by mechanical strain to form internal 
vesicles could also work in the opposite direction and lead to microvesicle formation. Again, galectin-3 
would need to accumulate underneath the plasma membrane for this to take place, which has not 
been demonstrated for endogenous galectin-3. Interestingly, more recent work found that galectin-3 
was present in the lumen of exosomes derived from MDCK cells, but not in microvesicles (Bänfer et 
al., 2018). This study used super resolution microscopy to visualise sorting of galectin-3 into MVBs, and 
found that recruitment of galectin-3 into exosomes was dependent on a direct interaction with Tsg101, 
a component of ESCRT-I (Bänfer et al., 2018). This difference could be evidence for different cell types 
using different routes for secretion.  
Additional work supports a model of release either via exosomes or via lysosomes, although this may 
exclusively be as part of a stress response. The induction of autophagy by cell penetrating peptide 
(CPP) recruits galectin-3 to the late endosome and/or lysosomes in HEK293 cells, although it was not 
determined whether galectin-3 was inside or on the surface of these vesicles (Chen et al., 2014). In 
other studies, galectin-3 was shown to accumulate inside endosomes (Schneider et al., 2010). It is not 
clear how galectins get into these vesicles, but potential routes are via internalisation from the plasma 
membrane or by crossing the endosome membrane, possibly via damaged vesicles. Galectin-3 
functions as a sensor of lysosomal damage (Papadopoulos and Meyer, 2017); it localises to damaged 
lysosomes and remains there for several hours, regardless of whether the cell dies or recovers (Aits et 
al., 2015). If these damaged lysosomes do represent part of a secretion pathway, only lysosomes that 
recover from damage could be involved in secretion. Regardless of how galectins enter lysosomes or 
endosomes, this pathway cannot represent a universal route for secretion as galectins are secreted 
from cells at a basal level, but it may be important for secretion induced by cellular stress.  
Overall, it remains unclear in which contexts these different pathways are used; for example, if 
different cell types or different conditions lead to release by either direct translocation or by EVs.  
3.1.2 Oligomerisation of galectin-3 may be required for secretion 
It has been reported that deletion of the first twelve residues of galectin-3’s NTD blocks the export of 
galectin-3 into the cell supernatant (Gong et al., 1999). The fact that the NTD is required for secretion 
is surprising given that all members of the galectin family known to be secreted use an unconventional 
pathway, yet the extended NTD is unique to galectin-3. Delacour et al. propose that it is not the NTD 




responsible for oligomerisation of galectin-3 (Delacour et al., 2009). Alternatively, as this study only 
looked at galectin-3 in the supernatant (Gong et al., 1999), it is possible that galectin-3 with a truncated 
NTD is in fact secreted but remains tightly bound to the cell surface. This is unlikely, as the NTD acts to 
increase binding affinity to galactomannans, and would be expected to increase avidity to galectin-3 
ligands (Miller et al., 2015). However, whether galectin-3 with a truncated NTD is present on the cell 
surface needs to be determined given that the mechanism by which the NTD alters galectin-3’s binding 
functions is unknown (Miller et al., 2015).  
If oligomerisation is required for secretion, this would not be a complete mechanism in itself but an 
important contributor to a pathway. Oligomerisation of galectin-3 may be a factor in direct 
translocation, similar to the requirement of oligomerisation of FGF-2 for direct translocation (Müller 
et al., 2015). In general, oligomerisation of proteins is also known to increase packaging into EVs (Shen 
et al., 2011), so galectin-3 oligomerisation may also contribute to this pathway. 
3.1.3 Aims 
To investigate the unconventional secretion of galectin-3, two specific questions were addressed. The 
first was whether glycans act as a tether to ensure one-directional transport across a membrane, in 
the same way that the unconventionally secreted protein FGF-2 uses heparan sulfate (Zehe et al., 
2006). The introduction of an R186S point mutation in the CRD abolishes binding to all but one of 179 
potential galectin-binding glycans (Salomonsson et al., 2010). This mutant has previously been used in 
work on endocytosis of galectin-3, which has shown that exogenous galectin-3 is endocytosed by 
epithelial cells, but that the R186S mutant is not endocytosed (Schneider et al., 2010). Other work has 
also demonstrated that the CRD of galectin-3 is required for endocytosis in epithelial cells, by 
exogenous addition of truncated forms of galectin-3 (Gao et al., 2012). For endocytosis of galectin-3, 
it is not possible to separate whether glycans are required for binding to the plasma membrane or for 
crossing it. As endocytosis and secretion are different processes, the question of whether glycans are 
required for secretion remains unanswered. In this chapter, the mutation was introduced and 
secretion was assessed by looking at galectin-3 levels on the cell surface and in the supernatant. If the 
R186S mutant is able to be secreted, this would imply that galectin-3 does not require glycan binding 
to cross the membrane.  
As all pathways to the cell surface require crossing a membrane, the second key question to answer 
was whether galectin-3 remains fully folded during its secretion, or whether post-translational 
unfolding and refolding is required. To address this question, dihydrofolate reductase (DHFR) fused to 
galectin-3 was used as a tool. Endogenous DHFR catalyses the reduction of dihydrofolate to 




synthesis, so inhibition of DHFR inhibits DNA synthesis and ultimately leads to cell death. As such, DHFR 
has been studied as a target for treatment of cancer and infection, which has resulted in the 
development of drugs such as methotrexate (Chen et al., 1984; Raimondi et al., 2019). When in 
complex with the drug methotrexate or aminopterin (a methotrexate analogue) DHFR becomes tightly 
folded (Rajagopalan et al., 2002). If the galectin-3-DHFR construct is still secreted when cells are 
treated with aminopterin, this would demonstrate that the construct does not unfold during 
translocation across a membrane, suggesting that galectin-3 alone does not unfold. These methods 
have been used previously to assess protein unfolding during unconventional secretion as well as 
transport across the mitochondrial membrane. For example, aminopterin has been shown to impair 
secretion of IL-1β-DHFR (Zhang et al., 2015). On the other hand, FGF-2, FGF-1 and S100A13 do not 
require unfolding to be secreted (Backhaus et al., 2004; Graziani et al., 2009). 
3.2. Methods 
3.2.1 Assessment of glycan binding requirement 
To assess whether glycan binding was required for secretion, a galectin-3 mutant that did not bind to 
glycans was used. GFP was fused to galectin-3, in order to be able to measure the construct inside cells, 
on the surface of cells, and in the supernatant.  
3.2.1.1 R186S GFP-galectin-3 construction 
To inhibit galectin-3 binding to glycans, an arginine 186 to serine (R186S) point mutation was 
introduced to the wild type GFP-galectin-3 plasmid, pEGFP-hGal3, using a QuikChange lightning kit, 
following manufacturer’s instructions. The position of R186 is highlighted in pink in Figure 3.1. Primers 
used to introduce the mutation are shown in Table 3.1. Secretion of wild type (WT) and R186S mutant 
protein constructs were assessed by Western blot and flow cytometry, as described in Chapter 2. GFP 





Figure 3.1: Structure of the WT CRD of galectin-3 in complex with beta-D-galactose. Figure generated 
using Mol* (Sehnal et al., 2018) from the crystal structure produced by Collins et al with PDB reference 
2MNM (Collins et al., 2007). Galactose and amino acid side chains in the carbohydrate binding site are 
represented as a ball and stick model, with the rest of the CRD represented as a ribbon. R186 is 
highlighted in pink.  
Table 3.1: Sequence of primers used in QuikChange lightning kit to introduce R186S mutation to 
pEGFP-hGal3. 
Primer Sequence 
Molecular weight  
(g mol-1) 
R186S F 5' TGGGGAAGGGAAGAAAGTCAGTCGGTTTTC 3' 9391 
R186S R 5' GAAAACCGACTGACTTTCTTCCCTTCCCCA 3' 9022 
3.2.1.2 Assessment of Western blot 
To calculate specific secretion of R186S GFP-galectin-3, bands were quantified as described in 
Chapter 2, and Equation 3.1 was used to compare the amount of WT and R186S construct in the 
supernatant. 
     
R186S GFP-galectin-3 construct intensity
WT GFP-galectin-3 construct intensity
     
R186S GFP-galectin-3 control intensity
WT GFP-galectin-3 control intensity
 




3.2.2 Unfolding assay 
To test whether galectin-3 needs to unfold to be secreted, a galectin-3-DHFR fusion protein was 
constructed and used to transiently transfect cells. Cells were treated with aminopterin to assess 
whether unfolding of the construct was required, as aminopterin leads to tight folding of the DHFR 
part of the construct.   
3.2.2.1 FLAG-Galectin-3-DHFR cloning and transfection 
A galectin-3-DHFR-3xFLAG plasmid (GeneArt) was initially used to transiently transfect cells, shown in 
Figure 3.2. Transfection was assessed by Western blot and by flow cytometry.  
 
Figure 3.2: Plasmid map of Galectin-3-DHFR-3xFLAG  
A new galectin-3-DHFR construct, FLAG-galectin-3-DHFR, was designed as the original galectin-3-DHFR-
3xFLAG construct could not be detected on the cell surface, despite transfecting cells (described in 
3.3.3.1). FLAG-galectin-3 was also constructed by site-directed mutagenesis of the FLAG-galectin-3-
DHFR construct to insert a stop codon after galectin-3, to be used as a control. These plasmids were 
assembled by Gibson assembly according to manufacturer’s instructions. Galectin-3 and DHFR were 
amplified from the existing galectin-3-DHFR-3xFLAG plasmid, and the plasmid backbone and FLAG tag 
was amplified from a FLAG-BRS3 pcDNA plasmid. Flexible linkers were added: GGGGSG between FLAG 
and galectin-3, and GGGGSGGGGS between galectin-3 and DHFR. Plasmid maps are shown in Figure 
3.3. Transfection with FLAG-galectin-3-DHFR was assessed by Western blot and flow cytometry, using 





Figure 3.3: Plasmid maps of FLAG-Gal3 and FLAG-Gal3-DHFR. The sequence of FLAG-Gal3 is the same 
as for FLAG-Gal3-DHFR, but with a stop codon after galectin-3. 
3.2.2.3 Aminopterin treatment 
Cells were transfected with these plasmids as described in Chapter 2 (2.1.3). 1 ml 0–50 µM aminopterin 
was added at 37 °C for 6 h. To test that these concentrations of aminopterin affect folding of DHFR, a 
native PAGE and Western blot was used. For the native PAGE, a 12 % PAGE gel was prepared at which 
both stacking and resolving gel had a pH 8.8. The gel was run at 100 V, 300 mA for 3 h at 4 °C to avoid 
denaturing proteins. Galectin-3 localisation on the cell surface was assessed by flow cytometry and 
localisation in the supernatant was assessed by Western blot, both described in Chapter 2. 
3.3 Results 
3.3.1 Glycan binding was not required for galectin-3 secretion 
To establish whether glycan binding was required for galectin-3 secretion, a single point mutation 
(R186S) was introduced in the CRD of GFP-galectin-3. To avoid using trypsin on adherent cells, 
suspension Hela cells (sHeLa) were transfected with wild type GFP-galectin-3 and R186S GFP-galectin-3 
and their secretion was assessed. Wild type and R186S GFP-galectin-3 were both successfully 
expressed in sHeLa cells, and the transfection efficiency was similar by western blot and flow cytometry 
(Figure 3.4A and C). Following a 24 h incubation in serum free medium, wild type GFP-galectin-3 was 
detected on the cell surface, but the R186S mutant was not (Figure 3.4B). However, both WT and R186S 
GFP-galectin-3 were detected in the medium by Western blot (Figure 3.4C). This demonstrated that 
neither the addition of GFP, nor the point mutation R186S, decreased galectin-3 secretion. 
Transfection of GFP alone was used as a control in the Western blot; as expected, GFP was only faintly 




the small amount of GFP in the supernatant indicated that the galectin-3 detected was not released 
due to cell death during the assay (Figure 3.4C). More of the R186S mutant was detected in the 
supernatant than WT GFP-galectin-3, which may in part be attributed to cell lysis, as actin in the 
supernatant also increased (Figure 3.4C). However, quantification of these bands shows that the ratio 
of R186S GFP-galectin-3:WT GFP-galectin-3 in the supernatant was consistently 1.5x more than the 
actin band in the supernatant from those cells. This suggests that although there was some additional 
cell lysis when cells were transfected with R186S GFP-galectin-3 compared to WT, this does not fully 
explain the result. It is likely that the additional R186S GFP-galectin-3 detected in the supernatant was 






Figure 3.4: Glycan binding was required for cell surface binding but not for secretion. 
(A) Representative histogram and percentage of cells in GFP+ gate for WT and R186S cells, showing 
transfection rate, n = 2. (B) Representative histogram shows that WT GFP-galectin-3 is present on the 
cell surface, but R186S mutant is not, n = 2. (C) (i) Representative Western blot of cell lysates and 
supernatants from cells transfected with constructs labelled, n = 3. Exposure times, antibodies used 
and molecular weight in kDa indicated. Actin is used here as a loading control. Both WT and R186S 
GFP-galectin-3 is detected in the supernatant as well as the cell lysate of transfected sHeLa cells. 
(ii) Quantification of bands detected in the supernatant for R186S GFP-Galectin-3 construct:WT 
GFP-galectin-3 construct, compared to control (actin) bands detected in the supernatant for R186S 




3.3.2 Secreted WT galectin-3 was able to bind to untransfected cells 
GFP-galectin-3 was only present on the cell surface when cells were transfected with WT 
GFP-galectin-3 and not R186S GFP-galectin-3 (Figure 3.4B, Figure 3.5A), as expected due to disruption 
of carbohydrate recognition and binding (Salomonsson et al., 2010). Interestingly, although only 
40-50 % of cells were transfected with WT GFP-galectin-3, approximately 90 % had GFP on the cell 
surface (Figure 3.5A). As GFP fluorescence was detected for 40-50 %, not 90 % of cells, this suggested 
that secreted GFP-galectin-3 was able to bind to other untransfected cells. Since the proportion of the 
galectin-3 on the cell surface is small compared to the total galectin-3 expressed, this might explain 
why the GFP signal is still comparable to the untransfected levels in cells with GFP-galectin-3 on the 
cell surface only. To further assess WT and R186S GFP-galectin-3 on the surface of untransfected cells, 
transfected cells were sorted based on their GFP fluorescence, to separate transfected cells from 
untransfected cells. After sorting, GFP levels were assessed by Western blot. As expected, cells that 
were sorted as GFP positive had high levels of GFP-galectin-3 in the cell lysate (Figure 3.5B). 
Additionally, a faint band could be seen in GFP negative population from the pool transfected with WT 
GFP-galectin-3, but not the R186S mutant (Figure 3.5B). It is important to note that any band visible by 
Western blot in the GFP negative sorted population would be expected to be much fainter than the 
GFP positive sorted population, since this would only be measuring GFP-galectin-3 on the cell surface 
and there would be no intracellular GFP-galectin-3. This result indicated that free GFP-galectin-3 in the 
media bound to untransfected cells, but the R186S mutant did not. This supported the idea that WT 





Figure 3.5: Secreted WT GFP-galectin-3 was transferred to untransfected cells. (A) Dot plot showing 
transfection rate, by GFP fluorescence, compared to cell surface GFP-galectin-3 levels, by anti-GFP 
antibody fluorescence, for WT and R186S GFP-galectin-3. (B) Western blot of cells sorted based on GFP 
fluorescence. The same blot is shown with different exposure times. Supernatant samples were 
collected before sorting. A faint band can be seen in the GFP negative population for cells transfected 
with WT GFP-galectin-3 but not in the R186S mutant transfected cells. Approximate cell numbers 





3.3.3 Optimisation of a galectin-3-DHFR construct to probe the folded state of galectin-3 during 
secretion 
3.3.3.1 Galectin-3-DHFR-3xFLAG could not be detected on the cell surface 
To determine whether galectin-3 could be secreted while fully folded, a galectin-3-DHFR-3xFLAG 
plasmid was used to transfect cells, and levels of the construct were measured in the cell lysate and 
supernatant. A schematic of the insert is shown in Figure 3.6A. The galectin-3-DHFR-3xFLAG construct 
was expressed in sHeLa and detected both in cells and the supernatant 24 h post transfection (Figure 
3.6B). However, it was not detected on the cell surface in either live or fixed and permeabilised cells 
(Figure 3.6C). Annexin-A2 FLAG and annexin-A2-DHFR-3xFLAG were used here as controls. Annexin-A2-
FLAG was detected by flow cytometry, indicating that the antibody is able to detect the FLAG tag in 
this assay, but annexin-A2-DHFR-3xFLAG was not detected (Figure 3.6C). Usually, annexin A2 is tightly 
bound to the cell surface in a Ca2+-dependent manner, and is only released from the cell surface by 
EDTA treatment. Annexin-A2-FLAG was not detected in the supernatant by Western blot (Figure 3.6B), 
showing normal annexin binding. However, annexin-A2-DHFR-3xFLAG was detected in the 
supernatant, suggesting that the addition of DHFR prevented annexin A2 from binding to the cell 
surface. Similarly, galectin-3-DHFR-3xFLAG was also detected in the supernatant by Western blot ( 
Figure 3.6B). 
The fact that both galectin-3-DHFR-3xFLAG and annexin-A2-DHFR-3xFLAG were both secreted but not 
detected on the cell surface suggested that the addition of DHFR-3xFLAG prevented the target protein 
from binding to the cell surface. As galectin-3 binds to glycans via its CRD at the C-terminus, it is likely 
that DHFR either occluded the CRD or that fusion to DHFR led to galectin-3 misfolding. An alternative 
explanation is that in the two constructs, DHFR occluded the FLAG epitope; in this case, the constructs 
would bind to the cell surface but would not be detected by an anti-FLAG antibody. However, this 
explanation does not account for why annexin-A2-DHFR-FLAG was detected in the supernatant by 




Figure 3.6: The galectin-3-DHFR-3xFLAG construct was not detected on the surface of sHeLa cells, 
but is present in the supernatant. (A) Schematic of the galectin-3-DHFR-3xFLAG, annexin-A2-DHFR-
FLAG and annexin-A2-FLAG plasmid inserts. (B) Western blot of cell lysate and supernatant samples 
from transfected cells shows that galectin-3-DHFR-3xFLAG both transfects cells at a similar level to 
annexin-A2-FLAG, and is secreted into the supernatant. Actin was used as a loading control. 




construct in (i) live and (ii) fixed and permeabilised cells. Where shown, error bars are standard error 
of the mean. Grey, untransfected cells; purple, annexin-A2-FLAG; blue, annexin-A2-DHFR-FLAG; red, 
galectin-3-DHFR-3xFLAG.  
3.3.3.2 FLAG-galectin-3-DHFR was detected on the cell surface and in the supernatant 
Two possible explanations for not detecting the galectin-3-DHFR-3xFLAG construct on the cell surface 
initially were that the addition of DHFR-3xFLAG to the CRD of galectin-3 stopped galectin-3 from 
binding to glycans on the cell surface, or that DHFR occluded the FLAG epitope so that the antibody 
could not access it. To address these possibilities, the FLAG tag was moved to the more flexible 
N-terminus of galectin-3, to allow for better access to the epitope. The new construct also included a 
flexible linker between galectin-3 and DHFR to improve accessibility to the glycan binding site. The 
annexin-FLAG construct, which was previously detected at the cell surface, also differed from the 
galectin-3-DHFR-3xFLAG constructs in that annexin-A2-FLAG used a 1xFLAG tag whereas the DHFR 
constructs included a 3xFLAG tag. As some anti-FLAG antibodies can have different affinities for 1xFLAG 
compared to 3xFLAG, the redesigned construct also used a 1xFLAG. A control construct, FLAG-
galectin-3, was also made, to confirm that the addition of DHFR does not affect the secretion of FLAG-
galectin-3. A schematic of these inserts is shown in Figure 3.7A. 
The redesigned FLAG-galectin-3-DHFR construct was expressed in sHeLa cells and detected in the 
supernatant, as was found for the first construct, indicating that the new construct could be secreted 
(Figure 3.7B). The control construct, FLAG-galectin-3, also was expressed in sHeLa cells, but surprisingly 
was not detected in the supernatant (Figure 3.7B). However, later results using a higher sensitivity 
detection reagent showed FLAG-galectin-3 in the supernatant (Figure 3.8C). Annexin A2-FLAG was also 
detected in the lysate and on the cell surface but not in the supernatant, as expected without EDTA 
treatment to release annexin A2 from the cell surface. By flow cytometry, both FLAG-galectin-3-DHFR 
and FLAG-galectin-3 were detected on the cell surface (Figure 3.7C). Overall, these results showed that 
new FLAG-galectin-3-DHFR was secreted and bound to the cell surface in the same way as galectin-3, 





Figure 3.7: The redesigned FLAG-Gal3-DHFR construct was detected on the cell surface and secreted 
into the supernatant. (A) Schematic of the redesigned 1xFLAG-galectin-3-DHFR. The short flexible 
linker protein sequence was GGGGSG, and the flexible linker protein sequence between galectin-3 and 
DHFR was GGGGSGGGGS. (B) Western blot of cells and supernatant fractions show that 
FLAG-galectin-3-DHFR transfects cells and is detected in the supernatant. Actin was used as a loading 
control. (C) Example flow cytometry plot and quantification of two replicates shows that the peak for 
FLAG-galectin-3-DHFR (red) is similar to the peaks for FLAG-galectin-3 (orange) and annexin-A2-FLAG 
(purple). All three constructs show a higher signal than the background untransfected cells (grey line).  
3.3.4 FLAG-galectin-3 did not need to unfold to be secreted 
To assess whether secretion of galectin-3 requires unfolding, the FLAG-galectin-3-DHFR construct was 
assayed in the presence and absence of aminopterin, which locks the DHFR part of the construct in a 
tightly folded state. Firstly, the concentration of aminopterin required to affect folding needed to be 
determined. To optimise this, sHeLa cells expressing FLAG-galectin-3-DHFR were treated with various 
concentrations of aminopterin, and distance migrated through a native PAGE gel was investigated by 
Western blotting. A more tightly folded protein would be expected to migrate further through the gel. 




assessed by native PAGE. Figure 3.8A shows that increasing concentrations of aminopterin caused a 
higher proportion of the FLAG-galectin-3-DHFR construct to migrate further, implying that aminopterin 
affected folding at the concentrations tested and that higher concentrations of aminopterin led to a 
decrease in the amount of protein in a flexible conformation. Therefore, concentrations of 5 µM or 
50 µM were used for further assays. Treatment with these concentrations did not affect secretion of 
FLAG-galetin-3-DHFR. There was no difference in the level of construct detected on the cell surface 
when treated with 0, 5 or 50 µM aminopterin, shown in Figure 3.8B. By Western blot, there was also 
no decrease in the amount secreted (Figure 3.8C). Actin staining in the supernatant (Figure 3.8C), used 





Figure 3.8: Aminopterin treatment did not affect secretion of FLAG-galectin-3-DHFR. (A) Native PAGE 
Western blot of FLAG-galectin-3-DHFR, showing that folding is affected by aminopterin treatment. The 
tightly folded construct (purple arrow) travels more quickly through the gel than the flexible protein 
(blue arrow). The lower band (green arrow) is likely to be tightly folded endogenous DHFR. With 
increasing concentrations of aminopterin, DHFR becomes tightly folded. (Bi) Representative histogram 
and (ii) quantification of cells stained with anti-FLAG antibody, n = 2. By flow cytometry, FLAG-
galectin-3-DHFR levels on the cell surface were not altered by aminopterin treatment. 
(C) Representative Western blot shows FLAG-galectin-3-DHFR was detected in the supernatant at 
similar levels with or without aminopterin treatment, n = 3.  
3.4 Discussion 
3.4.1 Galectin-3 does not require cell surface counter-receptors for externalisation 
The work here demonstrates that galectin-3 is able to be secreted, but does not bind to the cell surface 




GFP-galectin-3 mutant is secreted but does not bind to the cell surface cannot be conclusive in 
assessing the requirement for cell surface glycans. However, previous work in the Moreau lab has also 
shown that treatment with tunicamycin, a drug which inhibits N-linked glycosylation, reduces binding 
of galectin-3 to the cell surface while increasing galectin-3 levels in the supernatant (Stewart et al., 
2017). Moreover, knockout of MGAT1 and SLC35A2, two genes involved in N-linked glycan maturation, 
results in less galectin-3 on the cell surface and more in the supernatant (Stewart et al., 2017). 
Together, this demonstrates that galectin-3 does not use glycans in its secretion.  
These results also suggest that secreted galectin-3 is able to bind to non-transfected cells. Galectin-3 
has previously been reported to be able to transfer between cells, as demonstrated by the addition of 
exogenous galectin-3 onto different cell lines, including HeLa cells (Yang et al., 2017), human umbilical 
vein endothelial cells (Colomb et al., 2017) and Stanford University-Diffuse Histiocytic Lymphoma-6 
(SUDHL-6) cells (Clark et al., 2012). In these cases, exogenous galectin-3 was observed on the cell 
surface and colocalised with a cell surface receptor (Colomb et al., 2017), and also resulted in changes 
to cell migration (Colomb et al., 2017; Yang et al., 2017) or cell phosphatase activity (Clark et al., 2012). 
It has also been shown that recombinant galectin-3 can be taken up by LNCaP prostate cancer cells, 
which do not normally express galectin-3 (Baptiste et al., 2007). This has important implications for the 
pooled CRISPR screen, which will be discussed in Chapter 4. Although EVs specifically were not studied 
here, the finding that secreted galectin-3 can bind to other cells suggests that if EVs are used for 
secretion, galectin-3 released from EVs could bind back to the cell surface.  
Although not the intended purpose of the construct, the result that galectin-3-DHFR-3xFLAG was 
secreted but could not be detected on the cell surface may also provide support that glycan binding is 
not required for secretion of galectin-3, as it is very likely that the addition of DHFR occluded the CRD. 
However, on its own this is not conclusive, as an alternative explanation for this result is that the FLAG 
epitope was inaccessible in the flow cytometry assay. 
3.4.2 Unfolding of galectin-3 is not likely to be required for secretion 
The experiments shown here with the DHFR fusion protein demonstrate that FLAG-galectin-3-DHFR 
does not need to be unfolded to be secreted into the supernatant, implying that galectin-3 can be 
secreted without unfolding. This finding is not uncommon for unconventionally secreted proteins. 
Other unconventionally secreted proteins that do not require unfolding for secretion include FGF-2, 
FGF1 and S100A13 (Backhaus et al., 2004; Graziani et al., 2009). A galectin-1-DHFR construct has also 
been reported to be secreted in the presence of aminopterin, although the data are unpublished 
(Backhaus et al., 2004). On the other hand, IL-1β does require unfolding for secretion from HEK293T 




difference for IL-1β compared to these other proteins is that in this context, it is secreted via a vesicle 
intermediate, and translocation into vesicles is dependent on HSP90, a chaperone (Zhang et al., 2015). 
In contrast, FGF-2 is inserted into the plasma membrane. FGF-1 and S100A13 have not been directly 
shown to insert into the plasma membrane, but have been shown to disrupt liposomes to cause 
release of a fluorescent dye (Graziani et al., 2006). Additionally, mutations of FGF-1 which decrease its 
ability to disrupt liposomes also decrease its secretion from cells (Graziani et al., 2006), suggesting a 
direct interaction with the plasma membrane rather than a transporter protein. Furthermore, FGF-1 is 
exported in association with PS externalisation and the formation of membrane blebs (Kirov et al., 
2012). Together, this suggests that FGF-1 is also likely to be inserted into the plasma membrane for 
export rather than secreted through a pore.  
Some parallels between IL-1β secretion and galectin-3 secretion may have been expected, as both 
proteins have been found to directly interact with TRIM16 (Chauhan et al., 2016; Claude-Taupin et al., 
2018). TRIM16 is thought to recruit Il-1β for secretion via type III secretion (Claude-Taupin et al., 2018). 
Additionally, galectin-3 does not insert into the lipid bilayer of liposomes (Stewart et al., 2018), in 
contrast to FGF-2 and other directly translocated proteins. It is therefore more surprising that 
galectin-3 can be secreted while folded. However, this could be due to the different pathways for 
galectin-3 and IL-1β secretion, used in different contexts. Alternatively, it could be that when galectin-3 
crosses the membrane, other proteins are required to facilitate translocation. One aim of the CRISPR 
screen, described in Chapter 4, was to identify some of these putative proteins.  
3.4.3 Comparison to galectin-1 secretion 
As galectins are unconventionally secreted, it is logical to think that they would share a common 
mechanism for secretion. However, in contrast to the evidence that galectin-3 is secreted without 
requiring glycans, galectin-1 was previously found to require glycans on the cell surface for secretion 
(Seelenmeyer et al., 2005) in a similar way to the secretion of FGF-2, where transport to the cell surface 
using counter receptors to ensure transport is one-directional (Steringer et al., 2017; Zehe et al., 2006). 
These experiments used mutated versions of a galectin-1-GFP fusion protein that were unable to bind 
glycans, and also found that overall secretion of wild type galectin-1-GFP was decreased from clone 13 
CHO cells, which have defective UDP-galactose transporters, compared to wild type CHO cells 
(Seelenmeyer et al., 2005). Overall secretion was measured as the combination of cell surface protein 
and protein in the media. However, although overall levels of extracellular galectin-1-GFP were 
reduced from clone 13 CHO cells, these levels were not compared to total protein levels, and the level 
of galectin-1-GFP specifically in the medium of clone 13 CHO cells appeared to increase compared to 
wild type CHO cells (Seelenmeyer et al., 2005). Furthermore, galectin-1 was previously reported to be 




As it has been demonstrated that both galectin-3 and galectin-1 are secreted in the absence of glycans, 
it is unlikely that glycans would be required for galectin secretion, assuming galectins share a common 
pathway for secretion.  
The common structural feature of galectins is their CRD. Given the evidence here suggesting that 
galectin-3 can be secreted while folded but does not require a CRD able to bind glycans, it is possible 
that a correctly folded CRD is required for secretion. This might provide an explanation for the 
conflicting data surrounding galectin-1 secretion (Cho and Cummings, 1995; Seelenmeyer et al., 2005). 
If the galectin-1-GFP mutants that could not bind glycans also had a misfolded CRD, this could explain 
why secretion was blocked. This idea would have to be investigated further, as the structure of the 
galectin-1-GFP mutants (Seelenmeyer et al., 2005) has not been specifically studied. Since the CRD of 
prototypical galectins is required for dimerisation, this may fit with the idea that oligomerisation of 
galectin-3 is required for secretion, discussed in section 3.1.2 of this Chapter.  
3.4.4 Conclusion: pathways for galectin-3 secretion 
These findings do not specifically point towards any of the type I-III pathways, but instead provide 
additional insights into the mechanism for secretion of galectin-3: galectin-3 is likely to be secreted in 
a folded state and without glycans acting as counter receptors. These findings relate to the process of 
crossing a membrane, which is a requirement for all types of unconventional secretion, but does not 
define which membrane is crossed. Therefore, secretion in EVs as a route for secretion is not excluded 






Chapter 4: CRISPR screening to identify 




Genome-wide pooled CRISPR screening has emerged as an unbiased way to identify novel factors for 
a measurable phenotype. This chapter describes the optimisation and execution of a genome-wide 
CRISPR screen which aimed to identify novel regulators of protein secretion, using levels of galectin-3 
on the cell surface as a phenotypic readout. After multiple rounds of sorting, populations of cells with 
decreased cell surface levels of galectin-3 were isolated and sequenced by deep sequencing to identify 
the guides enriched or depleted compared to control populations. The MaGECK algorithm was used to 
generate a list of essential genes for upregulation of galectin-3 on the cell surface, of which 368 hits 
were selected for further validation, described in chapter 5. Initial results described in this chapter 







Questions remain regarding both conventional and unconventional protein secretion, particularly 
about regulation of secretion. Studies investigating specific aspects of secretion continue to reveal new 
information, but to uncover novel factors in protein secretion, unbiased methods must be employed, 
such as genome-wide CRISPR screening.  
4.1.1 Genome-wide CRISPR screening in mammalian cells provides an unbiased way to identify 
novel regulators of protein secretion  
Previously, pooled genome-wide CRISPR screens have been employed to investigate protein secretion. 
One screen, using the CRISPRi-v2 library (Horlbeck et al., 2016), investigated protein transport using a 
fluorescently-tagged membrane protein to assess the relative levels of protein trafficked to the cell 
surface compared to the total fluorescent protein expressed by the cells (Bassaganyas et al., 2019). 
This study successfully identified novel factors in protein transport, two of which were further 
investigated and found to have roles in Golgi function. While clearly a powerful way to investigate 
protein transport to the cell surface, this screen used a tagged membrane protein as a readout. 
Different factors in protein secretion may be uncovered by using an endogenous protein secreted into 
the extracellular space, rather than a membrane protein, as a readout. 
The Moreau lab previously demonstrated that pooled genome-wide CRISPR screening could effectively 
reveal key players required for glycoprotein secretion, using the GeCKOv2 library (Sanjana et al., 2014) 
and galectin-3 retention at the cell surface as a read-out (Stewart et al., 2017), as galectin-3 binds to 
β-galactosides resident on the cell surface (Nabi et al., 2015). An anti-galectin-3 antibody was used in 
FACS to identify and isolate cells which had lost surface galectin-3. Loss of galectin-3 at the cell surface 
may be the result of a number of different processes, outlined in Figure 4.1. Other than the knockout 
of galectin-3 itself, the most intuitive reason for a decrease in cell surface galectin-3 would be the 
deletion of a regulator of galectin-3 secretion. Additionally, deletion of a gene leading to a decrease in 
glycosylation or glycoprotein secretion would lead to a large decrease in cell surface galectin-3 levels. 
An overall decrease in galectin-3, which may be achieved by knockout of regulatory proteins such as 
transcription factors, would also lead to a decrease in cell surface galectin-3 levels. Although novel 
regulators of galectin-3 secretion were not identified in the GeCKOv2 screen, this study demonstrated 
that glycoproteins on the cell surface are not required for galectin-3 secretion (Stewart et al., 2017). In 
this way, galectin-3 was used as an indirect measure of glycoprotein transport to the cell surface via 
the ER-Golgi secretory pathway. Using a binding partner of glycoproteins rather than one particular 
glycoprotein allowed a broader picture of glycoprotein secretion to be drawn. The most significant hits 




loss of galectin-3 binding partners at the cell surface (Stewart et al., 2017). Only the most highly 
significant hits were taken forward for validation to avoid identifying false positives. Importantly, 
galectin-3 itself was not identified as a hit (Stewart et al., 2017). This does not mean that the screen 
did not work, as there are several possible reasons for a decrease of galectin-3 on the cell surface 
(Figure 4.1). It is likely that in a pooled screening context, galectin-3 in the media was able to bind to 
cells which did not secrete their own galectin-3, therefore masking the phenotype of true secretion 
mutants. This concept of galectin-3 transfer has been demonstrated in other cell types (Baptiste et al., 
2007; Clark et al., 2012; Colomb et al., 2017; Yang et al., 2017), and was also shown in sHeLa cells in 
Chapter 3, using GFP-galectin-3. If this transfer effect is large in the pooled screen, it is possible that 
no novel genes related to galectin-3 secretion would be identified, but in this case many genes related 
to glycosylation or glycoprotein secretion would be identified. This illustrates a key disadvantage of 
using a pooled screen in this context: that cells with different genotypes can interact with each other.  
 
Figure 4.1: Reasons for a decrease in cell surface galectin-3 during pooled CRISPR screening. Firstly, 
for a true galectin-3 secretion defect, galectin-3 would accumulate inside the cell and not be secreted. 
Compared to wild type, a decrease in glycosylation or glycoprotein trafficking would also result in 
galectin-3 being secreted but unable to bind to the cell surface. Finally, an overall decrease in galectin-3 
protein synthesis would lead to less galectin-3 on the cell surface, as well as less secreted galectin-3. 
However, other possible reasons that galectin-3 was not identified in this screen are that 
representation was not maintained throughout the sorting, or that gene targeting was inefficient. In 
the latter case, an improved library would be expected to give a greater number of hits. The GeCKOv2 
screen also identified further interesting genes in the top two hundred ranked hits, such as TRIM5 and 
TRIM34, yet these had lower significance (Stewart et al., 2017). The TRIMs have previously been shown 
to interact with galectins (Chauhan et al., 2016), so further investigation may provide more insight into 




4.1.1.1 Potential improvements to the GeCKOv2 screen 
The results of the GeCKOv2 screen clearly demonstrate the value of using galectin-3 to identify 
regulators of glycoprotein secretion. However, there were improvements that could be made in order 
to identify further novel regulators. A key improvement was to use the Brunello library instead of the 
GeCKOv2 library. The Brunello library is an optimised human CRISPR library designed based on two 
features: maximising activity and minimising off-target effects (Doench et al., 2016). This optimisation 
is achieved by maximising the rule set 2 score, which predicts sgRNA activity based on the target site 
within the protein, nucleotide counts, melting temperature of different regions; and by minimising the 
CFD score, which uses the PAM sequence, mismatch position and mismatch identity to predict off 
target effects (Doench et al., 2016).  
A further potential improvement to the GeCKOv2 screen was in the sorting strategy. The Moreau lab’s 
previous screen used stringent gates in every round of sorting, which may have meant that 
representation of guides was lost early on in the sorting process. To improve the sorting strategy and 
ensure that representation would be maintained throughout the sorting process, less stringent gates 
were used at the start of the process, increasing stringency with each round of sorting. Allowing more 
guides through the earlier rounds of sorting means that if a guide is a true hit, but is poorly 
represented, it is more likely that it will be taken through and selected in later rounds, a concept 
borrowed from other selection methods such as phage display (Carmen and Jermutus, 2002).  
Another way to ensure a wide range of hits were identified was to not only sort the negative population 
of cells which had lost galectin-3, but also to sort cells that had increased levels of galectin-3 on the 
cell surface: the positive population. CRISPR screens may be analysed using enrichment or depletion 
phenotypic selection, in which guides required for a phenotype are respectively enriched or lost in the 
test population compared to the control population. These are sometimes referred to as positive and 
negative selection respectively, but these terms will not be used in this chapter to avoid confusion with 
the names of sorted populations. In depletion screens, guides may be lost from the test population for 
multiple reasons, including effects on cell survival, making the inclusion of appropriate control 
populations especially important. Therefore, genes that upregulate galectin-3 levels on the cell surface 
could be identified by analysis of both guides enriched in the negative population and by guides 
depleted in the positive population. The reverse would also be able to identify genes that 
downregulate galectin-3 on the cell surface. This strategy was intended to avoid the disadvantage to 
enrichment screening that it tends to result in a small number of genes identified, as these dominate 




Overall, application of this modified method would be expected to again identify hits with glycosylation 
defects and novel regulators of conventional protein secretion, but the improved library and altered 
sorting strategy may allow for the possibility of identification of additional hits which are true 
galectin-3 secretion regulators. Secondary screening would then be used to validate the different hit 
types.  
4.1.2 Analysis of pooled CRISPR screens 
After deep sequencing of control and test populations, the output of a pooled CRISPR screen is a read 
count table: a list of the guides in the original library alongside a count of how many times each guide 
is represented in each population. The aim of analysis is to compare the unsorted library to treated 
populations with selection pressures applied. Guides that are enriched or depleted compared to the 
control population need to be identified, and there needs to be a way of identifying which genes are 
most significant by ranking the counts of enriched or depleted guides. Genes can then be ranked based 
on the guide ranking, to generate a hit list. This process is illustrated in Figure 4.2. A challenge with 
CRISPR screening is that traditional statistical methods, which typically assume a normal distribution, 
are not appropriate to identify hits from a read count table. As there are a large number of comparisons
 
Figure 4.2: Overview of CRISPR screen analysis. The CRISPR screen itself involves applying a selection 
pressure to an unbiased population of cells which have been targeted by a library of guides. This leads 
to enrichment and depletion of different guides in the treated population. The guides are sequenced 
to generate a read count for every guide. Based on this, the guides are ranked. As there are multiple 
guides per gene, the guide rankings are then used to generate a hit list of genes that are important for 




that need to be made, particularly in a genome-wide approach, correcting for these multiple 
comparisons presents another challenge. Often these methods can be too stringent, resulting in true 
positive hits being missed. 
4.1.2.1 Application of methods developed for siRNA screening analysis to CRISPR screens 
Computational methods that can be used to analyse pooled CRISPR screens were originally developed 
for siRNA analysis. A number of different analysis tools exist, such as RSA (Konig et al., 2007), RIGER 
(Luo et al., 2008), edgeR (Robinson et al., 2009), DESeq (Love et al., 2014) and limma-voom (Phipson 
et al., 2016; Ritchie et al., 2015). Although edgeR, DESeq and limma-voom are robust statistical 
methods to analyse RNA sequencing data, these methods do not allow for identification of significant 
genes based on ranking of multiple sgRNAs. RSA and RIGER are able to identify significant guides from 
sgRNA ranking, but RSA relies on fold change to identify hits, which results in a bias towards sgRNAs 
with a small read count (Konig et al., 2007). RIGER avoids this bias as it identifies hits based on the 
signal-to-noise ratio in the screen, and uses permutation to estimate significance (Luo et al., 2008). 
Permutation is a method in which a null distribution is created by shuffling data between groups which 
is then compared to the original distribution. This is repeated thousands of times, so no assumptions 
are made about how the data are distributed, and hits can be identified based on a pre-selected 
significance threshold that takes into account the likelihood of identifying a gene with a similar 
depletion score in the permutations. However, RIGER requires biological replicates for analysis, which 
is not always feasible for CRISPR screening, and it is less able to identify hits if fewer guides target a 
gene.  
4.1.2.2 Methods developed specifically for CRISPR screen analysis 
In 2014, the model-based analysis of genome-wide CRISPR-Cas9 knockout (MaGECK)-robust ranking 
aggregation (RRA) algorithm was developed, a method similar to edgeR and DESeq in that ranking 
guides from read count tables is modelled on the negative binomial distribution (Li et al., 2014). The 
negative binomial distribution is an adjusted Poisson distribution; modelling the data on this 
distribution allows an estimate of the sample variance and mean using sgRNAs with similar read 
counts. MaGECK-RRA also includes a gene ranking method, to score genes based on the sgRNA ranking 
using permutation to calculate statistical significance. Compared to RIGER and RSA, MaGECK-RRA 
identified novel, biologically meaningful genes in three publicly available datasets tested (Li et al., 
2014). In 2015, an update to the MaGECK algorithm was published, MaGECK-maximum likelihood 
estimation (MLE) (W. Li et al., 2015). As before, the data are modelled on the negative binomial 
distribution, but unlike RRA, MLE is also able to account for sgRNA knockout efficiency. The key 
difference between the methods is that MaGECK-MLE uses MLE to model the distribution, which 




2014; W. Li et al., 2015). A further difference is that MaGECK-MLE is able to compare multiple samples 
at the same time, rather than the pairwise comparison by MaGECK-RRA. Like MaGECK-RRA, MaGECK-
MLE uses permutation to generate p-values for each gene. 
4.1.2.3 Importance of sample quality 
For any method of analysis, assessment of sample quality is essential. For pooled CRISPR screening, it 
is important that there is a high number of cells per guide throughout the screen to maintain 
representation of all guides; > 400 cells per guide is recommended (Doench et al., 2016). A simple way 
to assess this aspect of quality is by the number of guides with zero read counts. If many guides have 
zero read counts in the unsorted population at the beginning of the screen, this would indicate that 
the library did not truly represent a genome wide screen and that coverage of cells per guide was too 
low. Li et al recommend that for an unsorted sample, < 1 % of guides should have zero read counts (W. 
Li et al., 2015); this percentage would be expected to increase throughout the sort as selection 
pressure is applied. An additional parameter of quality is the Gini index, a measure usually used in 
economics but here applied to assess evenness of sgRNA counts. Again, the Gini index score would be 
expected to increase as sorting progresses, but for an unsorted sample Li et al recommend a Gini 
index < 0.2 (W. Li et al., 2015). 
4.1.3 Aims 
The aim here was to perform an improved genome-wide screen using cell surface galectin-3 as a 
readout. This screen aimed to identify novel hits involved in both conventional and unconventional 
protein secretion that were not found in the first GeCKOv2 screen performed by the Moreau lab, which 
would be achieved primarily by using an improved library and an alternative sorting strategy. An 
additional aim was to improve on the analysis of the pooled CRISPR screen. The previous GeCKOv2 
screen was analysed using RSA (Stewart et al., 2017). Hits were not analysed using a statistical cut off 
value but by looking at the top 200 hits from the list. To improve on the analysis of the CRISPR screen, 
MaGECK would be used to analyse results. Additionally, re-analysing the GeCKOv2 screen using 
MaGECK would allow for a comparison of whether the change of library and screening strategy makes 
a difference to the hits identified. After analysis of the sgRNA count table generated from the CRISPR 





4.2.1 CRISPR-Cas9 screen optimisation 
It was important to optimise conditions before performing the screen. This focused on determining 
appropriate conditions to improve transduction efficiency and therefore allow lower volumes of virus 
library to be used, and on determining the optimal multiplicity of infection (MOI).  
4.2.1.1 Fluorescent lentiviral titration 
To determine optimal viral titre and an appropriate timeline for transduction, cells were transduced 
with lentivirus expressing clover, a green fluorescent protein. Suspension HeLa cells were first 
transduced with lentiviral Cas9 and selected with blasticidin by Kevin Moreau to create a stable cell 
line (sHeLa-Cas9). sHeLa-Cas9 cells were split 24 h before experiments in order that they were in mid-
log growth phase.  
To ensure only cells expressing Cas9 were present, 1.25 x 106 sHeLa-Cas9 per well were added to wells 
in a treated 12-well plate in a 2 ml volume of blasticidin medium. Only the middle two columns of the 
plate were used, as the cells in the outer columns were pushed to the edge of the wells by 
centrifugation, resulting in lower transduction rates in these wells. A range of 0-500 µl clover lentivirus 
(unknown titre) was added to each well. The plate was centrifuged at 1000 x g for 30 min at 20 °C and 
then incubated for 24 h at 37 °C, 5 % CO2. A cell lifter was used to detach cells from the well and each 
well was split into two wells of a non-treated 6 well plate. Next, 1 ml complete media was added to 
each well and cells were incubated for a further 24 h at 37 °C, 5 % CO2. For each condition, four images 
were taken using an EVOS fluorescence microscope, and R was used to count green cells and total cells 
to determine transfection efficiency 48 and 72 h after transduction. The R code was optimised between 
the different counts; both codes are shown in Appendix D. The first code used an image overlay and 
the optimised code used separate images for transmitted and green light. 
4.2.1.2 Polybrene titration  
To determine an appropriate polybrene concentration for improved transduction, a polybrene 
titration was performed using 10 or 100 µl clover lentivirus. Before centrifugation, polybrene was 
added to each virus volume for a final concentration of 0, 5 or 10 µg ml-1. All other transduction steps 
are as described in 4.2.2.1. The R code for separate images (Appendix Dii) was used, based on its 
improved precision.  
4.2.1.3 Puromycin titration 
The Brunello library has a puromycin resistance gene, so puromycin was titrated to determine an 
appropriate concentration to use. In a 6 well non-treated plate, 2.0 x 105 sHeLa cells were treated with 




were resuspended, a 10 µl sample was stained with 10 µl 0.4 % (w/v) trypan blue, and live and dead 
cells were counted in each well. 
4.2.1.4 Brunello library titration 
The Brunello library has a reported titre of 1.1 x 107 TU ml-1, but viral titre in these specific conditions 
and cell type needed to be determined. A titration of the Brunello library was carried out to determine 
viral titre and optimal screen conditions with this particular library. The key consideration here was 
the MOI. An optimal MOI would result in a high proportion of cells being transduced with exactly one 
guide, which therefore would target one gene. As puromycin was used to select transduced cells, an 
optimal MOI would also have low toxicity to ensure a low cell death rate. 
To ensure they were in mid-log growth phase, sHeLa-Cas9 cells were split 24 h before the experiment. 
In a non-treated 12 well plate, 1.25 x 106 sHeLa-Cas9 per well were added to wells in a 2 ml volume of 
10 µg µl-1 polybrene in complete media. 0, 50, 100, 300 or 500 µl Brunello library was added to each 
well with polybrene. The plate was centrifuged at 1000 x g for 30 min at 20 °C and then incubated for 
24 h at 37 °C, 5 % CO2. A cell lifter was used to detach cells from the well and each well was split into 
two wells of a non-treated 6 well plate in a 2 ml volume; one well with complete media and one well 
with complete media + 1 µg ml-1 puromycin. 
Cells were incubated for a further 48 h at 37 °C, 5 % CO2. Cells were resuspended in each well, a 10 µl 
sample was stained with 10 µl 0.4 % (w/v) trypan blue, and live and dead cells were counted. The 
percentage of transduced cells was calculated using Equation 4.1, and these numbers were normalised 
using Equation 4.2 in order to be used in modelling the Poisson distribution. 
𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 =  
% 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 + 𝑝𝑢𝑟𝑜𝑚𝑦𝑐𝑖𝑛
% 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 − 𝑝𝑢𝑟𝑜𝑚𝑦𝑐𝑖𝑛
 
Equation 4.1: Calculation of percentage of cells transduced as the specific survival rate. 
 
𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 % 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 =
% 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 − % 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 𝑚𝑖𝑛
100 % − % 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 𝑚𝑖𝑛
 
Equation 4.2: Normalisation of specific survival rate to give normalised transduction rate.  Here, the 
% specific survival min was the specific survival from using 0 µl Brunello library. 
The Poisson distribution (Equation 4.3) can be used to model lentivirus transduction of cell suspensions 




idealised curve the transduction efficiency for each volume of library. The percentage of cells 
transduced with exactly one virus (effective efficiency) could then be calculated. 




Equation 4.3: The Poisson distribution, where k = number of events, λ = mean number of events.  In 
relation to lentivirus transduction, k = number of infections per cell and λ = MOI. The transduction 
efficiency is the probability of a cell being transduced with any number of virions, so is defined by 
1 - P(0, λ), where the second term defines the probability of a cell receiving zero virions. 
Firstly, MOI values were calculated for each virus volume from P(0, λ), as shown in Equation 4.4. 




𝑦 =  
1 × 𝑒−𝑀𝑂𝐼
1
=  𝑒−𝑀𝑂𝐼 
 
𝑙𝑛 𝑦 =  − 𝑀𝑂𝐼 
 
𝑀𝑂𝐼 = −ln 𝑦 
Equation 4.4: simplification of P(0, λ), used to calculate MOI.  Here y is the probability of zero 
transductions per cell, calculated from (1 – normalised specific survival). 
Viral titre was then calculated using Equation 4.5. The average titre was then calculated, excluding one 
outlier (500 µl). MOI was then recalculated for each virus volume using the same equation; this 
calculated MOI value is less susceptible to variation than any MOI derived only for one specific virus 
volume used. The calculated MOI was then used both to calculate idealised transduction efficiency, 
1 - P(0, λ), and the effective efficiency, P(1, λ).  
𝑉𝑖𝑟𝑎𝑙 𝑡𝑖𝑡𝑟𝑒 (𝑇𝑈 𝑚𝑙−1) =  
𝑀𝑂𝐼 × 2.5 × 106 𝑐𝑒𝑙𝑙𝑠
𝑣𝑖𝑟𝑢𝑠 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑚𝑙)
 




4.2.2 Brunello library screen 
4.2.2.1 Transduction 
Cells were transduced with the Brunello library using conditions previously determined (section 4.2.1). 
It was important to have a high level of redundancy in the screen so that individual guides were not 
lost throughout the process; a representation of 400 cells per guide is recommended by Doench et al. 
(Doench et al., 2016). To allow for this representation, sHeLa-Cas9 cells were expanded to have 1 x 108 
cells and split 24 h before transduction so that they were in mid-log growth phase. In non-treated 
12 well plates, 1.25 x 106 sHeLa-Cas9 per well were added to 42 wells in a 2 ml volume of complete 
media with 10 µg µl-1 polybrene. Next, 90 µl Brunello library was added to each well, corresponding to 
a MOI of 0.506 and effective transduction efficiency of 30.5 %. The plate was centrifuged at 1000 xg 
for 30 min at 20 °C and then incubated for 24 h at 37 °C, 5 % CO2. A cell lifter was used to detach cells 
from the well, cells were pooled and plated into seven 15 cm non-treated dishes in 30 ml complete 
media + 1 µg ml-1 puromycin. Cells were cultured in complete media + 1 µg ml-1 puromycin for seven 
days, washing away dead cells as needed. After 72 h, transduced cells were resuspended, three 10 µl 
samples were stained with 10 µl 0.4 % (w/v) trypan blue, and live and dead cells were counted to 
measure transduction efficiency. 
4.2.2.2 Sorting 
Transduced cells expressing either very high or very low levels of cell surface galectin-3 were sorted, 
and enriched by multiple rounds of sorting, shown in Figure 4.3. For each sort, transduced cells were 
pooled and counted. In batches of 3 x 107, transduced cells were washed with 1 ml phenol red-free 
DMEM and stained with 1 ml 50 µg ml-1 anti-galectin-3-647 for 30 min at 4 °C. Cells were washed in 
5 ml DMEM, resuspended in 1 ml DMEM and filtered through 40 µm cell strainers. Stained cells were 
then analysed at the National Institute for Health Research (NIHR) Cambridge Biomedical Research 
Centre (BRC) cell phenotyping hub on a FACSAriaIII. Debris and doublets were excluded by gating for 
size and shape; sorting was based on anti-galectin-3-647 fluorescence, retaining the cells with the 
highest and lowest cell surface levels of galectin-3. Cells were sorted into tubes containing 1 ml 20 % 
serum-containing medium. After sorting, cells were cultured in 20 % serum-containing media for 
24-48 h, then cultured in complete media, which has 10 % serum. Full media recipes are described in 
Chapter 2, section 2.1.1.3. Samples of cells were counted, and when the population had expanded to 
5 x 107 cells, two samples were taken; 5 x 106 cells were frozen for guide sequencing, and 1 x 106 cells 
for assessment of surface galectin-3 levels by flow cytometry, using anti-galectin-3-647 as described in 
Chapter 2, section 2.1.5. Importantly, cells took different times to recover, so populations were 




recovery times to expand the population between sorts, the time between sorts was 14-24 days; as 
such, the entire sorting protocol from the first sort to the fourth sort took place over 64 days.  
 
Figure 4.3: Gating strategy across successive rounds of sorting. Three sorts were planned, shown in 
blue, with gating stringency increased with successive sorts in order to enrich as sorting rounds 
continued. A fourth sort, shown in green, was also performed to separate two distinct populations that 
were seen after the third sort, gating each population around a 5-10 % peak. As this was based on the 







Table 4.1: Sorted populations named based on their sort type, number, time since sort and replicate. 
Sample ID Sort type Sort number Days post-sort Replicate 
U1_0a Unsorted 1 0 a 
U1_8a Unsorted 1 8 a 
U2_8a Unsorted 2 8 a 
U3_10a Unsorted 3 10 a 
P1_0a Positive 1 0 a 
P2_8a Positive 2 8 a 
P3_11a Positive 3 11 a 
P3_11b Positive 3 11 b 
P3_11c Positive 3 11 c 
N1_0a Negative 1 0 a 
N1_8a Negative 1 8 a 
N2_8a Negative 2 8 a 
N3_10a Negative 3 10 a 
N3_13a Negative 3 13 a 
N3_13b Negative 3 13 b 
N4_4a Negative 4 4 a 
N4_7a Negative 4 7 a 
N4_7b Negative 4 7 b 
M4_4a Negative (mid) 4 4 a 
M4_7a Negative (mid) 4 7 a 
M4_7b Negative (mid) 4 7 b 
 
4.2.2.3 Library preparation 
To prepare samples for sequencing, DNA was extracted from frozen cell pellets using Gentra Puregene 
Cell kit and the concentration of DNA measured on a Nanodrop ND-1000. PCR was carried out in 
quadruplicate to amplify the amplicon containing the guide, with primers used to attach barcodes, 
stagger regions and sequencing adaptors for use in sequencing, as shown in Figure 4.4. The full 
protocol has been previously described (Doench et al., 2016; Root and Doench, 2016). Briefly, each 
well was set up to contain 10 µg genomic DNA, 0.5 µM uniquely barcoded P7 primer, 0.5 µM P5 stagger 
primer mix, 200 µM each dNTP, 7.5 units ExTaq and 1x ExTaq buffer in a total volume of 100 µl. PCR 




30 s; final extension at 72 °C for 10 min. One replicate from each sample was analysed on a 2 % agarose 
gel to confirm successful amplification.  
 
Figure 4.4: Amplicon containing sgRNA sequence. P5 and P7 primers both contain the P5 flow cell 
attachment sequence (green), the Illumina sequencing attachment primer (blue) and the vector primer 
binding sequence. The P5 primer contained a 0-8 nucleotide stagger region to increase diversity, here 
represented by “s” (purple). As this varies in length, the average length of the expected product is 354 
nucleotides. The P7 primer includes an 8 nucleotide barcode (purple) used to identify different 
samples. Each well in the 96 well plate has a unique barcode.  
A PCR pool was created by combining 30 µl from each PCR reaction, followed by purification using 
AMPure XP magnetic beads to retain only DNA fragments larger than 100 bp, following the protocol 
from the Broad Institute, available from Addgene (Root and Doench, 2016). An equal volume of the 




placed on a magnet to retain beads. Beads were washed three times with 70 % ethanol and purified 
PCR product was eluted with 500 µl EB buffer. The sample was analysed and DNA concentration was 
measured using a DNA 1000 chip on an Agilent 2100 Bioanalyzer. 
4.2.2.4 Sequencing and generation of sgRNA count table 
Sequencing was carried out by the Cancer Research UK (CRUK) genomics facility using the Illumina 
HiSeq 4000. Single end (SE) 50 sequencing was chosen as it reads 50 bases in one direction, giving full 
coverage of the guide within the amplicon. The output is a minimum of 300 x 106 reads, theoretically 
giving an average of 171 reads per guide in an unselected sample (i.e. unsorted at t = 0), as calculated 
in Equation 4.6. Sequencing files were in fastq format (available on the Gene expression omnibus (GEO) 
repository, for accession numbers see Appendix Ai). 
300 × 106 𝑟𝑒𝑎𝑑𝑠
23 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 × 76441 𝑔𝑢𝑖𝑑𝑒𝑠
= 171 𝑟𝑒𝑎𝑑𝑠 𝑔𝑢𝑖𝑑𝑒−1 𝑠𝑎𝑚𝑝𝑙𝑒−1 
Equation 4.6: Calculation of reads per guide per sample.  There are 76441 unique guides in the 
Brunello library. This equation calculates the average number of reads per guide in each sample if each 
sample were unsorted, assuming a uniform distribution of guides.  
PCR replicates were treated as technical replicates, so were combined into one file for the generation 
of a sgRNA count. Sort replicates are not strictly true biological replicates but were treated as biological 
replicates for MaGECK analysis. As these files were too large to be processed on a normal desktop 
computer, read counts were generated in stages by technical replicates using the MaGECK function 
mageck count. For each replicate, the command line input “mageck count -l Brunello_library.csv                 
-n --fastq” was used. Inputs used for -n and --fastq are shown in Table 4.2. The output of this function, 































4.2.3 MaGECK Analysis  
Data were analysed using both MaGECK-RRA (Li et al., 2014) and MaGECK-MLE (W. Li et al., 2015), 
using an enrichment sort type and using the sgRNA count as the input (generated as described above, 
4.2.2.4). Scores of the Gini index and number of zero read counts are automatically generated by 
MaGECK (W. Li et al., 2015) and were used to assess the spread of guides in the control and sorted 




For MLE analysis, samples were all compared to the first unsorted sample. In all analyses, median 
normalisation was used. Although there is a non-targeting sgRNA set that can be used for 
normalisation, normalisation by this method has been reported to bias results towards an 
overestimation of depleted genes, likely because DNA damage caused by Cas9 can induce global 
expression changes which are not controlled for by non-targeting sgRNAs which do not have these 
effects (Chen et al., 2018). Additionally, functional genomics analysis was performed using MaGECK-
RRA on each RRA comparison group using the Gene Ontology (GO) database (Mootha et al., 2003; 
Subramanian et al., 2005); this is a part of the MaGECK-RRA pipeline.  
A disadvantage to MaGECK is that with no replicates, the algorithm is likely to miss real hits. Here, 
multiple samples of populations were taken. While these are best analysed as biological replicates in 
the MaGECK algorithm, these should not be considered as true biological replicates as they did not 
come from an entire repeat of the screen. Due to this limitation, it was important to choose a high 
false discovery rate value, so as not to miss true positives in the screen. Here, a false discovery rate of 
0.5 was used. As secondary screening was planned to narrow down the list of hits (described in 
Chapter 5), false positives would be excluded at a later stage. Moreover, the borderline values revealed 
by quality control meant that it was important to be lenient with statistical cut off values. An FDR of 
0.25 was used for excluding hits identified from unsorted populations, to avoid hits unrelated to 
galectin-3 cell surface localisation. 
4.2.4 Functional genomics analysis of hits 
As an initial analysis of the hit list, analysis of processes was performed using Panther via Gene 
Ontology (Mi et al., 2019). Hit lists generated by MaGECK-RRA or MaGECK-MLE were used as the input 
list. Fisher's exact test was used with FDR values; hits were defined as having FDR < 0.05. The dataset 
for annotation was GO-slim Biological Process for pathway. MaGECK-RRA also performs functional 
genomics as part of the programme.  
To analyse how localisation of hits changed over time, hits were annotated according to their location 
within the cell with GO_Term mapper (Boyle et al., 2004), using the ontology aspect “Component”, 
organism “Homo sapiens” and ontology “generic slim”. Genes were annotated with the following GO 
terms: extracellular region (GO:0005576), plasma membrane (GO:0005886), cytoplasmic vesicle 
(GO:0031410), endoplasmic reticulum (GO:0005783) and Golgi apparatus (GO:0005794). Using R, 
genes were categorised as originating from “early”, “mid”, or “late” in the screen, according to the 
respective sorting rounds. Populations in each category are: Early (N1, P1); Mid (N2, P2); Late (N3, P3, 




4.2.5 Hit prioritisation 
As MaGECK-RRA and MaGECK-MLE together identified a large number of hits, a secondary screen was 
planned for validation, described in Chapter 5. However, there were still too many hits to take forward 
into a secondary screen, so hits were prioritised according to their known functions using UniProt 
annotations. To exclude genes with functions relating to transcription, translation, or glycosylation, 
genes with GO annotations “mRNA metabolic process”, “RNA binding” or “DNA Replication” were 
excluded. Additionally, genes with UniProt functions containing words or wildcards “DNA”, 
“transcription”, “translation”, “proteasome”, “ribosom*, “splic*”, “chromatin”, “chromosom”, 
“helicase”, “mRNA”, “nuclease”, “histon*”, “polymerase”, glycosylation”, “mannose”, “Glc” or “N-
linked” were removed. Genes with functions containing the mitochon* or RNA were assessed 
individually to decide whether to exclude them. Transcription and translation genes were excluded as 
these were most likely to be identified due to general cell stress-induced death, rather than directly 
being related to changes in protein secretion. Three genes related to glycosylation were included as 
positive controls that had been validated in the GeCKOv2 screen: MGAT1, SLC35A2 and SLC35A3. Other 
genes with known roles in protein secretion or glycosylation were included as further positive controls 
for secondary screening. Several genes with transport-related annotations were included in the hit list, 
both to validate the methods and to investigate genes which may be transport related but had not 
been shown to be involved specifically in secretion. 
All genes with unknown or unclear functions in secretion were taken forward into a shortlist for the 
secondary screen, as these were most likely to be novel hits. Unclear functions were identified by 
functional annotations such as “may regulate” or functions only annotated “by similarity”. Genes with 
known functions that did not seem to relate to the screen were excluded, such as odorant receptors. 
Genes with known functions that were unlikely to be interesting for secretion were also excluded. 
Pathway analysis, performed as part of MaGECK-RRA, was used as a complementary way to identify 
hits. Pathways that were biologically interesting and had an FDR < 0.05 were selected, and genes from 
each pathway that were in the top 500 hits in the RRA gene analysis were all selected for a separate 
pathway hit list. Additionally, if there were no genes from a pathway in the top 500, the top three 
genes from the top 1000 were selected. If there were no genes in the top 1000, that pathway was not 
used. In this way, some genes with an FDR > 0.5 could be included in the hit list. Pathways were 
manually grouped into more broad functional categories. Duplicates within and between categories 
were removed, then the top hits for each category were compiled and added to the hit list.  
Although this method of reducing the hit list to a manageable number is subjective, the shortlist 





4.3.1 Re-analysis of GeCKOv2 screen 
In order to be able to determine whether the screen performed in this chapter was an improvement 
on the previous GeCKOv2 screen in terms of the number of hits identified, the screens must be 
analysed in the same way. Therefore, MaGECK analysis was carried out on the GeCKOv2 screen. 
MaGECK-RRA analysis of the previous GeCKOv2 screen from the Moreau lab identified only four hits 
with a FDR < 0.5, one from the first sort and three from the second sort, shown in Table 4.3. The two 
top hits from the second sort are COG1 and SLC35A2, two of top six genes previously identified by RSA. 
SLC35A2 was previously validated as required for glycosylation but not for secretion of galectin-3 
(Stewart et al., 2017). 
Table 4.3: Genes identified from MaGECK-RRA analysis of GeCKOv2 CRISPR screen   
Gene ID Number of 
guides 
FDR Number of 
guides enriched 
Log2(fold change) Identified 
NPFFR2 6 0.163366 2 -8.8333 Sort 1 
COG1 6 0.024752 3 1.4285 Sort 2 
SLC35A2 6 0.131188 2 -8.1381 Sort 2 
PHLDA2 5 0.394389 1 -6.5636 Sort 2 
MaGECK-MLE analysis of the GeCKOv2 screen identified four hits from the first sort and 1252 from the 
second sort (see Appendix Aii). The six top genes identified previously by RSA were all in the 
glycosylation or protein transport pathways: SLC35A2, MGAT1, COG1, UNC50, SLC39A9 and MAN1A2 
(Stewart et al., 2017). Five of these six hits were also identified by MaGECK-MLE. The one that was not 
identified, SLC39A9, had two guides enriched in sort 2, but one guide depleted, which is likely why it 
was not identified as statistically significant by MaGECK. Pathway analysis of the MaGECK-MLE hits did 
not show any significant pathways, although other genes involved in glycosylation were identified as 
enriched in sort 2, such as the glycosyltransferases MGAT5B, GALNT15, GALNT8. The raw sgRNA count 
table is also available in the Apollo repository (see Appendix Aii). It is important to note that an 
unsorted population was not maintained throughout the GeCKOv2 screen, so a proportion of the hits 
identified are likely to have functions in cell survival, especially in the second sort. 
4.3.2 Optimisation of CRISPR screen 
It was essential to optimise CRISPR screening conditions for the use of the Brunello lentiviral library in 




and therefore the optimal number of cells with exactly one guide. If the MOI were too high, cells would 
be transduced with multiple guides, resulting in cells with multiple genes targeted, therefore breaking 
the one gene to one phenotype assumption that this screen relies on. If the MOI were too low, there 
would be a high proportion of cells killed by puromycin, which would be toxic to the small number of 
remaining transduced cells and could result in a poor representation of guides in the starting 
population. 
4.3.2.1 Fluorescent lentiviral titration provided a starting point for optimal lentiviral transduction 
Titration with lentiviral clover, a green fluorescent protein, was initially used to determine the overall 
lentivirus transduction efficiency of sHeLa-Cas9 cells, shown in Figure 4.5. For each virus volume used, 
a proportion of cells were fluorescent 48 h and 72 h after transduction (Figure 4.5A-C). There was a 
plateau in the number of fluorescent cells when > 200 µl of virus was added to each well, particularly 
apparent at 48 h. The titration also showed that there were more cells expressing GFP 48 h after 
transduction than 72 h. However, the results across these time intervals are not directly comparable 
as the image types were different, and therefore the code used to analyse images was different 
between samples. At 72 h, MOI was estimated using Equation 4.4 (Figure 4.5D). Since a low MOI was 





Figure 4.5: Titration of lentivirally-encoded clover. Four images were taken from randomly selected 
areas of each well and the number of green cells and total number of cells were counted to calculate 
the percentage of cells transduced. The percentage of cells transduced by each volume of virus is 
shown after (A) 48 h (light green square, ⬛) and (B) 72 h (dark green circle, ●). Error bars show standard 
error of the mean for the four technical replicates. As counts of green cells were done by different 
methods, data are not shown on the same graph. (C) Example images from the 72 h titration, showing 
typical transduction at 0 µl and 500 µl. (D) Estimation of MOI at 72, calculated using Equation 4.4.  
4.3.2.2 A high concentration of polybrene increased transduction efficiency 
Polybrene is a reagent that improves transduction, so it was tested in its recommended concentration 
range to try to reduce the library volume used while keeping transduction rate constant, thereby 
maximising use of the Brunello library. Figure 4.6 shows that the addition of 10 µg ml-1 polybrene 
increased transduction in all conditions tested, whereas 5 µg ml-1 polybrene only increased 
transduction efficiency when 10 µl lentiviral clover was used. This difference was clear only when 
100 µl of clover was used. As such, 10 µg ml-1 polybrene was chosen for use in the screen.  
Here, there were more cells expressing clover at 72 h than at 48 h in all conditions tested. Unlike Figure 
4.5, these results are comparable, as the same image type and counting method was used for all 






Figure 4.6: Titration of polybrene when cells were transduced with lentiviral clover. Four images 
were taken from randomly selected areas of each well and the number of green cells and total number 
of cells were counted to calculate the percentage of cells transduced. (A) Example images taken after 
48 h incubation. (B) Quantification of transduction. Groups are labelled with the virus volume used and 
the time at which fluorescence was measured. Red; no polybrene; green, 5 µg ml-1 polybrene added; 
blue, 10 µg ml-1 polybrene added. Data are grouped by virus volume used for transduction and time 
since transduction. Error bars represent standard error of the mean. 
4.3.2.3 Puromycin titration determined conditions for selecting only transduced cells 
Puromycin was used both to select for cells transduced with the Brunello library and to assess 
transduction efficiency. To avoid unnecessary toxicity, the lowest dose that would reliably kill all non-
resistant cells was required. As seen in Figure 4.7, 1 µg µl-1 puromycin resulted in a mean of 83 % cell 
death after 48 h, an acceptable level for assessment of transduction efficiency by specific survival rate. 
Cell death with 1 µg µl-1 puromycin is consistently greater than cell death with 0.5 µg µl-1 puromycin. 
Further increases in puromycin concentration did not greatly increase cell death, so a concentration of 
1 µg µl-1 puromycin was chosen for use in the CRISPR screen. Although 72 h incubation with puromycin 
resulted in a little more cell death than a 48 h incubation, the difference is small, and this result must 
be considered together with the lentiviral expression results (4.3.2.1). As lentivirus is best expressed 
in sHeLa after 72 h, puromycin was added 24 h after lentiviral transduction, allowing for an assessment 
of efficiency 48 h after puromycin addition and 72 h after transduction. Cells were then cultured in 
puromycin-containing media for seven days, in order to select only transduced cells. In this way 





Figure 4.7: Puromycin titration and analysis. Error bars shown are standard error of the mean, n = 2. 
4.3.2.4 Brunello library titration was used to select conditions based on MOI 
For reasons described above, survival rate was measured 48 h after addition of puromycin and 72 h 
after spinoculation with the Brunello library to establish the optimal MOI for the screen. The 
normalised data for transduction efficiency showed a plateau for survival when using > 300 µl 
(MOI > 1.685) of the Brunello library (Figure 4.8). Therefore, the data point for 500 µl was excluded 
from the calculation of the average viral titre. It is likely that this violates the assumption for the 
Poisson distribution that the event – here a virus transducing a cell – is rare. The calculated viral titre 
of 1.40 x 107 TU ml-1 is slightly higher than the reported viral titre for the Brunello library 
(1.1 x 107 TU ml-1), likely due to the use of polybrene and a different cell type. MOI values for different 
virus volumes were then calculated based on this calculated viral titre. 
Using the Poisson distribution, a MOI of 0.506 (virus volume of 90 µl) was selected for the CRISPR 
screen. This MOI predicts an overall transduction efficiency of 39.7 % and an effective transduction 
efficiency of 30.5 %, meaning that 77 % of transduced cells would have exactly one virus (Figure 4.8). 






Figure 4.8: Transduction efficiency 72 h after addition of the Brunello library as modelled by the 
Poisson distribution. The orange line shows the calculated overall transduction efficiency for any 
number of virus particles transducing a cell. Red data points show actual transduction efficiency data 
based on calculated MOI. The blue dashed line is the effective transduction efficiency, corresponing to 
the probablity of a cell receiving exactly one virus.  
4.3.3 CRISPR screen 
sHeLa-Cas9 cells were transduced with the Brunello library with a high level of redundancy of 400 cells 
per guide, calculated using the effective efficiency rate of 77 %. Transduction efficiency was assessed 
by counting live and dead cells 72 h after transduction with the Brunello library. The mean cell survival 
rate was 41.9 %, close to the expected rate of 39.7 %. After seven days in culture with puromycin-
containing media, dead cells were washed away so that only transduced cells remained.  
4.3.3.1 Cell sorting isolated distinct populations based on galectin-3 on the cell surface 
Following transduction with the Brunello library, cell sorting was employed to enrich populations 
expressing very high or very low levels of cell surface galectin-3 (Figure 4.9). After the first two rounds 
of sorting, no clear enrichment in the population of cells expressing high or low levels of cell surface 
galectin-3 could be seen (Figure 4.9). This was expected, as lenient gates (10 % then 2 %) were chosen 
for early rounds in order to avoid missing true positives. After a third round of sorting, two distinct 
populations were observed in the negative population N3, which were then separated by further 
sorting into a mid-negative M4 and a most negative N4 population. A small enrichment of positive cells 




The most negative population within N3 consisted of cells that had little or no galectin-3 bound to the 
cell surface but were likely able to secrete galectin-3 into the supernatant, so the excess of extracellular 
galectin-3 could bind to both the mid-negative population and the unaffected population of cells. In 
addition, the presence of a large number of cells with no cell surface galectin-3 meant that the 
remaining cells with cell surface galectin-3 effectively had a higher concentration of anti-galectin-3 
antibody available during staining. These two effects together meant that the unaffected population 
in N3 (grey cells in Figure 4.9, N3) appeared to have higher galectin-3 staining than earlier sorts. 
 
Figure 4.9: Flow cytometry of populations after selection by cell sorting based on cell surface 
galectin-3. After the initial two rounds, positive (P) and negative (N) populations did not show a change 
in galectin-3 levels on the cell surface, but after the third round of sorting, a small enrichment for 
positive cells was seen in P3 compared to P2 and two distinct populations were seen in N3. N3 was 
sorted further to separate these two populations.  
4.3.3.2 PCR successfully amplified the amplicon to create the pooled library 
Samples containing 5 x 106 cells each for the sorted and unsorted populations were collected and 
frozen for genomic DNA extraction and sequencing upon the completion of FACS enrichment. After 
extraction and PCR to amplify the amplicon, technical replicates from each sample were analysed by 
2 % agarose gel to assess success of the PCR and purity of the product. The amplicon was expected to 
be an average of 354 base pairs, and a band between 300 and 400 base pairs was seen for all samples 
apart from U1_0a, shown in Figure 4.10A. The U1_0a sample was re-extracted and all technical 




in Figure 4.10B. After pooling and purifying all technical replicates, sample size and purity was 
measured by Bioanalyser, which showed a single peak at 354 base pairs, shown in Figure 4.11. 
Quantification of the peak allowed DNA concentration to be accurately measured. 
 
Figure 4.10: Agarose gel of extracted amplicon. (A) One technical replicate from each sample resolved 
between 300 and 400 base pairs, as expected for the 351-359 base pair amplicon. The amplicon from 
U1_0a was not seen. (B) U1_0a DNA was extracted and the amplicon amplifyied again, here all 





Figure 4.11: Bioanalyzer trace showing a peak at 354 nucleotides. The two other peaks at 35 and 
10380 nucleotides are standards. 
4.3.4 Quality control and comparison of CRISPR screens 
Sequencing resulted in a high output of 397 x 106 reads in total, giving an expected mean of 174 reads 
per guide in an unsorted sample. Raw sequencing files from deep sequencing of all populations are 
available on GEO (Appendix Ai). The raw sgRNA count table is available in the Apollo repository 
(Appendix Aii). After guides were mapped using MaGECK, samples had a mean of 104 reads per guide. 
Calculating from the expected mean of 174 reads per guide, this was an average of 60 % mapped reads. 
To be able to compare whether the new screen was really an improvement upon the GeCKOv2 screen, 
it was important to look in detail at the quality of both the GeCKOv2 and the Brunello screen data. 
Using MaGECK, quality control measures including the Gini index and the number of guides with zero 
counts were used as a way to assess the distribution of guides in each sample, shown in Figure 4.12. 
In both screens, the Gini index of the unsorted or control population was below the recommended 
maximum threshold and increased after the first sort, indicating a good level of diversity in the control 
populations. For the GeCKOv2 screen, the Gini index increased dramatically after the first sort (Figure 
4.12Ai), indicating that the first sort imposed a high selection pressure. In comparison, the Gini index 
for early stages of sorting in the Brunello library screen remained at or below the recommended 
thresholds then increased throughout the sorting process (Figure 4.12Aii), indicating that diversity was 
maintained for longer and therefore suggesting that the improved sorting strategy was successful. 
The percentage of guides with zero counts followed the same pattern (Figure 4.12B). As explained by 




cells with normal levels of galectin-3 on the cell surface will be excluded through sorting, therefore 
increasing the number of guides with zero counts (W. Li et al., 2015). However, for both unsorted 
populations, the percentage of guides with zero counts started above the recommended maximum 
threshold of 1 %. For the GeCKOv2 screen, the initial percentage is 7.1 % (Figure 4.12Bi); for the 
Brunello screen, it is 1.7 % (Figure 4.12Bii), showing that the Brunello screen started with more 
diversity, much closer to the recommended threshold. Again, the more gradual increase in percentage 
of guides with zero counts throughout sorting in the Brunello library compared to the GeCKOv2 screen 
implies that the improved sorting strategy was successful.   
 
Figure 4.12: Quality control of sgRNA read counts. Recommended thresholds are indicated by red 
lines. Ideally, unsorted populations at early stages of sorting should be below these thresholds. (A) Gini 
index of each sample, a measure of evenness of sgRNA counts, for (i) GeCKOv2 screen and (ii) Brunello 
screen. (B) Percentage of guides with zero counts in each sample from (i) GeCKOv2 screen and 
(ii) Brunello screen. 
In MaGECK-RRA analysis, only two populations can be compared at a time. An initial comparison of 
U1_0a to the other unsorted population by MaGECK-RRA showed a significant difference between the 




U1_0a most correlated with the negatively sorted populations (Appendix E). Some degree of 
correlation is expected between all samples, as they all come from the same initial population of cells. 
However, the fact that U1_0a is most correlated with N4_7a suggested a contamination issue. Because 
of this, U1_0a was not used as the control group in any analysis, and instead U1_8a was used, which 
did correlate with other unsorted samples.  
4.3.5 Analysis of Brunello library CRISPR screen 
For RRA, the unsorted populations at the same timepoint that the populations were collected were 
used as the control; this was most appropriate as RRA can only compare two samples at a time. U1_8a 
was used as the control for MLE. This was appropriate for MLE as all populations are compared at the 
same time and so genes identified as hits in the later control populations could be excluded. Also 
excluded were hits that appeared in both analysis directions, for example, if a hit was both enriched in 
N1 and depleted in P1, unless one of these values was highly significant (FDR < 0.05) and the other was 
less significant (FDR > 0.25).  
4.3.5.1 An FDR of 0.5 was selected to generate the hit list 
One issue to address before analysis of hits was the selection of the cut-off value. As MaGECK analysis 
is able to identify both guides lost and enriched in the populations, two types of hits could be identified: 
(1) genes that upregulate galectin-3 on the cell surface, as their knockout would result in guide 
enrichment in the negatively sorted populations and guide depletion in the positively sorted 
populations; and (2) genes that downregulate galectin-3 on the cell surface, as their knockout would 
result in guide depletion in the negative sorted populations and guide enrichment in the positively 
sorted populations. The number of hits identified at different FDR values is shown in Table 4.4.  
Typically, FDR values of 0.05 or 0.1 are used for statistical analysis. Using an FDR of 0.1, MaGECK-RRA 
and MaGECK-MLE respectively identified 26 and 114 hits that upregulate galectin-3 on the cell surface. 
However, hits associated with changes in cell surface glycosylation were identified with false discovery 
rates > 0.1, suggesting that there may also be novel hits with higher false discovery rates. To be able 
to identify a greater number of novel hits, an FDR of 0.5 was used here. Using this FDR, MaGECK-RRA 
and MaGECK-MLE together identified 1044 genes that upregulate cell surface galectin-3 and 936 genes 
that downregulate cell surface galectin-3. However, only 51 and 59 genes respectively were identified 
by both analyses, as shown in Table 4.4. Encouragingly, the two most significant hits of those found by 
both methods were MGAT1 and SLC35A2, the two glycosylation-related hits validated in the GeCKOv2 
screen. These both had their most significant FDR in population N4. Given the large volume of data, 




Table 4.4: Number of hits identified for different FDR values, using MaGECK-RRA and MaGECK-MLE. 
Note that for MLE analysis, FDR value was halved for identifying and excluding genes from unsorted 























0.05 23 75 2 4 59 1 
0.1 26 114 3 5 138 1 
0.25 42 311 16 14 272 2 
0.5 126 969 51 163 832 59 
4.3.5.2 Functional genomics analysis identified processes related to glycosylation 
Pathway analysis was not included in the MaGECK-MLE pipeline, so pathway analysis was performed 
on the hit list using Panther (Mi et al., 2019). As shown in Figure 4.13, many pathways related to 
glycoproteins and glycosylation were identified in the list of hits that upregulate galectin-3 on the cell 
surface. This was expected based on the results from the previous GeCKOv2 screen. In contrast, there 
were no clear patterns in the significant pathways from the hit list associated with downregulated 
galectin-3 on the cell surface. Therefore, as there were so many hits overall, only the hits that 
upregulate galectin-3 on the cell surface were focused on for further characterisation. Another reason 
for this focus was the lack of a clear phenotype in the positive sorted population (Figure 4.9), making 
it less likely that hits which effected a large increase the levels of cell surface galectin-3 would be 
identified.  
Neither hit list generated by RRA analysis generated any significantly enriched pathways by Panther 
(Mi et al., 2019). However, pathway analysis was carried out as part of MaGECK-RRA, and also 
identified GO terms associated with glycosylation, transcription or translation and protein transport as 
processes enriched in the list of genes that result in upregulation of galectin-3 on the cell surface. 
Importantly, this method used the entire hit list and accounted for significance of genes identified, 
instead of using a restricted hit list. The identification of glycosylation-based pathways was to be 





Figure 4.13: Enrichment analysis of GO processes associated with MLE hit lists. Gene lists were 
annotated using the GO_Slim for biological process. Processes related to glycosylation or glycoprotein 
are highlighted in light blue.  
4.3.5.3 Location of hits varied with time of sort 
To look further at hits in the secretory pathway across the different sorts, GO_Term mapper (Boyle et 
al., 2004) was used to assign GO_Slim compartment terms to each gene in the hit list. Comparing the 
different sort types, the total numbers of hits identified in each compartment was similar between hits 




was also stratified into different time stages: early, post first sort; mid, post second sort; and late, post 
third sort, and post fourth sort if applicable. In the negative sorted population, fewer hits were 
identified in the early secretory pathway in the early stage of the sort, particularly in the ER, whereas 
more hits were identified at the plasma membrane and extracellular region at later stages (Figure 
4.14Bi). The number of hits lost from the positive population which localise to early secretory pathway 
compartments decreased as the screen progresses, with only one hit identified after the third sort 
(Figure 4.14Bii). Interestingly, very few hits were identified in the middle of the sort, but it is not clear 
why this is. One possible explanation is that cells expressing guides which were enriched initially did 
not survive after the second sort, which then allowed other hits to be enriched in later stages. While 
the unsorted control group maintained at the same time as sorting should have accounted for this, the 
control had not passed through a FACS machine, which was likely to be an additional selection pressure 






Figure 4.14: Location of hits in secretory pathway organelles. (A) Comparing hits enriched in the 
negative sort (green) to hits lost in the positive sort (blue). Similar numbers are seen in each 
compartment in the different selection types (B) Location of hits at different stages of the sort for 




4.3.5.4 Galectin-3 was not identified as a hit 
Looking specifically at the raw guide counts for galectin-3 (see Appendix A, E3), the guides are present 
at similar levels throughout the unsorted population, showing that a galectin-3 knockout does not 
result in a cell survival defect. Comparing the unsorted populations to the sorted populations, the 
galectin-3 guides are depleted throughout negative sorting, instead of enriched as would be expected, 
and are unchanged or enriched through positive sorting. However, none of these differences resulted 
in a significant change that could be identified by MaGECK. As the guides were represented throughout 
the screen, it cannot be that coverage was too low, and it is very unlikely that all four guides did not 
target galectin-3. Therefore, the fact that galectin-3 was not identified as a hit implies that galectin-3 
transfer between cells masked the galectin-3 knockout phenotype. 
4.3.6 Shortlist of hits for secondary screening 
As MaGECK-RRA and MaGECK-MLE together identified over 1000 genes that upregulate cell surface 
galectin-3, hits were prioritised for secondary screening. This prioritisation was subjective, but 
selection was based on both FDR values and function, with the aim of covering a broad range of 
pathways. The final full hit list is shown as a heat map in Figure 4.15. The origin of hits is also shown in 
Figure 4.15. More hits originating from MaGECK-MLE analysis are in the hit list than from MaGECK-RRA, 
partly because more hits were identified by this method (see Table 4.4). However, this is also 
theoretically a better method for identifying hits as the method was designed for multiple comparisons 
(W. Li et al., 2015).  
Positive controls known to be involved in glycosylation were also included in the hit list. Of the 368 
genes in the secondary screening shortlist, 146 are annotated as transport-related, as defined in 
Chapter 2. Not all of these transport-related hits would be related specifically to glycoprotein 
secretion, as this broad definition of transport also includes endocytosis and traffic between vesicles, 
as well as defining genes that are involved in transport of specific proteins. Of the 368, 119 were not 
annotated as transport-related or glycosylation related, and a further 91 hits were not annotated by 
the GO_slim, so were labelled as unknown. Together with pathway analysis, this suggested that the 




Figure 4.15: Heatmap of shortlist for secondary screening by FDR for upregulating galectin-3 on the 
cell surface in each population. Hits are categorised as related to protein transport, unrelated to 
protein transport or with unknown functions, as annotated by GO_Slim lists. In the population 
columns, grey indicates a not significant FDR > 0.5. Hits are shown on a white-red scale, where darker 
red indicates a more significant FDR, closer to 0. In the path column, hits are coloured by where they 




identified from both analysis methods; purple, identified from MaGECK-RRA pathway analysis. For hits 
that were identified by both methods and in the same population, the most significant FDR is used for 
the colour scale.  
4.4 Discussion 
CRISPR screens are often employed to identify genes essential for survival in different conditions. More 
recently, CRISPR screens have been used to study more complex phenotypes, but so far, this 
technology has rarely been used to investigate protein secretion. Here, a genome-wide CRISPR screen 
was optimised and performed in order to identify novel regulators of protein secretion. The result of 
this was a list of 368 hits, which remains to be validated; this validation will be described in Chapter 5. 
Overall, initial results show that the screen was of good quality and is likely to have identified novel 
regulators of secretion. 
4.4.1 Comparison of Brunello and GeCKOv2 CRISPR screen strategies 
The CRISPR screen performed here aimed to separate cells transduced with the Brunello library into 
distinct population of cells that expressed high and low levels of galectin-3 on the cell surface. Sorting 
was performed using an increasing stringency strategy. After three rounds of sorting, distinct negative 
populations were seen, then isolated by a further sort. In comparison to the GeCKOv2 screen (Stewart 
et al., 2017), this strategy took longer to isolate a population that had clearly lost galectin-3 on the cell 
surface. However, this was to be expected as the purpose of the lenient gating was to allow through 
more false positives initially so that true positives were not excluded by too stringent gating. Before 
hit validation, it was not clear whether this strategy had been successful. No distinct subpopulation 
was seen in the positive population after three sorts, although the population as a whole seemed to 
have more galectin-3 on the cell surface in comparison to previous rounds of sorting.  
Li et al. make recommendations for quality control of sgRNA counts in pooled CRISPR screens (W. Li et 
al., 2015). Here, these data come close to but do not always meet their recommended thresholds. The 
mean percentage of mapped reads, 60 %, is slightly below the minimum of 65 % recommended. Gini 
indices of the early populations are below the recommended maximum of 0.2, but the number of zero 
counts does not fall below the recommended maximum of 1 % of total sgRNAs. This is likely due to too 
low a sequencing depth; it is possible that there are more guides in the sample with very low 
representation that was not covered by the sequencing depth achieved here. While this was not ideal 
as it meant that the statistics may be underpowered, this can be somewhat compensated for in a 
selection of a lenient false discovery rate (FDR). A lenient false discovery rate has its own 




screening, described in Chapter 5, would address this by validating hits. Additionally, these 
recommendations were based on a limited number of publicly available CRISPR screening datasets, 
and it is possible that these recommended cut-off values are too stringent. 
In comparison to the GeCKOv2 screen, the Brunello screen had similar Gini index values for the control 
populations, but the Gini index increased quickly after one sort in the GeCKOv2 screen, and slowly 
throughout the Brunello sorting process. This was to be expected, as the sorting strategy for the 
GeCKOv2 screen was to immediately take 1 % of the population. However, it is interesting that the 
GeCKOv2 Gini index is 0.8 and 0.9 for sorts one and two respectively, whereas the Brunello screen 
samples have a maximum Gini index of 0.58. This suggests that the sorting strategy implemented here 
was successful, as more diversity in the population is maintained throughout sorting than in the 
GeCKOv2 screen, so there is a greater chance of retaining more true positives. While neither screen 
met the recommended percentage of 1 % of guides with zero counts in the unsorted sample, the 
Brunello library screen was much closer (1.7 % compared to 7.1 %). This again indicated that there was 
a better chance of identifying a greater number of true hits in the Brunello screen.   
Overall, the flow cytometry of the populations and quality control of the sequencing indicated that the 
CRISPR screen had been successful, and that it is likely that the aims of improving on the GeCKOv2 
screen were achieved. However, few conclusions can be drawn from these observations alone. To 
determine the success of the CRISPR screen, the guides enriched and lost in these populations needed 
to be identified. This would allow the identification of hits, and for further conclusions to be drawn 
regarding the success of this screening strategy. 
4.4.2 Comparison to TAC-GFP screen 
One other pooled CRISPR screen to investigate conventional protein secretion involved HeLa cells 
expressing TAC, a cell surface receptor, tagged with GFP. By using TAC-GFP, this screen had the 
advantage of measuring protein secretion by comparing the total protein fluorescence with cell surface 
protein, to exclude hits that depleted overall protein levels (Bassaganyas et al., 2019). Another key 
difference was that this screen used the CRISPRiv2 library, using nuclease-dead Cas9 (Horlbeck et al., 
2016). This results in gene silencing by transcription repression, rather than a knockout caused by 
cutting DNA. In comparison, as the Brunello screen was a knockout screen, there may be essential 
genes that could not be identified. An inactivation screen could have been used here; however, these 
approaches are complementary, and no single “genome-wide” screen can truly identify all regulators 
of a given process. The complementary nature of these different screens is a contributing factor as to 




The TAC-GFP screen identified 360 genes involved in conventional protein transport with FDR < 0.5 by 
MaGECK-RRA, of which 110 had FDR < 0.05 (Bassaganyas et al., 2019). Genes related to transcription 
and translation were also identified by this TAC-GFP screen, which were also found in the Brunello 
screen here. As the authors note, it is likely that these genes affect secretion indirectly, by regulating 
transcription and translation of proteins involved in the secretory pathway (Bassaganyas et al., 2019). 
Although more genes were identified as significant in the TAC-GFP screen than the Brunello screen as 
analysed by the same method, this may be expected as the TAC-GFP screen sorted 25 % of cells with 
the lowest cell surface protein to total protein ratio, whereas the Brunello screen ultimately sorted 1 % 
of cells with the lowest levels of cell surface galectin-3. The fact that the TAC-GFP screen also identified 
novel regulators of protein secretion demonstrates the utility of pooled genome-wide CRISPR 
screening as a starting point to investigate protein secretion.  
4.4.3 Comparison of analysis methods 
4.4.3.1 Re-analysis of GeCKOv2 screen 
The previous analysis of the GeCKOv2 screen used RSA to identify hits (Stewart et al., 2017). The 
re-analysis carried out here identified four hits by MaGECK-RRA, two of which were in the top six hits 
identified by RSA. This overlap is not surprising and demonstrates that both methods are capable of 
identifying biologically relevant hits. While RSA is likely to miss biologically relevant hits, here it appears 
that MaGECK-RRA may be too stringent an analysis. MGAT1, UNC50, SLC39A9 and MAN1A2, hits 
involved in glycosylation from the top six RSA hits (Stewart et al., 2017), were not identified by 
MaGECK-RRA. In contrast, MaGECK-MLE identified over 1000 hits in the GeCKOv2 screen, including 
five of the six top RSA hits, as well as other genes involved in glycosylation. The one gene that was not 
identified, SLC39A9, had guides both enriched and depleted, which is likely why it was not identified 
as a significantly enriched hit. The fact that other genes involved in glycosylation were identified by 
MaGECK-MLE suggests that there could be other hits to be identified from this dataset. On the other 
hand, glycosylation was not identified as an enriched pathway in the pathway analysis. Together, this 
confirms that while the GeCKOv2 screen was able to identify hits involved in glycosylation, there were 
improvements to be made to the screen in order to identify a greater number of relevant hits. 
4.4.3.2 Analysis method for Brunello screen 
It is surprising that very few genes were identified in common across the different MaGECK methods, 
unlike previously published work in which hit lists by both MaGECK methods were similar (W. Li et al., 
2015). However, this previous analysis stated that MLE and RRA gave similar results when two 
conditions were compared, rather than multiple conditions that were compared here. It is important 




populations are compared to different controls, due to the way they compare the data. However, 
comparing RRA and MLE analyses of the GeCKOv2 screen is directly comparable. As discussed above 
(4.4.3.1), it is likely that MaGECK-RRA is too stringent a method. While it is clear that far more hits are 
identified by MLE analysis, the fact that more hits were identified does not necessarily mean that the 
method was better, as many of these hits could be false positives. However, MaGECK-MLE was 
designed for multiple comparisons, so it is likely that it is a better method for this screen design. 
Without secondary screening, it is not possible to conclude which of the two MaGECK methods is 
better at identifying true hits. As such, hit lists from both methods were combined so that genes 
identified by both methods were taken forward for secondary screening.  
4.4.4 Problems in experimental design 
Several hits were identified with unclear functions in relation to protein secretion, implying that the 
Brunello screen was successful in its aims of improving on the GeCKOv2 screen in order to identify 
novel regulators. However, there are further improvements that could be made. A key issue was that 
although multiple samples were taken from the populations and treated as biological replicates for 
analysis, these are not true biological replicates. For a true biological replicate, the entire screen would 
have to be repeated from transduction. For practical reasons, this was not possible here, but true 
biological repeats would likely have addressed issues encountered including the quality control 
measures not meeting all recommended thresholds. The inclusion of multiple biological replicates 
greatly improves the likelihood that a highly significant hit will also be significant in secondary 
screening (Doench, 2018).  
Another improvement that could have been made would be to pass the control group through a FACS 
machine without applying any gating for galectin-3 cell surface levels. Here, control cells were 
maintained at the same time as the sorting control, but were not passed through the FACS machine. 
As sorting was a long process, it is likely that sorting itself exerted an additional selection pressure on 
the cells which was not accounted for by the control group. In the negative sorted cells, many cells 
expressing additional guides not involved in secretion were depleted throughout the screen, 
particularly those involved in survival; these may not have been depleted to the same extent in cells 
in the control group which had not been through the sorting process. This might help to explain the 
changes in location and identity of hits identified throughout sorting seen in Figure 4.15. Hits initially 
enriched by negative sorting after N1 might then fail to survive the further stress of the second sorting, 
which could explain why so few statistically significant hits were identified at N2. The remaining hits 
would also be more resistant to the stress of sorting, so further sorting would then result in an 
enrichment of these hits, which were both resistant to the pressure of the sorting process and had less 





Overall, these data suggest that the strategy of progressively increasing cell sorting stringency 
employed here does improve screening results for identifying regulators of glycoprotein secretion. 
While there was little enrichment visible by anti-galectin-3 staining in the early and middle populations, 
deep sequencing confirmed that sgRNA enrichment had taken place. Many of the hits enriched in the 
early sorted populations localise to the compartments in the early secretory pathway, particularly the 
ER, and this number decreases in later sorts. This is likely due to problems with cell survival; over the 
extended time period and stress derived from the four sorts, cells with ER defects in particular may be 
less able to survive. Across all sorted populations, the enrichment of many hits that are known to be 
in secretory and glycosylation pathways provides an initial validation of the success of the CRISPR 
screen. In comparison to the previous GeCKOv2 screen, here more hits known to have roles in the 
maturation or secretion of glycoproteins were identified. Moreover, there are many genes in- the hit 
list not known to have such roles. These hits may have roles in wider protein secretion, and further 
work is required to investigate this possibility. 
While pathway enrichment showed that the screen was successful in identifying regulators of 
conventional secretion, it is not immediately clear whether the screen could successfully identify 
regulators of unconventional secretion as there are no gene ontology annotations for this pathway. 
The fact that conventional pathways were identified does not rule out that the screen could also 
identify regulators of unconventional secretion. However, as galectin-3 was not identified as a hit here, 
it appears unlikely that this screen would be useful for identifying proteins involved in unconventional 
protein secretion. 
In summary, a large number of genes were identified as potential regulators of glycoprotein secretion, 
a selection of which have been taken forward for secondary screening. The improvements to the 
CRISPR screening method described here appear to have been successful, although secondary 






Chapter 5: validation of hits involved in 




In the previous chapter, a hit list of 368 genes required for the cell surface localisation of galectin-3 
was generated, of which 210 had no known role in protein transport. Disruption to galectin-3 cell 
surface localisation was initially intended to identify regulators of both conventional secretion of 
glycoproteins and of unconventional secretion of galectin-3. In this chapter, a small selection of hits 
were investigated for their role in direct regulation of galectin-3 on the cell surface. Since it was likely 
that the CRISPR screen primarily identified regulators of conventional protein secretion, the main focus 
of this chapter was to validate the hit list by arrayed siRNA secondary screening using assays for 
conventional secretion. This validation was particularly important given the low stringency of the false 
discovery rate used to identify them as hits. 
First, a glycoprotein secretion screen using ss-HRP was implemented, followed by a Golgi morphology 
screen. Using this approach, 93 genes were validated as important for glycoprotein secretion, of which 
51 were previously unknown to be involved in protein secretion. Many of these hits are also important 
for maintenance of the Golgi architecture. Five of these hits were investigated further, and two were 
focused on: GPR161 and TMEM220. Both of these proteins are novel Golgi-localised regulators of 
protein secretion whose knockdown decreases glycoprotein secretion and disrupts the Golgi structure. 
A putative mechanism for how GPR161 regulates secretion is suggested here, but further experiments 







The CRISPR screen described in Chapter 4 was intended to identify novel regulators of unconventional 
and conventional protein secretion. As galectin-3 was not identified as a hit, it was unlikely but not 
impossible that these genes were involved in directly regulating galectin-3 on the cell surface, either 
by regulating galectin-3 secretion or by regulating overall levels of galectin-3 in the cell. However, the 
hit list generated included many proteins already well-known to be involved in protein secretion, 
indicating that the aim of identifying novel regulators of conventional secretion was likely to have been 
achieved. Given the low FDR used, it was important to validate hits. There are two broad approaches 
to validate hits involved in conventional protein secretion: assessment of a specific protein’s transport 
to the outside of the cell, or assessment of the structure of the organelles in the secretory pathway. 
Some examples of the former include the use of horseradish peroxidase fused to a signal sequence 
(ss-HRP), which was first used in a genome-wide siRNA screen in Drosophila (Bard et al., 2006). Since 
then, ss-HRP has also been used in confocal microscopy to assess where it accumulates after 
knockdown of specific genes (von Blume et al., 2011; Von Blume et al., 2009). A similar method 
frequently employed is the use of vesicular stomatitis virus G (VSVG), which has been widely used since 
the 1980s, often for investigation of ER-Golgi traffic (Bergmann et al., 1981; Hirschberg et al., 1998; 
Kockx et al., 2012; Ong et al., 2010; Stüven et al., 2003). Both of these proteins are glycoproteins and 
follow the conventional secretory pathway for their export. In the latter case, disruptions to the ER or 
Golgi network are typically studied. The ER is a dynamic network of sheets and tubes spread 
throughout the cell (Chen et al., 2013; Powers et al., 2017). Recent developments in super resolution 
microscopy have allowed for movement through the ER to be visualised, showing that flow of cargo is 
active (Holcman et al., 2018). However, the fact that the ER is present throughout the cell means that 
it is difficult to observe ER disruption at the resolution given by wide-field or confocal microscopy i.e. 
without using super resolution microscopy. In contrast, the Golgi apparatus forms a compact ribbon 
localized in the perinuclear area under usual physiological conditions in mammalian cells, and 
disruption to this structure can be seen by confocal imaging, as will be discussed in detail below. 
5.1.1 Golgi apparatus architecture 
The Golgi apparatus is a ribbon structure, formed of Golgi stacks. Each stack comprises of at least three 
cisternae: the cis, medial and trans-Golgi, characterised by different resident proteins (Klumperman, 
2011). A model for the formation of the Golgi ribbon, which starts from vesicles and tubules, is shown 
in Figure 5.1 (Saraste and Prydz, 2019). At both sides of the Golgi, there is a network of branching 
tubules (Klumperman, 2011). The trans-Golgi network (TGN) is a continuous compartment comprised 
of the final trans-Golgi cisterna and a network of tubular branching structures, in which sorting to 




exit there are, but the proteins without any other specific sorting signal are trafficked to the plasma 
membrane to be secreted (Klumperman, 2011). Vesicles can be formed from all parts of the Golgi, but 
a distinctive feature of the TGN is that it is the only part of the Golgi to form clathrin coated vesicles 
(Glick and Luini, 2011).  
Given the essential role of the Golgi in glycosylation and its central role in the ER-Golgi-plasma 
membrane trafficking pathway, it follows that its proper organisation is essential for secretion of 
glycoproteins, and it has been shown computationally that Golgi architecture is required to form the 
glycan profile of a cell (Fisher et al., 2019). The pH of the Golgi, Golgi membrane dynamics and integrity 
of glycosyl transferases spaced along the cis, medial and trans-Golgi are all important for glycan 
synthesis (Stanley, 2011). The Golgi ribbon structure, although not absolutely required for transport, 
has been shown to facilitate anterograde transport, particularly of large cargo (Lavieu et al., 2014). 
During mitotic cell division, the Golgi apparatus breaks down in order to divide between the two 
daughter cells (Carlton et al., 2020). The steps of this process, modelled in Figure 5.1, appear to follow 
on from each other, with membrane unstacking in turn leading to fragmentation of cisternae into 
vesicles, mediated by ARF1 and COPI (Tang et al., 2008; Wang et al., 2008). The Golgi breakdown is 
essential for cell division; as there is one Golgi per cell, a daughter cell without a Golgi would be unlikely 
to survive for a long period of time. 
 
Figure 5.1: Model of Golgi apparatus architecture. Figure adapted from Saraste et al. (Saraste and 
Prydz, 2019). Golgi cisternae are built up from vesicles and tubules. Cisternae are thought to be held 
together by adhesion proteins to form a stack, which join to form the Golgi ribbon.  
 
5.1.2 Maintenance of Golgi architecture 
5.1.2.1 GRASP proteins 
Two Golgi reassembly stacking proteins (GRASP), GRASP55 and GRASP65 (also called GORASP2 and 
GORASP1 respectively) have been reported to be involved in maintenance of the Golgi stack, as their 
name implies. Both protein are coiled-coiled proteins anchored to the membrane of the Golgi (Bachert 
and Linstedt, 2010). The exact mechanism by which both proteins are involved in Golgi apparatus 
architecture has been disputed. The Wang group has shown that GRASP65, which is localised mainly 




together to form stacks, with unstacking proposed to be driven by phosphorylation (Tang et al., 2008; 
Wang et al., 2003), although this has not been shown directly. In contrast to this work, the Malhotra 
lab found that depletion of GRASP65 did not abolish stacking of cisternae, but did reduce the number 
of cisternae per stack (Sutterlin et al., 2004). Instead, they found that GRASP65 knockdown resulted in 
a defect in the organisation of the mitotic spindle, preventing cells from progressing further in the cell 
cycle than metaphase and ultimately resulting in cell death (Sutterlin et al., 2004). Taking these results 
together, it remains plausible either that GRASP65 oligomers could be involved in holding Golgi 
cisternae together to form a stack, or that GRASP65 has a less direct role in Golgi architecture 
maintenance. In either case, other proteins are also involved.  
One of these other proteins is GRASP55, a protein with a high level of homology to GRASP65. Knockout 
of GRASP55 by CRISPR-Cas9 resulted in a small dispersion of the Golgi; in this study, knockout of 
GRASP65 had no effect on Golgi morphology (Bekier et al., 2017). Similarly to GRASP65, GRASP55 forms 
oligomers which are disrupted by phosphorylation, and phosphorylation may lead to Golgi unstacking 
(Xiang and Wang, 2010). Again, it has not been demonstrated directly that GRASP55 oligomers hold 
cisternae together; it remains possible that GRASP55 mediates its effect on Golgi organisation 
indirectly.  
In accordance with the work from the Malhotra lab, later work from the Wang group found that 
knockdown of either GRASP65 or GRASP55 alone reduces the number of cisternae in a stack, while 
knockdown of both proteins together leads to stack disassembly; these proteins were suggested to 
have complementary roles as GRASP55 is localised to the medial-trans-Golgi, not the cis-Golgi (Xiang 
and Wang, 2010). Furthermore, simultaneous knockout of GRASP65 and GRASP55 by CRISPR-Cas9 was 
also reported to result in dispersion of the Golgi stack, which altered glycosylation (Bekier et al., 2017). 
However, another study by Lee et al. directly contrasted these results, finding that simultaneous 
knockdown of GRASP65 and GRASP55 had no effect on Golgi unstacking, but did result in an increase 
in luminal width of the Golgi cisternae (Lee et al., 2014). A more recent study generated a mouse with 
both GRASP55 and GRASP65 knocked out, and found no change in morphology of core Golgi stacks, 
but that knockout results in a shorter peripheral regions of the cisternae (Grond et al., 2020). It was 
suggested that the GRASP proteins function to link Golgi rims, but not the central stack (Grond et al., 
2020). 
5.1.2.2 Golgins 
Other proteins implicated in maintaining Golgi structure are the Golgins. Golgin family proteins have 
roles in vesicle capture, and can also interact with the GRASP proteins to help maintain Golgi structure 




Golgin-45, which interacts with GRASP55 (Bachert and Linstedt, 2010; Zhao et al., 2017). GM130 (also 
called golgin A2) is thought to recruit GRASP65 to the Golgi membrane in the correct orientation to 
facilitate interactions between adjacent Golgi membranes (Bachert and Linstedt, 2010). GM130 is 
required for correct localisation of Golgi enzymes within the Golgi and for efficient glycosylation, but 
interestingly is not required for secretion (Puthenveedu et al., 2006). GM130 remains localised to the 
cis-Golgi on depletion of GRASP65, so additional proteins must be involved in this localisation (Sutterlin 
et al., 2004). GM130 also interacts with general vesicular transport factor p115 (p115), a tethering 
protein which links GM130 to transport vesicles, but this interaction is important in supressing vesicle 
fusion during mitosis and is not important for Golgi ribbon formation (Nakamura et al., 1997; 
Puthenveedu et al., 2006).  
Interestingly, the study mentioned above by Lee et al. found that only a triple knockdown of GRASP55, 
GRASP65 and Golgin-45 disrupted Golgi stack organisation in addition to altering cisternal width (Lee 
et al., 2014). They also found that Golgi stacks have normal morphology when either GM130 or 
Golgin45 is overexpressed while GRASP55 and GRASP65 are knocked out (Lee et al., 2014). Together 
with the findings that GRASP55 and GRASP65 both need to be knocked down for Golgi stacks to be 
disrupted, this suggests some redundancy in the process. Lee et al. suggest that it is the level of 
adhesion protein expressed in a cell, rather than the presence of any one specific protein, that is 
responsible for Golgi stack maintenance (Lee et al., 2014). As highlighted by Grond et al., loss of 
GRASP55 and GRASP65 can affect other Golgi-related proteins, including GM130 which is depleted by 
this double knockout (Grond et al., 2020). Overall, while it is clear that GRASP and Golgin proteins are 
involved in Golgi architecture maintenance, the exact role they play remains uncertain.  
5.1.3 Golgi structure in protein secretion 
Golgi architecture has previously been demonstrated as a useful readout to identify regulators of 
protein secretion. The first genome-wide siRNA screen investigating protein secretion assessed ss-HRP 
secretion and then performed secondary screening of 130 genes to assess Golgi morphology in 
Drosophila S2 cells, which unlike mammalian cells have an arrangement of Golgi in randomly 
distributed unconnected cisternae (Bard et al., 2006; Stanley et al., 1997). This secondary screening 
classified cells with individual gene knockdown into four Golgi classes: fused with the ER (A), 
fragmented (B), aggregated (C) and not affected (D), based on the distribution of mannosidase II-GFP 
(Bard et al., 2006). Of the 130 genes, 57 (43 %) had altered Golgi morphology (classes A-C); ten with 
altered morphology were investigated in more detail, and nine were found to localise to compartments 
in the secretory pathway (Bard et al., 2006). This study identified the novel factor transport and Golgi 
organisation 1 (TANGO1) as a gene important for secretion, and whose knockdown led to Golgi 




investigating kinase and phosphatase regulators of protein secretion; 48 % of the 122 hits which 
disrupted ERGIC-53 localisation also had perturbations to Golgi structure (Farhan et al., 2010). In 
another, 159 kinases and phosphatases involved in regulating Golgi structure were identified by 
classification of Golgi as diffuse, fragmented or condensed (Chia et al., 2012). Cells with diffuse Golgi 
represent those in which Golgi markers were detected in the ER, while fragmented Golgi has been 
attributed to disconnection between Golgi stacks (Chia et al., 2012). Of the 159 hits identified, 58 % 
also affected protein secretion, assessed by secretion of luciferase fused to a signal sequence (Chia et 
al., 2012).  
Other specific investigations have also shown disruption to Golgi architecture alongside disruption to 
protein secretion. Silencing of p125A, a protein involved in COPII-coat formation, by RNAi results in 
both dispersion of the Golgi and a disruption to ER export of the model protein VSVG (Ong et al., 2010). 
Pathological mutations of ubiquilin 2, a protein that regulates protein degradation, result in both Golgi 
disorganisation and inhibition of ER-Golgi protein transport (Halloran et al., 2019). It is important to 
note that disruptions to the Golgi structure do not always result in protein transport deficiency; for 
example, GRASP65 knockdown does not alter transport of VSVG along the secretory pathway (Sutterlin 
et al., 2004), and in the screens discussed above there were several hits with disturbed Golgi structure 
that did not have protein secretion defects. (Chia et al., 2012; Farhan et al., 2010). 
5.1.4 Aims 
In Chapter 4, a list of 368 hits involved in galectin-3 localisation to the cell surface were identified. The 
main aim of this chapter was to validate that these hits are involved in protein secretion generally. This 
was not intended to be a technical validation of the Brunello library guides, which has been extensively 
performed (Doench et al., 2016), but to validate whether the hits identified are important for protein 
secretion; these different types of validation are discussed in a review (Doench, 2018). Here, arrayed 
secondary siRNA screening was carried out to validate hits involved in glycoprotein secretion and Golgi 
apparatus architecture. Combining this secondary screening approach with the CRISPR screen allowed 
the advantages of speed and reduced cost of pooled CRISPR screening to be taken together with the 
advantages of an arrayed screen in which genotype and phenotype remain strictly linked (Agrotis and 
Ketteler, 2015). As previously discussed in Chapter 4, the results from knockout and knockdown 
screens are not likely to be identical as the methods are complementary. 
Additionally, while it was unlikely that the CRISPR screen identified genes directly involved in regulating 
galectin-3 on the cell surface, this possibility had not been excluded. Another aim of this chapter was 
to characterise a small selection of hits that were most likely to be directly involved in regulating 




are proteins that form the chaperonin containing tailless (CCT) complex, also known as tailless complex 
polypeptide 1 ring complex (TRiC). As CCT is a chaperone with many substrates (Willison, 2018), it was 
possible that the CCT complex played a role in galectin-3 cell surface localisation. Therefore, these hits 
were investigated to understand how CCT proteins could potentially regulate levels of galectin-3 on 
the cell surface. 
As outlined above, the main aim of this chapter was to validate the hits as important for protein 
secretion. The pipeline of secondary screening to discover regulators of conventional protein secretion 
is shown in Figure 5.2. An initial arrayed secondary screen had the aim of assessing whether hits 
identified affected glycoprotein secretion. This was carried out using siRNA knockdown in HeLa cells 
expressing horseradish peroxidase fused to a signal sequence (HeLa-ss-HRP), a glycoprotein which is 
directed to the secretory pathway that has previously been used in screening for protein secretion 
(Bard et al., 2006; von Blume et al., 2011). Following this, a further screen of the genes important for 
ss-HRP secretion aimed to find whether these hits were important for maintenance of Golgi 
morphology, by immunostaining with Golgi markers. Again, this screen was carried out using siRNA 
knockdown in HeLa cells. After assessment of both ss-HRP secretion and Golgi morphology, five of the  
 
Figure 5.2: Pipeline of secondary screening. First, an siRNA screen using an ss-HRP assay to assess 
glycoprotein secretion was used to reduce the number of hits. Next, Golgi morphology was 
investigated, again using siRNA. Five hits were then selected from the genes whose knockdown led to 




hits validated by secondary screening were then further investigated with the aim of gaining a better 
understanding of how they affect glycoprotein secretion. Investigation started with a characterisation 
of subcellular localisation, and two Golgi-localised proteins were identified. One hit, GPR161, was 
further investigated for colocalisation with a putative interactive partner. 
5.2 Methods 
5.2.1 Secondary screening 
Based on having an unknown or unclear function in secretion, hits from the MaGECK analyses were 
selected to create a shortlist of 368 genes to be used in a secondary screen, described in Chapter 4. 
This shortlist was screened in two arrayed siRNA screens, using siGenome smart pools in which each 
plate contained two replicates of non-targeting siRNA as negative controls. Two of these genes did not 
have available siRNA, so the hit list was reduced to 366. 
5.2.1.1 HeLa-HRP assay for conventional secretion 
To screen for conventional secretion, HeLa cells expressing ss-HRP were used; in which the signal 
peptide directs HRP to be secreted. HeLa-ss-HRP cells were reverse transfected with the secondary 
screen library, as previously described (Pelkmans, 2018). Briefly, in optimised conditions, 80 µl of 
31 000 cells ml-1 were plated into wells of a 96 well plate containing a mixture of 20 µl 250 nM siRNA 
and 0.5 % (v/v) lipofectamine 2000 in OptiMEM and incubated at 37 °C, 5 % CO2. Medium was changed 
to fresh culture medium 48 h after transfection. Supernatants and cell lysates were assessed for HRP 
levels 72 h after transfection in opaque white 96 well CulturPlates by chemiluminescence using a Tecan 
M1000 Pro. 50 µl supernatant was transferred to wells of the white plate. Cells were washed with 
150 µl 1x PBS and then lysed with 100 µl 1x lysis buffer (see 2.1.6.1) for 5 min at room temperature, 
then 50 µl lysate was transferred to an opaque white plate. 150 µl ECL was added to the plates, the 
chemiluminescence was read on a Tecan M1000 Pro, using Luminescence mode with magenta 
attenuation. Luminescence signal from the cell lysate (CL), supernatant (SN) and the CL:SN ratio were 
each normalised as described in Chapter 2 (2.1.8.1), using the average of the two siRNA control wells 
for the maximum and the average of a media or buffer only column for the minimum. 
Hits from this assay were identified by a nonlinear regression method. To identify genes that were 
required for secretion of ssHRP, a line with a gradient of 1 was fit to the normalised CL luminescence 
vs normalised SN luminescence data. Outliers of this line, as identified by the ROUT method (Motulsky 
and Brown, 2006), are genes that result in an up or down regulation of conventional secretion. ROUT 




of y = 1 for the normalised CL luminescence:SN luminescence ratio line. Genes were annotated as 
described in Chapter 2 (2.1.10). 
5.2.1.2 Golgi morphology screen 
HeLa cells were reverse-transfected as described above (5.2.1.1), although here transfected in 96-well 
ViewPlates. At 72 h after transfection, cells were fixed in ice cold methanol for 5 min, washed in PBS, 
stained with appropriate primary and secondary antibodies and ProLong with DAPI, then observed 
using an Opera Phenix High-Content Screening System to obtain unbiased confocal images. Analysis 
was performed on CellProfiler (Carpenter et al., 2006) to define cells and Golgi, and to measure Golgi 
intensity, size, shape and granularity. Briefly, cells were defined as secondary objects by propagation 
from nuclei, using a global “minimum cross entropy” thresholding method. Golgi were defined within 
a broad pixel diameter range of 2-60 px, and using an adaptive two-class Otsu thresholding method. 
The classifier of CellProfiler Analyst (CPA) (Jones et al., 2009) was then trained using cells randomly 
chosen from the whole experiment. These were classified as having aberrant or intact Golgi until the 
sensitivity reached an acceptable level: 82 % and 77 % for the intact Golgi and aberrant Golgi classes, 
respectively; here, 65 cells were used. The CPA classifier was then used to define all cells as having 
intact or aberrant Golgi. 
5.2.2 Analysis of hits 
To find interacting partners of proteins of interest, the BioPlex network was used, a resource of 
proteins shown to interact by affinity purification-mass spectrometry (Huttlin et al., 2017, 2015; 
Schweppe et al., 2018). Default parameters were used to search the network. 
5.2.3 Co-localisation analysis 
To measure co-localisation between golgin A5 and either GM130 or TGN46, cells were stained as 
described in Chapter 2 (2.1.8), and observed using a Leica SP8 confocal microscope using a 40x 
immersion objective. A minimum of 22 cell images, taken from across three independent experiments, 
were selected as regions of interest from each siRNA treatment from confocal micrographs and 
analysed by selecting each cell as a region of interest and using the colocalisation studio plugin in Icy 
(De Chaumont et al., 2012). To be confident that siRNA knockdown was effective in cells selected from 
TMEM220 or GPR161 knockout conditions, only cells that with aberrant Golgi were selected, identified 
by the Golgi marker alone. Pearson’s coefficient with no threshold was recorded for each cell analysed. 
Data were tested for normality and equality of variance by the Shapiro-Wilk test and Bartlett’s K 
squared test, respectively. After passing normality tests, data were analysed in R by one-way ANOVA 





As described in Chapter 4, 368 hits were shortlisted, identified from across all populations of the 
CRISPR screen. As many of these hits were uncharacterised, they had the potential to represent novel 
regulators of protein secretion, but validation by secondary screening was required. 
5.3.1 Investigation of CCT proteins in regulating cell surface levels of galectin-3 
Since it was possible that CCT proteins directly regulated galectin-3 on the cell surface, CCT proteins 
were knocked down to assess their effect on galectin-3. Antibodies and siRNA were available for CCT2, 
CCT4, CCT5 and CCT7, so these proteins were studied. Western blot confirmed that the knockdown 
had been successful for CCT4, CCT5 and CCT7, although it was unclear for CCT2 siRNA, as shown in 
Figure 5.3A. Knockdown of some CCT proteins also resulted in knockdown of other CCT proteins. This 
has previously been reported in the case of CCT2, which also leads to a decrease in protein levels of 
CCT7 (Pavel et al., 2016), also observed here. Galectin-3 levels also decreased on knockdown of any 
CCT protein studied here. GAPDH was used as a loading control, as levels of actin decreased when any 
CCT protein was knocked down. As the CCT proteins are required to fold actin (Willison, 2018), it is 
likely that unfolded actin is degraded. Next, it was important to confirm that knockdown of CCT 
proteins did in fact alter galectin-3 levels at the cell surface. As expected, galectin-3 levels on the cell 
surface decreased for all CCT knockdowns tested when measured by flow cytometry, as shown in 
Figure 5.3Bi and quantified in Figure 5.3Biii. From these data, it remained possible that these hits were 
identified due to decreasing the overall level of in galectin-3 both in cells and on the cell surface. 
However, it was also important to assess conventional secretion upon knockdown. Major 
histocompatibility complex (MHC), a conventionally secreted glycoprotein, was assessed on the cell 
surface by flow cytometry. If MHC levels on the cell surface decreased on CCT knockdown, this would 
suggest that conventional secretion was affected. On the other hand, no change in MHC on the cell 
surface could mean conventional secretion was unaffected. In fact, MHC on the cell surface did not 
greatly change on CCT knockdown (Figure 5.3Bii, iii). To further probe whether there was a change in 
conventional protein secretion on CCT protein knockdown, secretion of ss-HRP was assessed by the 
ratio of supernatant and cell lysate HRP levels. In contrast to the results with MHC on the cell surface, 
knockdown of any CCT protein tested led to a decrease in ss-HRP secretion (Figure 5.3C), implying that 
the CCT proteins are important for conventional secretion. The most likely reason for this difference is 
due to the role of the CCT complex in folding actin and tubulin; because the CCT complex is essential 
for the formation of filamentous actin and microtubules, it is therefore important for general protein 
transport, as reviewed (Willison, 2018). It is likely that a change in the cytoskeleton results in a 




cell surface levels. Taking this together, it is likely that the CCT proteins were identified as hits due to 
their role in conventional glycoprotein secretion, not due to any possible role in directly regulating 
galectin-3 levels.  
Figure 5.3: Knockdown of CCT complex proteins. (A) (i) Western blot analysis of cell lysate, labelled 
with the antibody staining on the left and with the siRNA knockdown above, and (ii) quantification of 
band intensity of cell lysate, n = 3. Knockdown of CCT4, CCT5 and CCT7 is clearly seen at the protein 




although it is not clear that the antibody is specific to CCT2 as there were several non-specific bands 
using this antibody; the band thought to be CCT2 is indicated by an arrow. Knockdown of CCT5 and 
CCT7 also resulted in the knockdown of other CCT proteins. (B) Flow cytometry analysis of cells with 
CCT siRNA knockdown. Representative histograms of live cell surface staining for (i) galectin-3 and 
(ii) MHC, with (iii) quantification of percentage of cells in positive gates, n = 2. Error bars are standard 
error of the mean. Galectin-3 was decreased on the cell surface while MHC remained the same. (C) 
ss-HRP secretion measured 6 h (yellow) and 24 h (orange) after media was changed, from 3.1 x 104 
cells. Secretion was calculated by supernatant luminescence signal/cell lysate luminescence signal. All 
data are expressed relative to the average control siRNA for each condition. Error bars, where shown, 
represent standard error of the mean, n = 2. If not shown, n = 1. 
5.3.2 Optimisation of HRP assay conditions 
Given that CCT knockdown consistently reduced both galectin-3 levels on the cell surface and secretion 
of ss-HRP, CCT siRNA knockdown was then used to optimise the HRP assay. As shown, secretion was 
best measured 24 h after media was changed, which gave a greater dynamic range for the assay than 
after 6 h (Figure 5.3C). A comparison of the number of cells seeded showed that when compared to 
control siRNA, all CCT knockdown cells show reduced HRP secretion. Varying the number of cells made 
little difference to secretion levels, shown in Figure 5.4A. However, a comparison of the cell lysate and 
supernatant values separately showed that while there was little difference between luminescence in 
the cell lysates when different cell numbers were seeded (Figure 5.4Bi), seeding fewer cells resulted in 
a greater decrease in supernatant luminescence (Figure 5.4Bii). This suggested that when more cells 
were seeded, the amount of HRP secreted reached the limit of detection for the assay. Because of this, 





Figure 5.4: Optimisation of HRP assay. Secretion was calculated by supernatant luminescence 
signal/cell lysate luminescence signal. All data are expressed relative to the average control siRNA for 
each condition, with 3.1 x 104 (red) and 6.2 x 104 (blue) cells seeded. Error bars, where shown, 
represent standard error of the mean, n = 2. When (A) ss-HRP secretion was measured, there appeared 
to be little difference between results, but (B) differences were seen when (i) the cell lysate and (ii) the 
supernatant was plotted separately.  
5.3.3 HRP secondary screen 
To validate whether hits had a role in protein secretion, arrayed secondary screening was performed. 
HeLa-ss-HRP were transfected with pooled siRNA arrayed in a 96 well plate; each well had a pool of 
four siRNAs targeting one gene. The supernatant was collected and cells were lysed 72 h after 
transfection, and HRP levels were assessed by chemiluminescence. Knockdown that led to a decrease 




indicated genes that were important for glycoprotein secretion. Of the 368 genes targeted, knockdown 
of 93 genes resulted in less secretion of HRP (Figure 5.5A), listed in Figure 5.5B. As expected, many 
genes already known to be involved in protein secretion and glycosylation were identified by this 
screen. Of the 93 validated hits, 51 were not annotated with GO_Slim terms related to secretion or 






Figure 5.5: Secondary screen with ss-HRP to identify genes important for secretion. Approximately 
400 genes were screened in an arrayed siRNA knockdown format. (A) Mean of the normalised 
luminescence for both cell lysate and supernatant signals from two independent replicates. Points are 
coloured by their annotation from the hit list presented in Chapter 4. Those with significant divergence 
from control siRNAs, as identified by the ROUT method, are indicated by a circle (●); non-significant 
hits are indicated by a cross (x). Both genes known and not known to be involved in protein transport 
or glycosylation were identified as significant hits. (B) Mean values for normalised luminescence for 
cell lysate and supernatant (SN) signals of the 94 hits identified, again categorised using the same 
categories presented in Chapter 4. Here these hits are shown on a white-red scale, where darker red 
indicates a greater secretion defect. Both (i) genes annotated with transport-related terms and (ii) 
those without were identified. Several genes had no GO_Slim annotations; of these, genes with no GO 
annotations at all are indicated in italics. Genes defined as not related to protein transport have other 
annotations in the generic GO_Slim. 
To be able to compare the success of the analysis methods from Chapter 4, the method used to identify 
the hits was analysed. The 51 novel hits identified originated mostly from MaGECK-MLE analysis, as 
shown in Figure 5.6A. However, the proportion of hits identified from each of the two MaGECK 
methods, MLE and RRA, was similar (Figure 5.6B), indicating that both methods were good at 





Figure 5.6: Original method used to identify validated hits. (A) Origin of novel hits identified by 
secondary screening with ss-HRP. This graph presents the hits from Figure 5.5A, coloured according to 
the analysis method they were identified by in Chapter 4. (B) Comparison of origin of novel hits 
identified as a percentage of the full hit list.  
5.3.4 Golgi morphology screening 
The 93 hits identified from ss-HRP screening were then further investigated for changes in ER and Golgi 
morphology, using the same arrayed siRNA knockdown as before. At 72 h after siRNA transfection, 
cells were fixed and analysed by immunofluorescence, using an antibody against GM130, a marker of 
cis-Golgi membranes. Cells were also stained using an antibody against calnexin, an ER marker. At the 
resolution used, no quantifiable changes in ER morphology were identified (data not shown). However, 
many cells showed changes to Golgi morphology. Images were collected and classified as having 
aberrant or intact cis-Golgi using the machine learning platform within CellProfiler (Carpenter et al., 
2006; Jones et al., 2009), as shown in Figure 5.7A and B (for unprocessed images, see Appendix Aii). 
Many of the silenced genes resulted in an increase in aberrant Golgi compared to the control wells, 
which had approximately 20 % aberrant Golgi. Of the 93 hits, 78 had over 30 % of cells with aberrant 
Golgi and 42 had over 50 % of cells with aberrant Golgi. Genes with more than the median percentage 






Figure 5.7: Secondary screen for disruption to Golgi morphology. (A) Workflow of Golgi morphology 
screen. (B) Training set used to train the CellProfiler Analyst (CPA) classifier to distinguish between 
aberrant and intact Golgi. Using this training set, sensitivity was 77 % for aberrant Golgi class and 82 % 
for the intact Golgi class. Examples of control and test images classified using CPA are also shown. Cells 
with aberrant Golgi are labelled with 1; cells with intact Golgi are labelled with 2. (C) Percentage of 
cells with aberrant Golgi for the hits above the median from secondary screen. Hits are arranged 
alphabetically and coloured by cell count, with darker blue spots representing more confluent wells. 
Five of these hits were further characterised, indicated with blue rectangles.  
5.3.5 Further investigation of specific hits 
Five hits were selected for further investigation: GPR161, TMEM220, FAM98B, FAM102B and MXRA7. 
These hits had all been validated as having protein secretion defects by the HRP screen and were in 
the top half of hits with aberrant Golgi in the Golgi screen. All had unclear functions in protein secretion 




Firstly, these hits were validated further using siRNA knockdown and confocal imaging. Cells were 
stained for TGN46 and GM130 to confirm an aberrant Golgi phenotype; knockdown of all five hits 
resulted in a change to Golgi structure, shown in Figure 5.8. To see whether protein secretion was 
affected, cells were stained for SEC31, which is required to form COPII vesicles, and for MHC, a protein 
that is usually secreted and anchored in the plasma membrane. For all five hits, SEC31 distribution was 
more diffuse than in control cells, and plasma membrane localisation of MHC was not detected (Figure 
5.8).  
 
Figure 5.8: Immunostaining of HeLa cells treated with siRNA to knockdown each of the five genes 
indicated above the images. Cells were stained with the antibodies against the proteins indicated in 
green or red on the left. For all images, DAPI staining is shown in blue. Here, SEC31 and MHC-I imaging 
was performed by Kevin Moreau, original magnification 20x. 
5.3.5.1 Localisation of FLAG-tagged hits 
As these five hits are poorly characterised in the literature, cDNA constructs of each of these genes 
fused in frame to a FLAG-tag were used to study the subcellular localisation of each corresponding 
protein (Figure 5.9). In particular, it was interesting to see whether any hits localised to the ER or the 
Golgi, as these are key organelles in the secretory pathway. HeLa cells were transiently transfected 
with cDNA, then fixed 24 h after transfection. Fixed cells were immunostained for FLAG and either 




as seen by its colocalisation with TGN46 (Figure 5.9A), whereas TMEM220 and MXRA7 both partially 
colocalised with calnexin, indicating that they are found at the ER (Figure 5.9B, C). FAM98B was 
nucleocytoplasmic (Figure 5.9D). Finally, FAM102B was found both at the plasma membrane and in 
the cytosol (Figure 5.9E). However, it is important to note that the overexpression of these FLAG-
tagged constructs may not reflect the endogenous protein localisation, as some dominant negative 
effect might happen when using the cDNA construct. This appeared to be the case for TMEM220, as 
the TGN46 immunostaining seemed compromised in the transfected cells, with transfected cells not 
showing Golgi staining (Figure 5.9B).  
 
Figure 5.9: Localisation study for new regulators of glycoprotein secretion. Fluorescence microscopy 
images of HeLa cells expressing a FLAG-tagged cDNA construct show each protein’s localisation by co-
staining with either an ER marker, calnexin, or a Golgi marker, TGN46. In the merged images, FLAG 
staining is shown in green and calnexin or TGN46 staining is shown in red. The subcellular localisation 
of each protein construct is indicated in green on the cell diagrams. Darker shades of green are used 
to indicate the most prominent location if the construct localises to more than one compartment. A-E 
show expression of FLAG-tagged (A) GPR161, (B) TMEM220, (C) MXRA7, (D) FAM98B and (E) FAM102B. 




To validate the localisation of GPR161 and TMEM220, specific antibodies were used. Staining the 
endogenous proteins confirmed that GPR161 localised mainly to the Golgi, shown in Figure 5.10Ai. 
Furthermore, knockdown of GPR161 showed only background staining and no Golgi staining (Figure 
5.10Bi). Unlike the FLAG-tagged construct, endogenous TMEM220 localised to the Golgi and not the 
ER, shown in Figure 5.10Ai. This Golgi residence was similarly confirmed using siRNA (Figure 5.10Bii). 
It was therefore likely that the overexpression of TMEM220 caused a perturbation in the trafficking of 
proteins from the ER to the Golgi. 
 
Figure 5.10: Endogenous localisation of GPR161 and TMEM220. (A) Colocalisation fluorescence 
microscopy showed that both (i) GPR161 and (ii) TMEM220 colocalise with TGN46 and GM130, two 
Golgi markers, and not with calnexin, a marker of the ER. (B) siRNA knockdown of (i) GPR161 or 
(ii) TMEM220 demonstrates that the antibodies used to detect these endogenous proteins only 
specifically detect protein at the Golgi. Original magnification 20x. Note that these experiments were 
performed by Kevin Moreau.  
5.3.5.2 Rescue of GPR161 and TMEM220 
As both GPR161 and TMEM220 localised to the Golgi, and it was clear from the Golgi morphology 
screen that the Golgi apparatus was altered by knockdown of these genes, these specific hits were 
further investigated. To confirm that knockdown of the hits was responsible for the phenotype of 




at least partly rescued by expression of the FLAG construct, as TGN46 localised more tightly together 
and was perinuclear, shown in Figure 5.11. On the other hand, TMEM220 did not seem to be rescued 
(Figure 5.11). As seen previously, overexpression of TMEM220-FLAG seemed to lead to a perturbation 
in the trafficking of proteins from the ER to the Golgi, which may be why a rescue was not seen here. 
These experiments help to validate the siRNA for GPR161 used here. 
 
Figure 5.11: siRNA-rescue experiments. Genes were knocked down with siRNA, then rescued by 
expressing the appropriate FLAG-tagged construct. Cells were stained with DAPI, anti-FLAG and 
anti-TGN46 to observe the effect on the Golgi after siRNA knockdown and rescue.  
5.3.6 GPR161 was important for golgin A5 localisation 
The results thus far demonstrated that GPR161 is a new Golgi-resident protein. Interestingly, the 
BioPlex network (Huttlin et al., 2017; Schweppe et al., 2018) showed that GPR161 interacts with 
golgin A5 (also known as golgin-84), which is known to contribute to maintaining Golgi morphology, 
likely by its interaction with Rab1A (Diao et al., 2003; Liu et al., 2016; Satoh et al., 2003). Further 
support for this interaction has come from colocalisation fluorescence microscopy, which showed that 
golgin A5 and FLAG-GPR161 colocalised (Popa et al., 2020).  
Here, GPR161 was knocked down to investigate whether the GPR161-golgin A5 interaction was 
required for localisation of golgin A5. As a control, TMEM220 was also knocked down, to be able to 
determine whether any change observed was due to the specific action of GPR161, or due to disruption 
of the Golgi more generally. The knockdown of GPR161 did not alter the colocalisation between 
golgin A5 and GM130; if there was any change, it may be a small increase in colocalisation given that 
disruption of the Golgi caused by TMEM220 knockdown led to a small decrease in colocalisation (Figure 




TGN46, but this effect was larger and more significant for GPR161, indicating that the effect from 
GPR161 knockdown was partly due to the aberrant Golgi structure and partly due to a specific effect 
mediated by GPR161 (Figure 5.12B). A possible explanation for these results is that GPR161 is required 
for golgin A5 to be located to the trans-Golgi network; without GPR161, golgin A5 is restricted to the 
cis-Golgi. Therefore, GPR161 may serve to recruit golgin A5 to the trans-Golgi membrane in order to 





Figure 5.12: GPR161 and TMEM220, two novel Golgi-resident proteins involved in protein secretion, 
regulate glycoprotein secretion by different mechanisms. (A) Colocalisation of Golgin A5 with GM130, 
(i) representative microscopy images, original magnification 40x, and (ii) quantification of 
colocalisation by Pearson’s coefficient. No significant difference between groups in colocalisation was 
detected when either GPR161 or TMEM220 was knocked out, tested by ANOVA. (B) Colocalisation of 
Golgin A5 with TGN46, (i) representative microscopy images, original magnification 40x, and 
(ii) quantification of colocalisation by Pearson’s coefficient. Tukey HSD post-hoc test results after 
ANOVA are indicated above the graph: *, p < 0.1; ***, p < 0.001. Colocalisation of golgin A5 with 
TGN46 decreased on GPR161 knockdown more than for TMEM220 knockdown. For (A) and (B), at least 





In this chapter, arrayed siRNA secondary screening of the hit list presented in Chapter 4 validated 93 
hits as reducing the secretion of ss-HRP. Importantly, 51 of these genes were previously unknown to 
be regulators of protein secretion. While only a few were further investigated, this list of 51 genes will 
serve as a useful resource for other researchers investigating conventional protein secretion. Following 
secondary screening, five of the hits were investigated further. These hits were selected from the hits 
that both had a decrease in ss-HRP secretion and had altered Golgi architecture. These did not 
necessarily have the highest rank as measured by these assays, but were chosen from the list of top 
hits based on having potentially interesting functions. Further investigation of GPR161 indicated that 
a likely mechanism for its regulation of protein secretion is via an interaction with Golgin A5. 
5.4.1 Hits validated as involved in protein secretion 
Here, 93 of the 368 hits identified from the CRISPR screen were validated as being important for 
conventional protein secretion, as tested by the ss-HRP assay. While over half of these are novel hits, 
demonstrating the utility of the CRISPR screen approach to identify novel genes involved in protein 
secretion, this result also highlights the importance of secondary screening to validate CRISPR screen 
hits. Here the FDR was 0.5, indicating that 50 % of the hits could be expected to be false positives. 
Actually, only 25 % of the hits were validated in the ss-HRP screen. When separated into functional 
categories given in Chapter 4 (Figure 4.15), approximately 25 % of each category is represented in the 
validated list, although of the smaller category of hits involved in glycosylation, 42 % of the hits were 
validated by the ss-HRP screen. Given that only 37 of the 146 hits known to be involved in protein 
secretion were validated here, it is possible that using siRNA to knockdown genes, rather than a 
complete knockout, led to some hits being missed which would have been identified by knockout 
secondary screening.  
It is also possible that further hits involved in secretion might be validated by a different secondary 
screening method, which might increase the number of validated hits to be in line with the FDR. For 
example, Bard et al. noted that knockdown of genes involved in cholesterol biosynthesis resulted in a 
block of ss-HRP secretion (Bard et al., 2006), showing that the assay used can result in hits not directly 
related to protein secretion being identified. Similarly, the secreted luciferase assay used by Chia et al. 
identified a number of SNARE proteins whose depletion resulted in an increase in luciferase secretion, 
thought to be due to a diversion of luciferase to lysosomes which is defective upon knockdown of these 
SNARE proteins (Chia et al., 2012). Indirect assay effects such as these are due to expression of 
exogenous proteins, and would imply that other complementary methods looking at endogenous 




range of screening methods is highlighted by the optimisation using CCT proteins, which found no 
change in the level of MHC on the cell surface, most likely due to a change in both internalisation and 
externalisation. However, the relatively low rate of validation of hits already known to be involved in 
transport may alternatively be an issue with the GO_Slim annotations; as categories are so broad, 
genes involved in trafficking of only specific proteins are also included within the “transport” category.  
Since the results of the previous two chapters and the work on CCT proteins in this chapter indicated 
that the CRISPR screen was unlikely to be able to identify regulators of galectin-3 secretion, secondary 
screening did not focus on this. Although unlikely, it has therefore not been ruled out that such 
regulators could have been identified. An additional secondary screen of the hit list to measure 
galectin-3 in the supernatant, for example by an ELISA, would show definitively whether regulators of 
galectin-3 secretion were able to be identified from this screen.  
5.4.2 Further investigation into Golgi-localised hits 
5.4.2.1 GPR161 
GPR161 is a G-protein coupled receptor (GPCR) that is involved in neural tube development and acts 
as a regulator of cell signalling pathways, including Sonic hedgehog (Shh) signalling, protein kinase A 
(PKA) signalling, retinoic acid signalling and Wnt signalling (B. I. Li et al., 2015; Mukhopadhyay et al., 
2013). Previous work has demonstrated an interaction between GPR161 and PKA (Bachmann et al., 
2016). The interaction with PKA subunits is interesting, as a PKA signalling pathway has previously been 
shown to regulate retrograde transport from the Golgi to the ER, which indirectly also affects 
anterograde traffic (Cancino et al., 2014). Previous work found that PKA regulatory subunits binding to 
GPR161 results in its transport to the plasma membrane to signal through PKA (Bachmann et al., 2016). 
Here, overexpressed or endogenous GPR161 was not observed at the plasma membrane, suggesting 
that a different mechanism may be important here. Instead, GPR161 was found to localise to the Golgi, 
and is likely to be involved in regulation of Golgi morphology and glycoprotein traffic. This finding fits 
with the emerging idea that GPCRs are able to regulate protein trafficking (Añel and Malhotra, 2005). 
It has recently become clear that GPCRs function at membranes other than the plasma membrane 
(Eichel and von Zastrow, 2018), and previous work has suggested that a Golgi-resident GPCR regulates 
transport from the Golgi (Añel and Malhotra, 2005), although the specific GPCR involved remains 
unknown (Añel and Malhotra, 2005; Eichel and von Zastrow, 2018). The finding that GPR161 localises 
to the Golgi, and that its knockdown leads to a change in Golgi structure, highlights it as a candidate 
to be one such unknown transport-regulating GPCR. 
The BioPlex network for GPR161 shows an interaction with golgin A5, as well as with five PKA subunits 




role in intra-Golgi vesicle capture (Wong et al., 2017) and contributes to maintaining Golgi morphology 
(Diao et al., 2003; Liu et al., 2016; Satoh et al., 2003). Depletion of golgin A5 leads to dispersion of the 
Golgi throughout the cytoplasm (Diao et al., 2003), and golgin A5 is required for Golgi reassembly in a 
cell free assay (Satoh et al., 2003). It has been suggested that golgin A5 could act to stack cisternae at 
the trans-Golgi, in a similar way to GRASP55 and GRASP65 (Satoh et al., 2003). Like GRASP55 and 
GRAPS65, golgin A5 is phosphorylated in mitosis (Diao et al., 2003). Golgin A5 has also been shown to 
directly interact with Rab1A (Diao et al., 2003; Liu et al., 2016; Satoh et al., 2003), and as Rab1A is also 
required for Golgi stability, it is likely that this interaction is important for maintenance of Golgi 
morphology (Liu et al., 2016). 
While the role of golgin A5 in vesicle tethering and Golgi maintenance is becoming clearer, its specific 
localisation within the Golgi is not clear. Images of human osteosarcoma U-2 OS cells in the human 
protein atlas show that golgin A5 localises specifically to the Golgi, but not to the cis-Golgi (Thul et al., 
2017). However, electron microscopy (EM) in HeLa and epidermal A431 cells showed that while 
golgin A5 was found throughout the Golgi, most (66 %) was in the cis-Golgi network, and also found 
that GM130 and golgin A5 localise to different regions of the cis-Golgi (Diao et al., 2003). In contrast, 
golgin A5 was found throughout the Golgi stack by EM in normal rat kidney epithelial (NRK) cells (Satoh 
et al., 2003). More recent work, also using EM, found golgin A5 localised to COPI-coated vesicles in a 
cell-free assay, where it acts as a tether to target vesicles to the cis-Golgi (Malsam et al., 2005). The 
fact that golgin A5 was present in COPI-coated vesicles suggests that at one point, it must also be found 
in the medial- or trans-Golgi membranes.  
Here, golgin A5 was found to colocalise with both GM130 and TGN46 by confocal microscopy, although 
localisation with TGN46 was higher than with GM130, suggesting an increasing localisation specifically 
to the trans-Golgi, consistent with results from Satoh et al. (Satoh et al., 2003). Furthermore, the data 
here suggest that the interaction between GPR161 and golgin A5 is important for maintenance of the 
Golgi architecture and function. On GPR161 knockdown, golgin A5 colocalisation with TGN46 
decreased, while golgin A5 colocalisation with GM130 did not decrease. Together, this suggests that 
GPR161 is required for golgin A5 localisation to the trans-Golgi, potentially for its role in retrograde 
trafficking from the trans- to cis-Golgi. This possible mechanism would have to be investigated further. 
In vitro, golgin A5 and GPR161 have been confirmed to interact via an affinity purification experiment 
in which GPR161 pulled down golgin A5 from the lysate of HEK293T cells (Huttlin et al., 2017; Schweppe 
et al., 2018); additionally, golgin A5 and GPR161 have also been shown to colocalise by confocal 
microscopy (Popa et al., 2020). Initially, it would be important to confirm that golgin A5 and GPR161 




on fixed cells. If this were confirmed, further experiments involving mutated forms of GPR161 and 
golgin A5 could be used to investigate the importance of interaction. If expression of mutated forms 
of GPR161 and golgin A5 which were unable to interact with each other resulted in a similar 
perturbation of Golgi structure, this would indicate that their interaction was essential for 
maintenance of Golgi structure.  
5.4.2.2 TMEM220 
TMEM220 is a transmembrane protein that, when used as a bait protein for HEK293T lysate, has been 
shown to interact with both actin and testis-specific GAPDH (GAPDHS) in the BioPlex network. (Huttlin 
et al., 2017; Schweppe et al., 2018). Actin, and the cytoskeleton in general, is well known to contribute 
to protein trafficking along the secretory pathway; for example, it is recruited to the Golgi by a complex 
of SPCA1 and active cofilin, where it is suggested to form a membrane domain required to initiate 
sorting of secretory cargo (Gurel et al., 2014; Pakdel and von Blume, 2018; von Blume et al., 2011). It 
is possible that TMEM220 acts as an anchor for actin on the Golgi membrane. Initial experiments by 
Kevin Moreau investigated the colocalisation of actin and TGN46 on TMEM220 knockdown compared 
to control cells, but no difference in colocalisation was found (unpublished data). However, this was 
confocal imaging at 20x magnification, and as actin is throughout the cell, it is hard to detect changes 
in colocalisation. As such, this evidence is not conclusive.  
Alternatively, TMEM220 could affect protein secretion via an interaction with GAPDH. However, it has 
not been shown that TMEM220 and GAPDH specifically (rather than GAPDHS) interact with each other, 
so this would first have to be demonstrated before this potential mechanism is pursued. GAPDH has 
recently been implicated in protein secretion via inhibition of ADP ribosylation factor GTPase activating 
proteins (ARFGAPs) (Yang et al., 2018). Specifically, GAPDH is recruited to the Golgi under starvation 
conditions, where it inhibits COPI fission, cargo transport from the Golgi to the plasma membrane, and 
endocytic pathways by inhibiting the GTPase activating protein (GAP) activity of specific ARFGAPs 
(Yang et al., 2018). If TMEM220 and GAPDH do interact, it is possible that TMEM220 regulates this 
recruitment.  
5.4.3 Conclusions 
The results in this chapter demonstrate that novel regulators of glycoprotein secretion were identified 
by arrayed screening of a selection of genes identified from MaGECK analysis of the pooled CRISPR 
screen. It is not clear whether these regulators are specific to glycoprotein secretion; they may be more 
general regulators of protein secretion. In any case, this list of 51 novel genes involved in secretion 
should be a useful resource for other researchers. For many of the genes validated by ss-HRP screening, 




impaired. After additional investigation, two proteins from the hit list localise to the Golgi. While the 
mechanism by which the two novel Golgi-localised genes identified in this chapter is not confirmed, it 








The work presented in this thesis has made progress in understanding both conventional and 
unconventional secretion. Specifically, further insights into the mechanism of galectin-3 secretion have 
been gained, and novel regulators of conventional secretion have been identified; one, GRP161, has 
been further investigated. Overall, the thesis achieved many of its aims, but did not identify regulators 
of galectin-3 secretion, or more broadly, of unconventional protein secretion. In this chapter, the broad 
implications of this work are discussed, as well as open questions that remain. These questions will be 





6.1 Galectin-3 unconventional protein secretion 
Galectin-3 is a cytosolic protein that is secreted without entering the conventional secretory pathway 
for its export to the extracellular space, as reviewed (Popa et al., 2018) and discussed in Chapters 1 
and 3. However, the mechanisms underlying its secretion remain poorly understood. Therefore, the 
first aim of this thesis was to provide further insights into the mechanism of galectin-3 secretion; 
specifically, to clarify the role of both cell surface glycans and unfolding of galectin-3 in secretion. 
Previous work on whether galectin-1 required glycans on the cell surface for secretion had been 
contradictory (Cho and Cummings, 1995; Seelenmeyer et al., 2005), but recent work in the Moreau lab 
has shown that glycosylation could be disrupted while galectin-3 was still secreted (Stewart et al., 
2017). The results presented in Chapter 3 agree with this finding, and show that galectin-3 does not 
need to bind to glycans to be secreted. Additionally, the results here show that galectin-3 does not 
require unfolding to be secreted, which is a new and important insight. This is in line with the finding 
that several other unconventionally proteins do not require unfolding for secretion (Backhaus et al., 
2004; Graziani et al., 2009), including galectin-1 (Backhaus et al., 2004). 
6.1.1 Pathways for galectin-3 secretion 
As mentioned above, the route that galectin-3 uses for secretion remains an open question. Previous 
work has implicated either direct translocation across the plasma membrane or release in EVs as 
pathways for secretion, and these are likely to be used in different circumstances (Popa et al., 2018). 
The findings of Chapter 3 that neither unfolding nor cell surface glycans are required for secretion do 
not specifically implicate either direct translocation or release in EVs as a pathway for galectin-3 
secretion; either pathway could be used with these conditions fulfilled. If direct translocation is used 
for galectin-3 secretion, the results presented in Chapter 3 show that glycans are not required to pull 
galectin-3 in one direction across the membrane. Therefore, the question of the pathway galectin-3 
uses for secretion remains open. 
Importantly, of these two pathways, only direct translocation is able to fully explain galectin-3 
secretion; if galectin-3 were released in EVs it would remain sequestered in the lumen of EVs separated 
from the external leaflet of the plasma membrane. While galectin-3 has been shown to be in EVs 
(Bänfer et al., 2018; Mehul and Hughes, 1997), many questions remain surrounding this pathway. 
Firstly, do EVs represent a basal route for secretion, or are they only relevant under conditions of 
cellular stress? If EVs are important under normal conditions, how do they release galectin-3 in order 
for it to function on the cell surface? Do all cell types use EVs for galectin-3 secretion or is this pathway 




6.1.2 Direct translocation as a pathway for secretion 
Although direct translocation provides a more complete explanation for galectin-3 secretion than 
release in EVs, questions also remain surrounding the possible direct translocation for galectin-3. 
Previous work in liposomes has suggested that galectin-3 is able to move across the lipid bilayer using 
only an interaction with cholesterol (Lukyanov et al., 2005). However, more recent work has cast doubt 
on this suggestion (Stewart et al., 2018). Therefore, the question remains as to what machinery is 
required. For the secretion of FGF-2, the minimal machinery comprises of three parts. First, PI(4,5)P2, 
which recruits FGF-2 to the membrane; second, the ability of FGF-2 to oligomerise to form a pore, 
which is dependent on phosphorylation by Tec kinase; and third, heparan sulfate proteoglycans, which 
ensure one-directional transport (Brough et al., 2017; Steringer et al., 2017). Na2+/K+-ATPase facilitates 
initial recruitment of FGF-2 (Legrand et al., 2020), and is essential for FGF-2 secretion from cells, but is 
not required for FGF-2 to cross the membrane in a model system. Although it has been suggested that 
these key steps could be generalised to other unconventionally secreted proteins (Brough et al., 2017), 
the work presented in Chapter 3 demonstrates that glycans for galectin-3 do not act in the same way 
as heparan sulfate for FGF-2. However, there are points that need to be addressed in order to 
determine whether the first two steps apply to secretion of galectin-3. 
6.1.2.1 Recruitment to the plasma membrane 
Firstly, it needs to be shown that endogenous galectin-3 is able to accumulate under the plasma 
membrane, which so far has only been assumed by similarity to galectin-1. This could be demonstrated 
by immunohistochemistry, in the same way as it was for galectin-1 (Cooper and Barondes, 1990). It 
would be important for both permeabilised cells and non-permeabilised cells to be studied at a high 
resolution, in order that galectin-3 bound to the cell surface could be distinguished from galectin-3 
inside cells. Secondly, while the disordered N-terminal domain is required for both oligomerisation and 
secretion of galectin-3 (Gong et al., 1999; Lin et al., 2017), galectin-3 does not insert into the membrane 
of liposomes (Stewart et al., 2018). Therefore, many questions remain surrounding the step of 
translocation. Does galectin-3 form a pore for its own secretion? If it does not, is another protein 
involved, as is the case for IL-1β secretion? As has previously been suggested (Delacour et al., 2009; 
Popa et al., 2018), is oligomerisation required for translocation? 
6.1.2.2 Galectin-3 oligomerisation 
Oligomerisation of galectin-3 has been investigated in detail using NMR spectroscopy. Galectin-3 forms 
oligomers both by NTD-NTD interactions between molecules, and by NTD-CRD interactions, in which 
many NTD interact with the CRD of one galectin-3 molecule, both inter-and intramolecularly (Lin et al., 
2017). The NTD-NTD interactions are thought to form pentamers of galectin-3 (Ahmad et al., 2004). It 




the interaction is “fuzzy”, meaning that there is no single residue responsible for oligomerisation (Lin 
et al., 2017). Therefore, unlike for FGF-2, a single point mutation could not be used to determine 
whether oligomerisation is required for secretion. However, Lin et al. found that deletion of the first 
20 residues resulted in a stronger interaction between the NTD-CRD, while larger deletions of up to 
100 residues reduced oligomerisation of galectin-3 (Lin et al., 2017). Since deletion of the first 11 
residues was found to block secretion (Gong et al., 1999), it may be that a weaker interaction between 
the NTD and CRD is required for secretion. A more thorough investigation of localisation of the 
truncated form of galectin-3 would be interesting. For example, if a transient pore of galectin-3 is 
formed in a lipid bilayer for its secretion, it could be that with the stronger interaction caused by 
deletion of the first 10-20 residues, galectin-3 oligomers cannot disassemble and would therefore be 
trapped in the membrane. An initial experiment to address this could be a comparison of localisation 
of the truncated version to wild type galectin-3 by high resolution microscopy. 
6.2 Alternative screening approaches to identify regulators of unconventional protein 
secretion 
Overall, the mechanism within either putative pathway that galectin-3 uses for secretion remains 
unclear, and the same can be said of the pathway mechanisms for unconventional secretion in general. 
Regardless of the mechanism by which galectin-3 moves across a lipid bilayer, there are likely to be 
other regulators involved. For example, are there regulators of galectin-3 secretion that make 
secretion more efficient while not being absolutely required for translocation? Moreover, are there 
general regulators that control the secretion of many different unconventionally secreted proteins? 
The question of how to identify broad regulators or principles in unconventional protein secretion 
remains. 
Another aim of this thesis was to identify regulators of galectin-3 secretion. Although the pipeline of 
CRISPR screening followed by secondary screening presented here was intended in part to identify 
regulators of galectin-3 secretion, it is very likely that the screen was not capable of this. This is due to 
the observed transfer of galectin-3 between cells, described both in the literature (Clark et al., 2012; 
Colomb et al., 2017; Yang et al., 2017) and in Chapter 3, and because galectin-3 itself was not identified 
as a hit in the CRISPR screen described in Chapter 4. Additionally, many of the hits identified here 
resulted in a change to Golgi morphology, shown in Chapter 5. Given that all types of unconventional 
protein secretion of leaderless proteins avoid using the Golgi apparatus, it is unlikely that these would 
have an effect on unconventional protein secretion, although it is possible that some could have an 




possibility of identifying other factors affecting galectin-3 secretion from this had not been ruled out. 
Overall, it is very likely that an alternative screen design would be required to identify regulators either 
of galectin-3 secretion, or of unconventional secretion more generally. 
6.2.1 Cell surface galectin-3 in arrayed screening 
The simplest way to avoid the issue of galectin-3 transfer between cells would be to use an arrayed 
screen for galectin-3 on the cell surface. However, although a seemingly simple solution, it would be 
very impractical to carry out FACS on every gene knockdown individually. In fact, genome-wide arrayed 
screens have so far rarely been used due to the increased cost and technical difficulties performing 
such a screen (Agrotis and Ketteler, 2015). Unless screening for essential genes, subsets are typically 
screened, such as the kinome or the druggable genome. One recent arrayed screen that assessed cell 
morphology developed a machine learning method that enables the application of this method for 
genome-wide screening (Groot et al., 2018), but as yet this has not been performed. If an arrayed 
screen were to be implemented in this case, an initial screen must first be carried out to reduce the 
pool screened by FACS. For example, galectin-3 in the supernatant could be assessed by ELISA. Cells 
with a low level of galectin-3 free in the supernatant would have a genotype that led to either a 
decrease in secretion of galectin-3 or an overall decrease in protein production. This would leave a 
smaller number of hits to screen by FACS. Even so, automation would be required to effectively 
perform a screen in this way, and as there would likely still be a high number of cell pools to sort 
individually, this would still be impractical.  
6.2.2 Alternative pooled screening approaches using cell surface galectin-3 
If regulators of galectin-3 secretion were to be identified by a pooled genome-wide CRISPR screen, 
there would have to be a way of avoiding the identification of genes that merely resulted in a lack of 
glycoproteins on the cell surface. One way of doing this would be by first identifying and excluding cells 
with reduced cell surface glycoproteins. Ricinus communis agglutinin (RCA) is a β-galactoside-binding 
lectin (Wu et al., 2006) which has previously been used to assess glycans on the cell surface by flow 
cytometry (Mathew and Donaldson, 2018). RCA is available directly conjugated to FITC, which could 
be used to assess the binding partners of galetin-3 without looking at galectin-3 levels, therefore 
assessing glycoprotein secretion alone. If cells with low levels of RCA binding were first excluded by 
FACS, cell sorting with anti-galectin-3-647 antibody could then be used to identify regulators of 
galectin-3 secretion. This method may also exclude cells with an overall decrease in protein production 
in the initial sorting step with RCA, therefore leaving a pool in which the only cells with a decrease in 
galectin-3 cell surface levels would have a gene knocked out that is involved in regulating galectin-3 
secretion. This method would have to be carefully optimised, as high levels of RCA have been reported 




An alternative method would be finding a way of retaining galectin-3 at the cell surface that did not 
depend on glycans. This could be achieved by expressing a cell surface protein fused to a protein that 
binds to galectin-3 with high affinity, such as a single chain variable fragment (scFv) of anti-galectin-3 
antibody. In this way, galectin-3 released from cells that lacked cell surface glycoproteins would be 
retained by the anti-galectin-3 scFv, so no additional rounds of sorting would be required. Cells with 
no cell surface glycoproteins that are able to secrete galectin-3 would still retain galectin-3 at the 
surface via the scFv, and therefore genes involved in glycosylation would not be identified. A similar 
idea would be to express galectin-3 fused to streptavidin binding peptide (SBP), and express a cell 
surface protein fused to streptavidin. However, these screening methods may still identify hits not 
involved in galectin-3 secretion, even if they avoided hits that regulate glycosylation, since regulators 
of the cell surface protein-scFv/streptavidin fusion construct could also be identified. This problem 
could be avoided by using multiple different membrane proteins to retain galectin-3 on the cell 
surface. Using a range of proteins secreted both conventionally, both using typically secreted proteins 
that follow the ER-Golgi pathway and proteins post-translationally inserted into the ER-Golgi pathway, 
as well as type IV unconventionally secreted proteins, could alleviate this issue.  
6.2.3 Using an alternative protein on the cell surface 
Overall, there is no guarantee that a CRISPR screen using galectin-3 would be capable of identifying 
regulators of unconventional secretion, given that the localisation of galectin-3 at the cell surface is 
dependent on conventional secretion. It is possible that the use of another unconventionally secreted 
protein could be used which would not have this problem. For example, annexin A2 is unconventionally 
secreted (Popa et al., 2018) and, binds to phospholipids dependent on Ca2+ (Gerke and Moss, 2002). 
Therefore, when secreted, annexin A2 remains tightly bound to the cell surface unless treated with 
EDTA, as shown by the absence of annexin A2 in the supernatant in Chapter 3 when annexin A2-FLAG 
was used as a control construct. Since annexin A2 directly binds phospholipids on the cell surface, a 
genome wide CRISPR screen using cell surface annexin A2 as a readout would avoid identifying 
regulators of conventional secretion. In a similar way to the CRISPR screen with galectin-3, this method 
may identify regulators of Ca2+ levels as well as regulators of annexin A2 secretion. However, as some 
mechanisms already known to regulate annexin A2 secretion involve Ca2+, this may not present the 
same challenges as for galectin-3. 
6.2.4 General regulators of unconventional protein secretion 
The question still remains whether there are general regulators of unconventional protein secretion. 
So far, some general regulators have been proposed, but it is not clear whether there are any general 
factors that regulate a basal level of secretion, as opposed to exclusively being involved in secretion 




(Keller et al., 2008). Caspase-1 was already known to be involved in IL-1β secretion, as it cleaves 
pro-IL-1β to its mature form (Dinarello, 1998), and it was more recently shown that formation of 
mature IL-1β by caspase-1 and release of IL-1β are distinct events (Galliher-Beckley, 2013). 
Additionally, IL-1β is secreted through a gasdermin-D pore formed by GSDMD-N, a product of caspase 
cleavage (Evavold et al., 2018; Heilig et al., 2018).  
The suggestion that caspase-1 is a general regulator of unconventional protein secretion has proven 
controversial. Keller et al. used a proteomics approach to identify proteins secreted from keratinocytes 
that had been irradiated with ultraviolet light for four hours that required caspase-1 for secretion, and 
identified 77 proteins, of which seven are known to be unconventionally secreted (Keller et al., 2008). 
Caspase-1 itself is not constitutively active but is activated by stress via the inflammasome (Franchi et 
al., 2009), and has also been implicated as a cell death protease (Denes et al., 2012). Throughout the 
Keller et al. paper, cells were irradiated with ultraviolet light to induce cellular stress. Although levels 
of both IL-1α and FGF-2 were shown to be decreased when caspase-1 was inhibited, both proteins 
were still secreted to some extent, demonstrating that caspase-1 is not the sole factor controlling their 
release from cells. Moreover, FGF-2 has been demonstrated to be secreted using minimal machinery 
which does not include caspase-1 (Steringer et al., 2017). As such, caspase-1 does not appear to be a 
general regulator of unconventional secretion, but could be a regulator of multiple unconventionally 
secreted proteins in stress conditions.  
Similarly, GRASP55 has also been proposed as a general regulator of type III and IV unconventional 
secretion (Gee et al., 2018; Malhotra, 2013; Rabouille et al., 2012), but again this only appears to be 
relevant in ER stress conditions, when activation of the unfolded protein response leads to increased 
expression of GRASP55 (Gee et al., 2018; van Ziel et al., 2019). IL-1β secretion is dependent on 
GRASP55 from activated macrophages; here it was found that GRASP55 modulates the unfolded 
protein response (Chiritoiu et al., 2019). 
6.2.4.1 Identification of general regulators of unconventional protein secretion 
If there are general regulators of unconventional secretion, these would be expected to be identified 
by screens using multiple different unconventionally secreted proteins. Two proteins, annexin A2 and 
galectin-3, have some similarities in what is known about their secretion. It has been proposed that 
both require oligomerisation to be secreted by direct translocation, and both are associated with EVs 
(Popa et al., 2018). Given these similarities, performing an altered galectin-3 screen, as described 
above (6.2.2), alongside a screen sorting based on cell surface annexin A2 levels (6.2.3), could be 
effective to identify general regulators of conventional secretion. Alternatively, an initial pooled 




screening with a different protein to identify more general regulators of unconventional protein 
secretion.  
6.3 Regulators of conventional protein secretion 
While the pathway for conventional secretion has been known for many years, there are several 
unknown aspects of this pathway. In particular, the regulation of parts of the conventional pathway 
remain unclear; specific unknown aspects are introduced in Chapter 1 and will be further discussed in 
this section. One aim of the CRISPR screen presented in this thesis was to identify some of these 
unknown regulators, which was achieved in Chapter 4 and 5. In Chapter 4, CRISPR screening was used 
as a tool to discover novel regulators of conventional protein secretion. A large number of hits were 
identified, with many already known to have a role in conventional protein secretion, implying that 
this approach was effective. In Chapter 5, several of these hits were validated as important for 
conventional protein secretion. Five of these validated hits were investigated further: FAM98B, 
FAM102B, GPR161, MXRA7 and TMEM220. By microscopy, all were confirmed to have a phenotype of 
a disrupted Golgi and disrupted secretion. Two of these, GPR161 and TMEM220, were found to localise 
to the Golgi. GPR161 is likely to mediate its effect on protein secretion and the Golgi structure via an 
interaction with golgin A5.  
In comparison to three other genome-wide screens for protein secretion, none of the five hits were 
previously identified by either Bard et al. (Bard et al., 2006), Simpson et al. (Simpson et al., 2012) or 
Bassaganyas et al. (Bassaganyas et al., 2019). It is not particularly surprising that none of the hits were 
identified in the screen of Drosophila cells by Bard et al. Of the five hits, only three have orthologues 
in Drosophila: FAM98B, FAM102B and MXRA7, and of these only MXRA7 has homology classed as high 
(53 %) (Hu et al., 2011). On the other hand, it is initially surprising that none of the five hits were 
identified by either Simpson et al. or Bassaganyas et al., as both of these screens also used HeLa cells. 
However, the criteria for inclusion in the list of 697 validated hits by Simpson et al. was that secretion 
of tsO45G was strongly inhibited by two siRNAs, and on average 2-3 siRNAs were used per gene. 
Therefore, it is possible that the five genes here did not meet this criteria and resulted in a milder 
phenotype, or that one or both siRNAs did not effectively target the gene. For the Bassaganyas et al. 
screen, the difference may be explained by the different screening methods. Here, all five of the hits 
were identified by MaGECK-MLE, with only one (FAM98B) being identified by both MaGECK-RRA and 
MaGECK-MLE (Figure 4.15). As Bassaganyas et al. used MaGECK-RRA and not MaGECK-MLE to identify 




Looking at Chapter 4 and 5 together demonstrates both the utility of pooled CRISPR screening in 
identifying novel regulators of protein secretion, and the importance of secondary screening to 
validate these regulators. With a validation rate of ~25 %, the likelihood of picking a true hit from the 
initial hit list is low. However, the overall approach; using genome-wide pooled screening to narrow 
down to a shortlist of hits for arrayed screening, is clearly powerful for the purpose of identifying novel 
hits. The importance of secondary screening, and careful planning of CRISPR screening pipelines, is 
discussed more generally in a recent review (Doench, 2018). 
6.3.1 Pooled CRISPR screen using galectin-3 to investigate conventional protein secretion 
The pooled CRISPR screen in Chapter 4 identified many hits that are well-known to be associated with 
protein transport to the cell surface and secretion, such as coat proteins, including COPA and COPG2; 
Rab proteins such as RAB4B, RAB7A, RAB11FIP1 and RAB11FIP3; members of the exocyst complex 
involved in targeting vesicles to the plasma membrane, including EXOC4, EXOC5 and EXOC6; proteins 
involved in vesicle fusion within the Golgi, including NSF; and the SNARE proteins VAMP3, VAMP5 and 
VAMP8. Other proteins have less direct roles, such as CCT2, CCT4 and CCT8, which are chaperones 
required to fold actin, which in turn is required for transport within the cell. The identification of 
proteins such as these that are well-known to be involved in the secretory pathway was a good initial 
validation step of the screen.  
It is important to note that these results also indicated that this screen was not a comprehensive way 
to identify every regulator of protein secretion, since other well-known factors in conventional protein 
secretion were not identified. This is also evident, for example, by looking at the members of the CCT 
protein complex. There are eight members of the CCT protein complex, of which five (CCT1, CCT2, 
CCT4, CCT5 and CCT7) primarily function in ATP hydrolysis and three (CCT3, CCT6 and CCT8) function 
in substrate binding (Kalisman et al., 2013). It would be expected that knockdown of any one subunit 
would have a similar effect on secretion as another, particularly as knockdown of one subunit results 
in the depletion of protein levels of other subunits (Pavel et al., 2016). However, only three were 
identified by the CRISPR screen. Furthermore, knockdown of two CCT genes not identified, CCT5 and 
CCT7, did decrease levels of galectin-3 on the cell surface, shown in Chapter 5. While this could indicate 
that the screen was not saturating, as was the case in the previous screen using the GeCKOv2 library 
(Stewart et al., 2017), there are other factors involved as well. Hits identified have other characteristics 
defined by the screen, such as the ability to survive multiple rounds of sorting. Therefore, factors which 
affect secretion but are also involved in the response to cell stress would not be expected to be 




Since any screen cannot comprehensively identify all regulators of conventional secretion, there are 
still regulators that remain unknown. One example of an area of conventional protein secretion that 
remains unclear is the packaging of cargo into COP-coated vesicles. Given that proteins involved in the 
coat protein complex were identified in the pipeline described in Chapter 4 and 5, perhaps regulators 
of packaging were also identified. Here, seven genes identified and validated had no GO annotations. 
It would be interesting for future researchers to investigate whether any of these genes could be 
involved in sorting or packaging cargo into COP-coated vesicles. However, there are many challenges 
in researching these hits, specifically around the lack of validated reagents such as antibodies by which 
they could be investigated. As shown by the investigation of TMEM220 in Chapter 5, simply 
overexpressing the protein with a tag can lead to altered behaviour of the protein.  
6.3.2 Comparison of MaGECK analysis methods 
How to correctly analyse a CRISPR screen is a complex question to answer, and different research 
groups use different methods, or even develop their own algorithms for this. Overall, while MaGECK 
appeared to be an appropriate way to analyse the data, the fact that there are two versions of MaGECK 
further complicated the issue. Here, both MaGECK methods were used, and the results were 
compared. From Chapter 4 alone, it was not possible to know which method of analysis was better to 
identify novel hits, but validation of hits in Chapter 5 allowed for a better comparison of methods. 
Although a greater number of hits were identified from MaGECK-MLE, as shown in Chapter 5, Figure 
5.6A, the proportion of hits identified from each of the two MaGECK methods, MLE and RRA, are 
similar (Figure 5.6B), indicating that both methods were good at identifying true positive hits compared 
to false positives. A greater percentage of hits identified by MaGECK-RRA were validated compared to 
those identified by MaGECK-MLE, but MaGECK-MLE identified a greater number of hits overall. Since 
many of these hits were validated, it appears that MaGECK-RRA was too stringent a method to reveal 
many novel hits as it missed many true positives. While MaGECK-MLE had a slightly lower validation 
rate, the absolute number of true positives identified by this method was greater. Pathway analysis 
identified fewer true positives as a percentage, showing that the FDR is a good measure of how likely 
the gene is to be a hit. It is also important to note that some hits were manually excluded based on 
their known function, such as in transcription. If these hits were included, the validation rate may well 
have been higher to align better with the FDR, but given that the aim here was to identify biologically 
interesting novel hits, these were not included in secondary screening. 
6.3.3 Additional hits for further investigation 
In Chapter 5, only five of the 51 novel hits identified were analysed further. All five hits were important 
for both Golgi morphology and secretion of MHC. After investigation of their subcellular localisation, 




protein secretion due to its interaction with golgin A5, as GPR161 knockdown decreased colocalisation 
of golgin A5 with TGN46. TMEM220 may affect protein secretion either by an interaction with actin or 
with GAPDH, but further investigation is required to understand its role in secretion. However, there 
were several other interesting hits, either with a proposed role in protein secretion, or with no 
confirmed role in protein secretion. Three of these will be discussed in more detail here. 
6.3.3.1 COL14A1 
A particularly interesting question in conventional protein secretion is how large proteins are secreted. 
While proteins such as procollagen are transported from the ER to the Golgi, it is unclear how this 
happens since procollagen is larger than COPII vesicles are thought to be (McCaughey and Stephens, 
2019; Stephens and Pepperkok, 2002). It has been suggested that either tunnels or large COPII-
dependent carriers are involved in this transport (McCaughey and Stephens, 2019; Raote and 
Malhotra, 2019). Interestingly, one of the hits identified in this screen is a collagen, COL14A1. 
Knockdown of COL14A1 was in the top ten for significance on the ss-HRP assay, and resulted in 
approximately 50 % of cells with aberrant Golgi morphology. These cells also had altered cell 
morphology and there were fewer cells per well in the morphology screen compared to control cells. 
This would be an interesting hit to investigate further, as it raises the question of whether some 
collagens could have a role in the secretory pathway, and if so, whether this role is linked to their own 
secretion.  
6.3.3.2 MARCH2 
Other proteins identified in this screen have recently been identified by other researchers as involved 
in protein transport, albeit with unclear roles, such as MARCH2. Previously, MARCH2 was identified as 
a likely regulator of traffic between the Golgi network and endosomes (Nakamura et al., 2005), and as 
such was included in the “transport” category defined in Chapter 4 when identified as a hit in the 
CRISPR screen. In Chapter 5, secretion of ss-HRP was moderately decreased on MARCH2 knockdown, 
and knockdown resulted in approximately 80 % of cells having aberrant Golgi morphology, confirming 
that MARCH2 has a role in protein secretion. However, the specific role of MARCH2 in protein secretion 
is unclear.  
Recent work has shown that MARCH2 ubiquitinates ERGIC3, targeting it for degradation (Yoo et al., 
2019). Secretion of specific proteins were also assessed in this study, and in contrast to the work 
presented in Chapter 5, it was found that depletion of MARCH2 resulted in increased secretion of 
haptoglobin but did not significantly affect secretion of two other proteins, α1-antitrypsin or 
transthyrin. Knockdown of ERGIC3 reduced secretion of α1-antitrypsin and haptoglobin, and it was also 




was also assessed by secretion of signal sequence-GFP (ss-GFP) in a similar assay set up to the 
secondary screening with ss-HRP used here. The key differences compared to the ss-HRP assay in 
Chapter 5 are that GFP is not usually glycosylated (Paris et al., 2010), and in this case secreted ss-GFP 
was measured by Western blotting after precipitation of proteins. Although no significant difference 
in ss-GFP secretion was found, it is not clear if the ss-GFP assay is sensitive enough to detect a change 
in secretion, as secretion was measured with no positive control (Yoo et al., 2019). As ERGIC3 is thought 
to function in both anterograde and retrograde traffic, it is possible that ERGIC3 is involved in the 
anterograde traffic of the specific proteins assessed. If ERGIC3, like its yeast ortholog, is also involved 
in retrograde traffic back to the ER, it is likely that depletion of MARCH2 results in less secretion overall 
if traffic back to the ER increases, which could explain why MARCH2 was identified in the CRISPR screen 
and validated by the ss-HRP assay. Alternatively, MARCH2 could target proteins other than ERGIC3 in 
the secretory pathway to effect a change in levels of protein secretion. Overall, as few targets of 
ERGIC/Erv46 have been identified for either anterograde or retrograde trafficking, further work is 
needed to determine how MARCH2 affects protein trafficking.  
6.3.3.3 TMEM199 
Another interesting hit identified here is TMEM199. In Chapter 5, TMEM199 was found to have a mild 
but significant secretion defect in secretion of ss-HRP, and approximately 50 % of cells had an aberrant 
Golgi structure on TMEM199 knockdown. Since TMEM199 had no previously proven role in protein 
transport or secretion, it was categorised in Chapter 4 as unrelated to transport. However, a previous 
study used a bioinformatics approach and found TMEM199 has some homology (24 %) to a yeast 
protein known to be involved in ER-Golgi traffic (Jansen et al., 2016). This study also found TMEM199 
localised to the ERGIC and COPI vesicles, and mutations in TMEM199 lead to CDGs (Jansen et al., 2016). 
TMEM199 has since been identified as a regulator of hypoxia-inducible transcription factors (HIFs) 
from a gene-trap forward genetic screen using HIF1α-GFP levels as a readout (Burr et al., 2016; Miles 
et al., 2017). Specifically, TMEM199 was identified as a V-ATPase assembly factor, and in contrast to 
the work by Jansen et al., it was found that TMEM199 localises to the ER (Miles et al., 2017). V-ATPases 
have a wide range of functions; they are well known to acidify intracellular compartments, and they 
also have a role in proton transport across the plasma membrane (Nishi and Forgac, 2002; Pamarthy 
et al., 2018). A subunit of V-ATPase, V0, has also been proposed to have a structural role in vesicle 
fusion, but this remains controversial and it is not clear whether the observed change in membrane 
trafficking is driven by the change in pH as opposed to V0 acting as a fusion protein, as reviewed 
(Marshansky and Futai, 2008; Merz, 2015). If V0 does have a structural role in vesicle fusion, it seems 
unlikely that TMEM199 would be involved in this as it has been shown to assemble V-ATPase (Miles et 




pipeline; knockdown of either subunit resulted in a mild to moderate decrease in ss-HRP secretion and 
40-50 % of cells having aberrant Golgi morphology. These were classed as transport related due to 
their role in endocytosis and transport of membrane proteins, but whether they have a role in protein 
secretion into the extracellular space is not clear (Marshansky and Futai, 2008; Merz, 2015).  
Since disruption of TMEM199 results in a phenotype of decreased glycosylation (Jansen et al., 2016), 
it is likely that both the initial identification of TMEM199 as a hit in the CRISPR screen and the alteration 
in Golgi structure observed in Chapter 5 is related to the role of TMEM199 in glycosylation. Mutations 
in V-ATPases have also been correlated to disorders of glycosylation, although the mechanism by which 
these mutations lead to a glycosylation defect is unclear, as reviewed (Guillard et al., 2009). Therefore, 
it is possible that identification of TMEM199 here is linked to its role in V-ATPase assembly. This seems 
likely given that ATP6V0D1, and ATP6V0E1 were also validated here, but it remains possible that these 
hits act on secretion using different underlying mechanisms. For example, if the V0 subunits are 
involved in vesicle fusion, but TMEM199 regulates secretion via its role in V-ATPase assembly or 
another as yet unknown role. Overall, it is unclear how the role of TMEM199 in V-ATPase function 
could be linked to glycosylation and secretion, or if these functions are linked at all. Further 
investigation to understand the mechanism by which TMEM199 acts on secretion of glycoproteins, 
including clarification of the localisation of TMEM199, would be helpful to further understand both the 
role of TMEM199 in secretion, and to understand CDGs caused by TMEM199. 
6.4 Conclusions  
In this thesis, additional insights into the mechanism of galectin-3 secretion have been gained; 
specifically, galectin-3 is now known to be secreted without requiring cell surface glycans and without 
being unfolded. The ability to be secreted while folded is a common feature shared with a number of 
other unconventionally secreted proteins, and so points towards a consensus in unconventional 
secretion. The ability to be secreted without cell surface counter receptors has also been shown for 
another galectin, galectin-1, but other unconventionally secreted proteins do require receptors on the 
cell surface, demonstrating one aspect of the diversity in unconventional secretion. Overall, much 
remains to be discovered surrounding unconventional protein secretion. The work presented here on 
galectin-3 is significant as it adds to the knowledge around unconventionally secreted proteins; the 
more unconventionally secreted proteins are studied, the clearer a picture of diversity and consensus 
in this process can be revealed.  
Additionally, a pipeline of pooled genome-wide CRISPR screening followed by arrayed siRNA secondary 




analysis method was successfully optimised by utilising an improved library, an increasing stringency 
gating method, the use of both enrichment and depletion sort types and an appropriate analysis 
method, allowing for a large number of significant hits to be identified. Following this, the importance 
of secondary screening is highlighted by the relatively high rate of false positives identified; however, 
the use of secondary screening demonstrates that true positives can be easily identified. Application 
of these principles to other researchers’ screening methods should allow for successful identification 
of novel factors in other areas of cell biology. 
Finally, this thesis presents a list of 51 novel factors validated as involved in protein secretion. This list 
should be a useful tool for other researchers to further investigate. Two of these factors, GPR161 and 
TMEM220, were found to be Golgi-localised, and it is likely that GPR161 regulates protein secretion 
via its interaction with golgin A5. Overall, this thesis achieved several of its aims, and has made 
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Appendix A: Supporting files available in 
repositories 
i: Files deposited in GEO repository 
Raw sgRNA counts are available in .fastq format in the Gene Expression Omnibus repository. Negative 
populations and control populations are available with accession number GSE133692: 
https://identifiers.org/geo/GSE133692. Positive populations and the unused control group U1_0a are 
available with accession number GSE157864: https://identifiers.org/geo/GSE157864. 
ii: Files deposited in Apollo repository 
The following files are deposited in the Apollo repository, DOI: https://doi.org/10.17863/CAM.57330 
 
A1: Raw sgRNA count for GeCKOv2 screen (Stewart et al., 2017), .txt file. 
A2: MaGECK-MLE output for GeCKOv2 screen, .txt file. 
A3: Raw sgRNA count for Brunello screen, .txt file. 
A4: MaGECK output for Brunello screen, .xlsx file. 
A5: siGenome smart pool plate layout, .xlsx file. 
A6: Luminescence values generated from ss-HRP screen, .txt file. 
A7: Unprocessed image files generated from Golgi morphology screen, zipped folders (.zip) containing 





Appendix B: DNA sequences of plasmid 
inserts 
Sequences of inserts of plasmids used in this thesis are given below. All DNA sequences are 5’ -> 3’. 
Further plasmid details are provided in Table 2.1. 
















































































































Appendix C: P5 and P7 primers 
i: P5 primers 
Table C.1: DNA sequences of P5 primers 





















ii: P7 primers 
All P7 primers have the DNA sequence: 
5’ CAAGCAGAAGACGGCATACGAGATNNNNNNNNGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCT 
     ACTATTCTTTCCCCTGCACTGT 3’ 
 
NNNNNNNN represents a barcode to identify samples from different wells. Barcodes and identifiers 
are shown in Table C.2 
 
Table C.2 DNA Barcode sequences of P7 primers.  All DNA sequences are 5’ -> 3’.
Well  Name Barcode sequence Reference 
A01 P7_01 CGGTTCAA 74251305 
A02 P7_02 GCTGGATT 74251306 
A03 P7_03 TAACTCGG 74251307 
A04 P7_04 TAACAGTT 74251308 
A05 P7_05 ATACTCAA 74251309 
A06 P7_06 GCTGAGAA 74251310 
A07 P7_07 ATTGGAGG 74251311 
A08 P7_08 TAGTCTAA 74251312 
A09 P7_09 CGGTGACC 74251313 
A10 P7_10 TACAGAGG 74251314 
A11 P7_11 ATTGTCAA 74251315 
A12 P7_12 TATGTCTT 74251316 
B01 P7_13 ATTGGATT 74251317 
B02 P7_14 ATACTCGG 74251318 
B03 P7_15 TATGAGAA 74251319 
B04 P7_16 GCACAGTT 74251320 
B05 P7_17 CGTGGATT 74251321 
B06 P7_18 TAGTAGAA 74251322 
B07 P7_19 GCACGATT 74251323 
B08 P7_20 CGGTAGCC 74251324 
B09 P7_21 TAGTTCTT 74251325 
B10 P7_22 TACAAGTT 74251326 
 
Table C.2 – continued from previous page 
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Well  Name Barcode sequence Reference 
B11 P7_23 ATCACTGG 74251327 
B12 P7_24 CGCATCAA 74251328 
C01 P7_25 GCACGACC 74251329 
C02 P7_26 TACACTCC 74251330 
C03 P7_27 CGGTCTAA 74251331 
C04 P7_28 ATGTTCGG 74251332 
C05 P7_29 CGTGGACC 74251333 
C06 P7_30 ATTGAGCC 74251334 
C07 P7_31 TAGTTCGG 74251335 
C08 P7_32 CGGTGAGG 74251336 
C09 P7_33 CGTGAGTT 74251337 
C10 P7_34 ATCAGATT 74251338 
C11 P7_35 TAGTGATT 74251339 
C12 P7_36 CGGTTCGG 74251340 
D01 P7_37 TATGGACC 74251341 
D02 P7_38 GCCAAGTT 74251342 
D03 P7_39 CGCAGACC 74251343 
D04 P7_40 CGACCTCC 74251344 
D05 P7_41 GCCACTGG 74251345 
D06 P7_42 GCGTAGTT 74251346 
D07 P7_43 CGCAAGTT 74251347 
D08 P7_44 CGACAGTT 74251348 
D09 P7_45 CGCATCTT 74251349 
D10 P7_46 ATGTTCAA 74251350 
D11 P7_47 GCGTAGAA 74251351 
D12 P7_48 ATGTAGCC 74251352 
E01 P7_49 TAACTCAA 74251353 
E02 P7_50 CGTGAGCC 74251354 
E03 P7_51 ATCAGAGG 74251355 
E04 P7_52 TATGGAGG 74251356 
E05 P7_53 GCGTTCAA 74251357 
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E06 P7_54 CGCAAGAA 74251358 
E07 P7_55 CGACAGCC 74251359 
E08 P7_56 CGACTCGG 74251360 
E09 P7_57 TACAAGAA 74251361 
E10 P7_58 CGCAGATT 74251362 
E11 P7_59 ATTGCTCC 74251363 
E12 P7_60 GCACTCGG 74251364 
F01 P7_61 ATGTTCTT 74251365 
F02 P7_62 ATGTCTCC 74251366 
F03 P7_63 GCACTCAA 74251367 
F04 P7_64 TAGTAGCC 74251368 
F05 P7_65 CGTGTCAA 74251369 
F06 P7_66 GCGTTCTT 74251370 
F07 P7_67 GCCAAGCC 74251371 
F08 P7_68 GCACCTCC 74251372 
F09 P7_69 GCACCTGG 74251373 
F10 P7_70 GCCAGACC 74251374 
F11 P7_71 CGCAAGCC 74251375 
F12 P7_72 TACATCAA 74251376 
G01 P7_73 GCGTAGCC 74251377 
G02 P7_74 CGACAGAA 74251378 
G03 P7_75 TAGTCTGG 74251379 
G04 P7_76 ATCAAGTT 74251380 
G05 P7_77 TAGTAGTT 74251381 
G06 P7_78 ATACTCTT 74251382 
G07 P7_79 CGGTAGTT 74251383 
G08 P7_80 ATACGAGG 74251384 
G09 P7_81 CGCACTGG 74251385 
G10 P7_82 TACAGACC 74251386 
G11 P7_83 GCGTGACC 74251387 
G12 P7_84 TATGTCGG 74251388 
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H01 P7_85 CGACTCTT 74251389 
H02 P7_86 GCGTTCGG 74251390 
H03 P7_87 ATACCTAA 74251391 
H04 P7_88 CGGTGATT 74251392 
H05 P7_89 TAACGACC 74251393 
H06 P7_90 ATACAGCC 74251394 
H07 P7_91 CGACGACC 74251395 
H08 P7_92 ATCACTAA 74251396 
H09 P7_93 CGACCTGG 74251397 
H10 P7_94 TATGTCAA 74251398 
H11 P7_95 TAACCTAA 74251399 





Appendix D: R codes for cell counts 
i: R code for counting green cells and total cells from tif image overlay 





library(EBImage)   
  
# load the file.  
img <- readImage("C:/Users/Steph Popa/Documents/_R/Cell count 
analysis/170511 gfp/500 b2.tif") 
  
display(img, method = "raster")  # shows the image within R.  
  
# Count cells 
nmask = thresh(img, w=12, h=12, offset = 0.001) 
nmask = opening(nmask, makeBrush(9, shape = 'gaussian')) 
nmask = fillHull(nmask) 
nmask = bwlabel((nmask)) 
  
display(nmask, all = TRUE, method = "raster") 
  
cellNo <- max(bwlabel(nmask)) 
  
  
# Count green cells 
nmask = thresh(img, w=12, h=12, offset = 0.07) 
nmask = opening(nmask, makeBrush(5, shape = 'gaussian')) 
nmask = fillHull(nmask) 
nmask = bwlabel((nmask)) 
  
display(nmask, all = TRUE, method = "raster") 
  
GreenNo <- max(bwlabel(nmask)) 
 
ii: R code for counting green cells and total cells from tif images from separate channels 











# Count cells 
  
# load the file.  
trans <- readImage("C:/Users/Steph Popa/Documents/_R/Cell count 
analysis/170511 gfp/trans/500 1.tif") 
  
display(trans, method = "raster")  
  
# Blur & segment 
  
nmask = thresh(trans, w=12, h=12, offset = 0.015) 
nmask = opening(nmask, makeBrush(5, shape = 'gaussian')) 
nmask = fillHull(nmask) 
nmask = bwlabel((nmask)) 
  
display(nmask, all = TRUE, method = "raster") 
  
  
cellNo <- max(bwlabel(nmask)) 
  
  
# Count green cells 
  
# load the file.  
green <- readImage("C:/Users/Steph Popa/Documents/_R/Cell count 
analysis/170512 gfp/green/500 1.tif") 
  
display(green, method = "raster")  
  
# Blur & segment 
nmask = thresh(green, w=9, h=9, offset = 0.008) 
nmask = opening(nmask, makeBrush(5, shape = 'gaussian')) 
nmask = fillHull(nmask) 
nmask = bwlabel((nmask)) 
  
display(nmask, all = TRUE, method = "raster") 
  






Appendix E: MaGECK-MLE quality 
control map 
 
Figure E.1 Pearson correlations for each sample pair from populations collected from the Brunello 
CRISPR screen. Samples are arranged by how closely they correlate with each other, as shown on the 
right hand side of the comparison table. Squares are labelled by the Pearson correlation; squares 
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